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Abstract 
 
Since its discovery over a decade ago, DISC1 has become one of the most promising 
candidate genes for Schizophrenia and associated chronic mental disorders.  This notion 
has been supported by a wealth of evidence from genetic and biochemical studies.  With 
multiple interacting partners, DISC1 acts as a scaffold protein, orchestrating vital 
signalling pathways that underpin neurodevelopment and signalling.  While the aetiology 
of Schizophrenia is poorly understood, loss of DISC1 protein function remains one of the 
proposed disease mechanisms.  Furthermore, its tendency to form aggregates is 
reminiscent of neurodegenerative illnesses such as Alzheimer’s and Parkinson’s disease.  
C-terminal truncation of DISC1 (TrDISC1) is known to decrease neurite outgrowth and 
number in the PC12 cell line, abolish protein interaction with proteins such as Ndel1 and 
also disrupt vital physiological process such as mitochondrial transport.  However, very 
little is known about the underlying disease mechanism at the molecular level. 
In order to gain insight in to the role of DISC1 pathway in Schizophrenia and associated 
mental illnesses, I studied novel post translational modifications of DISC1.  The main 
conclusion of my thesis is that these modifications affect DISC1 turnover and its scaffold 
function. 
In the first part of my thesis, I provided the first direct evidence that DISC1 can be 
SUMOylated.  Peptide array technology was used to SUMOylate and map potential SUMO 
acceptor lysines on DISC1, in vitro.  As detecting SUMO conjugates in cells is challenging, I 
utilised the “Ubc9 fusion directed SUMOylation” method (UFDS) to discover that K643 as 
the one of the SUMO target sites.  Mass spectrometric analysis was employed to 
corroborate this novel post translation modification on DISC1.  Preliminary evidence was 
also provided that SUMO conjugation of DISC1 obliterates its interaction with DIXIN, 
while having no effect on Ndel1 binding.  This is an interesting finding since DISC1-DIXIN-
Nudel form a protein complex to regulate neuronal migration during cortical 
development.  While SUMOylation has been implicated in pathological protein 
aggregation, a hallmark of many psychiatric illnesses, this work provides an experimental 
framework to understand DISC1 aggregation which disrupts intracellular mitochondrial 
transport.    
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In the second part of my thesis, using biochemical and mass spectroscopy analysis, I 
demonstrated that DISC1 protein levels are regulated by the ubiquitin proteasome 
system (UPS).  Using an siRNA library screen, Fbxw7 was identified as a key Fbox protein 
which functions as a key component of an SCF E3 ligase complex that catalyses ubiquitin 
transfer to the DISC1 protein.  Peptide array studies identified a phosphodegron motif on 
DISC1 which interacts with  SCFFbxw7 following a dual phosphorylation event by a yet 
unidentified kinase.  Based on this experimental evidence, a hypothesis was developed 
that this novel protein – protein interaction may have a great potential for therapeutic 
intervention to address the loss DISC1 of function, a proposed disease mechanism for SCZ 
and associated chronic mental disorders.  According to my hypothesis, inhibiting SCFFbxw7 
mediated ubiquitination of DISC1 stabilises DISC1 which may compensate for the low 
cellular levels or dysfunctional DISC1 protein.  
The proposed hypothesis was addressed in the third section.  Using structure activity 
relation analysis and peptide array studies, a disruptor peptide was developed which 
interferes with SCFFbxw7 – DISC1 phosphodegron/CPD peptide (Cdc4 phosphodegron).  
Two lead peptides were identified which successfully stabilised DISC1 protein levels in 
HEK293 cells.  These peptides had no effect on the protein levels of other vital Fbxw7 
substrates suggesting their specificity towards DISC1- SCFFbxw7 interaction.  I also explored 
iPS cell technology, which has the potential to provide innumerable patient specific 
neurons for disease modelling, to test the effect of the lead peptides.  My work provides 
preliminary evidence of DISC1 protein stabilisation following treatment with the lead 
peptides in the neuronal progenitors differentiated from Schizophrenia patient specific 
iPS cells.     
In the final section, High throughput screens (HTS) were performed to identify non-
peptide, small molecule inhibitors of this novel PPI.  A quantitative and reliable 
fluorescence polarization (FP) binding assay was developed and optimized based on 
SCFFbxw7 – DISC1 phosphodegron/CPD peptide interaction to perform the HTS.  The hits 
identified in these screens require more intense characterisation in secondary screens to 
validate their effect as modulators of this interaction.  
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The work described in this thesis has uncovered 2 novel post translational modification 
and identified the E3 ligase involved in regulating DISC1 turn over.  My work has also laid 
the foundation for the design and discovery of both peptide and non-peptide, small 
molecule inhibitors of the DISC1-Fbxw7 interaction.  These inhibitors can serve as both 
pharmacological tools and for further investigation of the role of this novel interaction in 
DISC1 pathway and the vital physiological functions it is involved in.  Furthermore, this 
work also indicates the feasibility of controlled and directed differentiation of patient 
specific iPS cells in to neurons, which act as a useful tool for disease modelling.  
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1.  
 
Introduction 
  
 
1.1  Schizophrenia  
Schizophrenia (SCZ) is a chronic and debilitating mental illness, affecting nearly 1% of the 
worldwide population (Perälä et al., 2007).  It is mainly characterised by a condition 
known as psychosis, which is a hallmark of the onset of SCZ.  Symptoms are primarily 
classified as positive symptoms, such as altered behaviour and thoughts, hallucinations 
and/or delusions and negative symptoms such as lack of motivation and interest, poor 
speech.  On the other hand, it is also believed that other factors such as behavioural and 
environmental influences may also contribute collectively to the development of this 
disease.   
 
Behavioural and genetic studies over a wide range of populations have implied that the 
incidence of SCZ is often prevalent in families, which have a high incidence of other 
mental illnesses.  It has been established the risk of developing SCZ is directly related to 
the biological association to an affected individual (Middleton et al., 2002).  Several 
studies show that males have a higher incidence of SCZ than females although this 
difference was not observed at ages younger than the age of 17 (Jablensky et al., 1992, 
Jablensky, 2000, McGrath et al., 2004, Kleinhaus et al., 2011).  This difference may be 
attributed to the differential neurodevelopmental processes in the sexes, a notion 
supported by evidence provided by imaging studies (Lenroot et al., 2007).  However, 
nearly 60% of patients with SCZ have neither first nor second degree relative(s) with the 
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disorder which highlights the complexity of the disease (Gottesman and Erlenmeyer-
Kimling, 2001).  Linkage studies have established an association between SCZ 
susceptibility and loci associated with brain development such as 22q11–13, 6p, 13q, and 
1q21–22 (Pulver, 2000).  This also supports the belief that SCZ is a developmental disease.  
Although it is inheriTable, so far, no particular pattern of inheritance has been reported , 
possibly due to the complex interaction between genetic and  environment factors.  
Stress and smoking were also named as possible risk factors for SCZ (Hays, 2000).  
However, these factors don’t explain all the symptoms of the disease.  In the absence of a 
specific diagnostic marker, SCZ is mainly diagnosed by a comprehensive mental health 
evaluation by health care professionals.   
 
Anatomical abnormalities such as reduced relative head circumference was reported at 
birth in individuals who later developed this disorder (Lewis and Levitt, 2002).  
Researchers reported significant cortical thinning, reduction in grey matter density and an 
increase in lateral and third ventricle volumes.  However, MRI (magnetic Resonance 
Imaging) studies failed to reach a statistical significance in the reduction of total brain 
volume In affected individuals (Shenton et al., 2001).  Other structural abnormalities in 
cerebral volume, glial processes, neurite lengths and synapse number have also been 
reported in SCZ patient brains (Bertolino et al., 1996).  Despite much research, much 
remains to be discovered about the underlying molecular events that lead to the 
pathophysiology of this illness.   
 
Several research groups identified many candidate susceptibility genes that confer 
considerable risk for SCZ and associated psychiatric illnesses.  Various hypothesis have 
been proposed linking SCZ to dopamine receptor signalling (Harrison, 2000, Bertolino, 
1999, Grima et al., 2003) and serotonin (Slowik, 1967, Robledo, 1961).  To date, nearly 
100 genes have been proposed to be possible susceptibility factors, though only very few 
have been verified in follow-up studies.  The first publication identifying ‘DISC1’ as a 
possible genetic factor for SCZ triggered much interest in gaining a better understanding 
of the molecular mechanisms behind its signalling role in neurons (Millar et al., 2000c).  
 
3 
 
1.2. DISC1 (Disrupted In Schizophrenia) 
DISC1 was first discovered as a potential candidate susceptibility gene for SCZ, when a 
balanced translocation (1; 11) (q42:q14) was identified in a large Scottish family with a 
number of psychological disorders (Millar et al., 2000a).  Chromosomal translocation can 
be defined as an event in which a segment of a chromosome is detached and 
interchanged with a different chromosome segment.  This can be detected by 
karyotyping.  Of all the family members karyotyped, nearly a third of the members 
carrying the truncation have been diagnosed with various psychological disorders, 
including SCZ, bipolar disorder and unipolar depression.  LOD (linkage of the odds ratio) of 
3.6 and 4.5 has been achieved for SCZ and schizoaffective disorders respectively 
(Blackwood et al., 2001).  However, the disease penetrance is insignificant as certain 
family members diagnosed with the psychiatric disorder carried a normal karyotype 
(Blackwood et al., 2001).  Another subgroup within the family also included translocation 
carriers, which showed no abnormality in mental state with no known history of 
psychiatric illness.  This suggests that the translocation may not lead to major 
disturbances in brain function in all the members (Blackwood et al., 2001).   
 
Published in 2000, Miller and colleagues cloned the gene directly disrupted by the 
translocation and named it as DISC1 (Disrupted in SCZ).  A non-coding antisense RNA to 
the DISC1 locus was identified and named as DISC2.  It was hypothesised that this 
antisense RNA could be involved in regulating the DISC1 gene expression (Millar et al., 
2000c).  Numerous  studies have confirmed these original observations that link 
disruption in the DISC1 gene with SCZ (Millar et al., 2001, Chubb et al., 2008, Devon et al., 
2001, Millar et al., 2000c, Brandon et al., 2004, Clapcote et al., 2007).  The DISC1 locus has 
been found to be associated with SCZ, bipolar disorder, autism, depression and other 
associated psychiatric illnesses (Song et al., 2010, Hennah and Porteous, 2009).   
 
Population based case studies identified ultra-rare mutations, which were found to be 
associated with a 2% risk for SCZ (Song et al., 2008).  Three common amino acid variants 
R264Q, L607F and S704C were identified to be associated with the risk of SCZ and 
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associated disorders (Chubb et al., 2008, Bradshaw and Porteous, 2012). In particular, the 
DISC1 SNP S704C has been shown to be associated with SCZ and major depression in 
several populations (Callicott et al., 2005, Hashimoto et al., 2006).  Additionally, studies 
reported that F607 allele carriers had significant morphological abnormalities, such as 
reduced grey matter in superior frontal gyrus and anterior cingulate cortex in F607 
homozygotes, while S704C variants exhibited severe positive SCZ symptoms.  In light of 
this data, it is surprising that none of the genome wide association studies identified a 
common DISC1 variants that may independently increase the risk of developing SCZ or its 
associated illness.  However, the precise underlying biology still needs to be elucidated 
(Nakata et al., 2009). 
 
1.2.1. DISC1 structure 
Although DISC1 has been shown to be associated with number of mental disorders, not 
much information is available about its tertiary structure.  Therefore, it becomes 
increasingly difficult to understand the physiological effects of several reported 
mutations, truncations and SNPs in DISC1.  However, genomic DISC1 structure is well 
conserved in low organisms including macaque (Macaca mulatta), mouse (Mus 
musculus), rat (Rattus norvegicus) zebrafish (Danio rerio) and pufferfish (Fugu rubripes) 
(Chubb et al., 2008).  
 
Located on chromosome 1, the human DISC1 gene spans over 415 kbp with 13 exons.  
Exon 9 is the largest and covers about a third of the entire gene in humans.  The size of 
this exon is relatively conserved in other species and this may be the evidence that this 
exon is functionally significant (Chubb et al., 2008).  The Scottish translocation occurs in 
exon 8, causing exons 9 to 13 to move to chromosome 11.  As depicted in Figure 1.1, the 
full length human DISC1 protein has been hypothesised to have a globular N terminus 
(encoded by exons 1 and 2), a α helical and coiled-coiled region in the C terminus which 
carries many protein interaction sites (Millar et al., 2000c, Chubb et al., 2008, Ma et al., 
2002b).  C terminus is more conserved within species compared to the N terminus.  C 
terminus contains self-association domains which lead to formation of stable dimers 
(Leliveld et al., 2009).  Sequence analysis studies revealed the presence of conserved 
nuclear localisation signal (NLS) in the N terminus.   
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Nearly 40 splice variant transcripts of DISC1 have been reported so far.  However, no clear 
information is available about their existence at the protein level.  Characterised DISC1 
protein isoforms in humans include Long (L) 854 amino acids (100kDa); Long Variant (Lv) 
832 amino acids (~98 kDa); Short (S) 678 amino acids (~75kDa).  EST (Extension Sequence 
Tags) studies show that L and Lv forms are conserved across various species (Taylor et al., 
2003).  RT-PCR analysis of mRNA levels in post mortem brains of adult humans show high 
levels of full length DISC1 and low levels of other variant transcripts (Lipska et al., 2006).  
Antibodies raised against different regions of DISC1 detect number of bands at various 
molecular weights using Western blotting techniques.  The bands observed at higher 
molecular weights have been speculated to be multimers of various isoforms or post 
transnationally modified isoforms (James et al., 2004b).  Oligomerisation of DISC1 was 
initially proposed by Brandon et al (Brandon et al., 2004). Narayanan and colleagues 
reported biochemical characterisation of full length DISC1 oligomerisation using size 
exclusion chromatography and analytical ultra-centrifugation studies (Narayanan et al., 
2011).  Their studies show that although the common variant S704C, tends to form higher 
molecular weight oligomers, this SNP has no effect on its interaction with Ndel1 
(Narayanan et al., 2011).  Residues 403-504 on DISC1 were identified by biochemical 
studies on region specific DISC1 mutants and were shown to constitute a self-association 
domain (Kamiya et al., 2005a).  Immunoreactive, detergent insoluble DISC1 aggregates 
were identified in nearly 20% of post mortem brains with chronic psychiatric illnesses  
(Leliveld et al., 2009).   
 
 
Figure 1.1  Schematic representation of proposed DSIC1 tertiary structure.  
Adapted from (Chubb et al., 2008, Soares et al., 2011), this picture shows largely 
disordered N terminal head domain, which harbours a nuclear localisation signal (NLS), 
SF motif (Ser and Phe rich).  The C terminal domain consists of a series of coiled-coiled 
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domains which were implicated in protein interactions and self-association.  
Translocation break point t(1;11) is indicated with an arrow (at amino acid position 
597).   
 
1.2.2. DISC1 tissue Expression and sub cellular localisation 
Though DISC1 is mostly discussed in the context of neuronal signalling, its expression is 
not just confined to brain but ubiquitously expressed in various other tissues.  Placenta, 
kidneys and heart have the highest expression of DISC1 transcripts.  Abundant DISC1 has 
been detected in the dentate gyrus of adult human brain by James et al (2004), although 
relatively low expression has been detected in hippocampal pyramidal cells (James et al., 
2004a, Millar et al., 2000b).  Northern blotting studies revealed the presence of various 
DISC1 transcripts in various parts of the brain (Millar et al., 2000b).  Similar DISC1 
transcript expression patterns have been reported in mouse brain (Ma et al., 2002c).  The 
consistent observation of prominent expression of DISC1 transcripts in hippocampus 
across species is interesting as the hippocampus is associated with a number of 
neurocognitive and other behavioural disorders (Chubb et al., 2008).  DISC1 expression 
has also been observed in cerebral cortex, sub ventricular zone and olfactory bulb (Ma et 
al., 2002a, Schurov et al., 2004b, Miyoshi et al., 2004).  DISC1 co localises with Nestin and 
SOX2 in these regions, which are sites for neurogenesis.  This  suggests a role of adult 
neurogenesis in the pathophysiology of SCZ (Mao et al., 2009a), (Schurov et al., 2004a, 
Kim et al., 2012).    
 
DISC1 protein localisation in mammalian cell lines and cultured neurons has also been 
investigated by several groups.  DISC1 was shown to be localised to multiple subcellular 
compartments such as the centrosome (Miyoshi et al., 2004), microtubules (Morris et al., 
2003), mitochondria (James et al., 2004a)  nucleus (Sawamura et al., 2005a) and synapse 
(Camargo et al., 2007).  It was observed that the localisation varied with the cell type and 
the antibodies employed for probing.  Co-localisation of overexpressed DISC1 with PSD95 
in primary cultures of hippocampal neurons (Bradshaw et al., 2008), presence of 200kDa 
DISC1 protein in post synaptic density cell fractions and the presence of other major 
DISC1 interacting proteins in the synaptic fractions strongly supports DISC1 localisation as 
an important factor for synaptic signalling.  Notably, synaptic dysfunction has also been 
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implicated in SCZ (Harrison and Weinberger, 2005).  In spite of the data described above, 
the two major sites of DISC1 verified by many groups was mitochondria (Atkin et al., 
2011, James et al., 2004a, Millar et al., 2005a) and nucleus (Sawamura et al., 2008, 
Brandon et al., 2005, Ma et al., 2002a).  Punctate distribution of endogenous DISC1 has 
also been reported in mouse cortical neurons, a distribution, which has been replicated 
by overexpressed C terminally GFP tagged DSIC1 in HeLa cells and mouse cortical neurons 
(Brandon et al., 2005).  Immunocytochemistry studies confirmed the localisation of DISC1 
with cytoskeleton proteins α-tubulin and MAP2 (Microtubule Associated Protein 2) in 
cultured mouse neurons (Brandon et al., 2005).  Multi subcellular localisation of DISC1 
implicates its involvement in diverse cellular processes mediated by multiple interacting 
partners.  
 
1.2.3. DISC1 in Neuronal signalling and development 
DISC1 possess multiple interacting partners that demonstrate its pathological relevance 
and represent potential for therapeutic intervention.  Initial studies that identified a 
number of putative DISC1 interacting partners utilised yeast -2-hybrid screens (Ozeki et 
al., 2003a) (Camargo et al., 2007).  Many of these interacting partners have been 
validated by several groups using a range of biochemical techniques.   
 
Most of the interacting partners can be now be categorised in groups of proteins involved 
in: cytoskeleton regulation, cell cycle control, signal transduction and central nervous 
system signalling.  DISC1 forms immune complexes with F actin (Miyoshi et al., 2003b), 
alpha tubulin (Brandon et al., 2004), MAP2 (Brandon et al., 2005) suggesting its 
association with cytoskeleton.  Upon analysis of the DISC1 sequence, it was found to be 
similar to those involved in cytoskeleton and transport.  Many cytoskeletal proteins are 
involved in signalling pathways at the synapse, thereby increasing the chances of DISC1 
playing a role in neuronal signalling pathways and suggesting a contribution of DISC1 to 
neurological disorders.  DISC1 and mitofilin association has been noted  in human cell line 
and culture mouse neurons (Park et al., 2010).  DISC1 knockdown directly effects mitofilin 
stability and activity of mitochondrial enzymes like NADH dehydrogenase (Park et al., 
2010).  
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Several groups independently characterised interacting partners of DISC1 such as LIS1, 
Ndel1 and Nde1.  These are crucial centrosomal proteins, which are involved in neuronal 
migration, neurogenesis and neurite outgrowth (Bradshaw et al., 2009, Kamiya et al., 
2005a).  Dishevelled axin (DIX) domain containing 1 (DIXDC1) is another DISC1 interacting 
partner and DISC1-DIXIN complex is known to modulate neuronal proliferation and 
migration via Wnt/GSK3β/ β-catenin signalling  (Mao et al., 2009b, Singh et al., 2010).  
While knockdown of DISC1 decreases hippocampal progenitor proliferation, DISC1 over 
expression has the opposite effect.  This effect was also known to be mediated by Wnt 
signalling pathway of which GSK3β is one of the major component.  The kinase activity of 
GSK3β is inhibited upon its interaction with the C terminus region of DISC1, leading to 
stabilisation of β catenin protein which translocates in to the nucleus to modulate 
translocation of various neurodevelopmental genes (Bradshaw and Porteous, 2010, Ming 
and Song, 2009).  This has pharmacological relevance as lithium chloride, a GSK3β 
inhibitor has been widely employed in management of bipolar disorder (Ming and Song, 
2009).  
 
The DISC1 interactome contains a number of proteins specifically localised at the synapse.  
TNIK (TRAF2- and NCK interacting Kinase) is one of the PSD (Post Synaptic Density) 
localised DISC1 interacting partners whose activity is inhibited when in complex with 
DISC1 (Bradshaw and Porteous, 2012).  Kal7 which encodes multifunctional Rho GDP/GTP 
exchange factor, is one of the candidate genes whose transcripts were found at reduced 
levels in SCZ patients (Hill et al., 2006) and an independent study identified KALRN locus 
(includes all KAL isoforms) to be associated with SCZ in a GWAS in Japanese population 
(Mandela et al., 2012),(Ikeda et al., 2011).   
 
DISC1 role in cAMP signalling is emphasised by its interaction with PDE4enzymes.  PDEs, a 
large family of phosphodiesterases are the only means of degrading cAMP, a crucial 
secondary messenger in many physiological pathways (Houslay et al., 2005).  Mammalian 
PDE4 enzyme family consists of four gene subtypes with multiple isoforms constitute 4 
sub family (PDE4A, PDE4B, PDE4C, and PDE4D)(Houslay, 2001). PDE4 inhibitor, rolipram 
9 
 
was elucidated to exhibit anti-psychotic effects in mice.  In the absence of PDE4 subtype 
specific inhibitors, knockout mice were generated to understand the contribution of each 
subtype to the rolipram mediated effects (Zhang et al., 2002).  Deficiency of PDE4D gene 
produced antidepressant-like effects suggesting that this subtype mediates the effects of 
PDE4 inhibitor (Zhang et al., 2002).  Biochemical studies also established a direct 
interaction between PDE4 isoforms and DISC1.  PDE4 isoforms were co-
immunoprecipitated with 100kDa isoform of DISC1 and using peptide array studies, PDE4 
binding sites on DISC1 have been mapped (Murdoch et al., 2007).  A more recent study 
elucidated that ATF4-DISC1 act as repressor complex and regulates PDE4D9 transcription 
(Soda et al., 2013). Using ChIP-PCR, it was determined that DISC1 binds to PDE4D gene 
locus via ATF4, as it lacks DNA binding domain.  Increased levels of PDE4D9 transcripts 
and protein levels were reported in embryonic mice brains in which ATF4 and DISC1 were 
knocked down using shRNA technology (Soda et al., 2013).  PDE4D9 was also shown to 
co-localise with DISC1 in the cytosol in cultured hippocampal neurons, emphasising the 
involvement of DISC1 in cAMP regulated pathways (Soda et al., 2013). DISC1 interacting 
partners in the context of neural signalling and development are discussed in depth in this 
review article (reviewed in Bradshaw and Porteous (2012)).  As described by Costas et al, 
DISC1 can be best termed as a ‘hub’ protein forming a centre point for the orchestration 
and  regulation of several cellular pathways and exerting its function by protein-protein 
interactions (Costas et al., 2013).  Interactors of DISC1 and epistatic gene regulation 
between them have also been shown to be associated with SCZ risk (Millar et al., 2005b, 
Burdick et al., 2008).  
 
The role of DISC1 in psychiatric illness has also been highlighted by a number of genetic 
studies in mice.  Although it is impossible to model positive, negative and cognitive 
symptoms entirely in a mouse, models based on single endophenotype can be developed.  
To date, seven different mouse models have been generated to investigate the outcome 
of altered DISC1 function.  A study by Clapcote et al, reported depression-like behaviour 
in mice with ENU induced Q31L mutation, while mice with the L100P mutation exhibited 
SCZ-like behaviour.  Notably, both had reduced brain volumes, even though they all 
expressed normal levels of all DISC1 isoforms (Clapcote et al., 2007).  It is interesting to 
note that both the above mutations fall in the region on DISC1 known to be involved in 
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PDE4B interaction (Murdoch et al., 2007).  Both the mutants have shown reduced binding 
to PDE4B while lower PDE4B enzyme activity was reported only in Q31L mutants 
(Clapcote et al., 2007).  PPI (prepulse inhibition) deficit was observed in both these 
mutants, as seen in patients with certain psychiatric illness.   
 
A mutant mouse strain carrying two termination codons in exon 7 and 8 and a premature 
polyadenylation site in intron 8 were developed (BAC-DC Tg mice).  This led to complete 
elimination of the 100kDa and 70kDa DISC1 isoforms, while only a low level of the 
truncated DISC1 protein product was detected using Western blot analysis (Kvajo et al., 
2008).  Histological studies confirmed reduced cerebral cortex volume and enlarged 
lateral ventricles, while reduced neuronal proliferation and neurogenesis was also 
reported in this model (Jaaro-Peled, 2009).  Three other models have been generated in 
which the N terminal DISC1 peptide (1-597 residues, TrDISC1) was overexpressed, 
potentially replicating t(1;11) translocation (Pletnikov et al., 2008).  A mouse model which 
expresses the C terminal DISC1 peptide (671-852 residues) carrying crucial binding sites 
for Ndel1 and LIS1 has also been generated (DISC1-cc transgenic mice) (Li et al., 2007).  All 
these mouse models were intensely characterised for behavioural, histological and 
biochemical abnormalities, as summarised in following review papers - (Jaaro-Peled, 
2009, Kellendonk et al., 2009).  However, the simplest approach, a knockout DISC1 
mouse, has proven difficult to produce due to the complexity involved in DISC1 isoforms 
which are not fully characterised yet.  
 
 
1.3. Post Translational Modification (PTM) 
Post-translational modification (PTM) is the covalent attachment of additional chemical 
groups, lipids, sugars or polypeptides to a protein mediated by various enzyme cascades 
(Walsh et al., 2005).  Translated proteins are folded and subjected to certain enzyme 
catalysed modifications on their amino acid side chains or peptide backbone.  Nearly 5% 
of the genome encodes for enzymes that catalyse PTMs such as ligases, kinases, 
phosphatases, and hydrolases (Walsh et al., 2005).  PTM may involve covalent additions 
of a co-factor or a co substrate.  Examples include ATP-dependent phosphorylation and 
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acetyl CoA dependent acetylation (Walsh et al., 2005).  The other type of PTM involve 
covalent conjugation of 8 – 10 kDa such as ubiquitin or ubl (ubiquitin like) to the side 
chain of amino acids on the target substrates, examples include SUMOylation and 
Ubiquitination which are reviewed under sections 1.4 and 1.5 respectively. 
 
These modifications individually or collectively increase the functional diversity within the 
proteome.  They most often involve a cascade of enzymes, which in turn are tightly 
regulated by either another post translational modification, spatial or temporal 
separation.  They are critical in determining the protein fate – conformational changes, 
stability, activity (for enzymes) and sub cellular localisation.  However, it should be noted 
that PTMs can occur at any stage during or at the end of the life time of a protein.  In 
most of the cases, they also regulate the cellular signalling cascades responding to 
extracellular stimulus, as in the case of the CNS where synaptic communication between 
neurons is tightly regulated (Wilkinson et al., 2010).  PTMs have been implicated in 
cardiovascular disease, psychiatric disorders and cancer (Anderson et al., 2009, 
Ciechanover and Iwai, 2004). 
 
To date, phosphorylation was the only PTM, reported on DISC1 using mass spectroscopy 
studies.  Thr50, Ser58 and Ser713 are three phosphorylation sites on DISC1 identified, in 
which the latter two sites are conserved in mouse (Ser54 and Ser710 respectively) 
(Ishizuka et al., 2011c).  Site directed mutagenesis and in vitro phosphorylation assays 
found that PKA and Cdk5 phosphorylated hDISC1 fragment at Ser713 (Ser710 in mouse).  
This phosphorylation has also been reported to influence the progression of progenitor 
proliferation to post-mitotic neuronal migration.  Unphosphorylated form of DISC1 
preferentially bind to GSK3β and modulates Wnt signalling.  In converse, phosphorylated 
DISC1 forms specifically co-localise with BBS proteins (Bardet-Biedl syndrome) at the 
centrosome (Ishizuka et al., 2011a).  A previously identified PKA mediated 
phosphorylation site on hDISC1, Ser58 (Ishizuka et al., 2011c) was known to influence 
nuclear localization of DISC1 in HeLa cells (Soda et al., 2013, Ishizuka et al., 2011c). 
Phosphorylated WT DISC1 Ser58 was predominantly cytosolic, while the mutant DISC1 
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S58A was nuclear in the presence of okadaic acid, a serine/threonine phosphatase. This 
phosphorylation event also reduced DISC1 interaction with ATF4 (Soda et al., 2013).  
 
 
1.4. SUMOylation 
SUMOylation is a post translational modification which involves a covalent attachment of 
SUMO proteins (Small Ubiquitin like Modifier) on to substrate.  SUMO (also known as 
GMP1, UBL1, PIC1)  proteins are present in all eukaryotes with and their homologues in 
yeast are called Smt3 and Pmt3 (Hay, 2001).  Human genome encodes 4 SUMO proteins 
(SUMO 1 – SUMO 4).  So far, only three of the SUMO proteins have been characterized.  
SUMO1 is the best-studied isoform of this family.  SUMO 2 and 3 isoforms differ only by 
three residues at their C terminus and so collectively they are referred as SUMO 2/3.  The 
functional role of SUMO4 has not yet been elucidated.  SUMO proteins are about 10 kDa 
in size and resemble ubiquitin in their three dimensional structures, however, sequence 
alignment shows less than 20% similarity with the ubiquitin.  A flexible 20 amino acids tail 
is absent in ubiquitin and over all surface charge distribution is also significantly different 
(Hay, 2005).  Like ubiquitination, SUMOylation involves an active enzymatic cascade 
where the SUMO moiety (single or as chains) is/are covalently added on to ε-amino group 
of lysine residues that present on the surface of substrate proteins.   
 
Figure 1.2, represents a schematic of SUMO conjugation cycle.  SUMO proteins are 
expressed in immature forms, which are processed by the protease activity of SUMO 
specific isopeptidases (SNEPs).  In this processing step, variable stretch of the C terminus 
(4, 11 and 2 amino acids from SUMO 1, 2, 3 respectively) is cleaved off, to expose the 
glycine –glycine domain.  Following this action, the protein is considered as the matured 
SUMO moiety.  This SUMO maturation step is followed by its activation by a 
heterodimeric E1 enzyme (SAE1–SAE2 in humans/Uba2–Aos1 in S. cerevisiae) that uses 
ATP to adenylate the C-terminal Gly residue of SUMO.  This results in formation of a 
thioester bond between the C-terminus of SUMO and a Cys residue in active site of SAE2, 
releasing AMP (Hay, 2001, Meulmeester and Melchior, 2008).  Next step involves the 
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transfer of SUMO from E1 enzyme, SAE1-SAE2 to catalytic Cys residue on Ubc9 (SUMO E2 
enzyme) resulting in a thiol-ester bond formation.  Ubc9 then transfers the SUMO to the 
substrate in the final step.  An iso peptide bond is formed between the ε amino group of 
the target lysine and the C terminal glycine of SUMO.  This transfer is sometimes 
facilitated by SUMO E3 ligases which act as adaptor proteins and docking stations 
(Wilkinson and Henley, 2010) that increase the fidelity of the SUMO conjugation.  The 
exact role of SUMO E3 ligases in this step has been the subject of debate and a firm 
consensus has not been reached.  SUMO E3 ligases are mainly characterised by the 
presence of a SP-RING (SUMO Protease- Really Interesting Gene of Interest) motif, which 
is similar to the Ubiquitin RING E3 ligases (discussed under ubiquitin E3 ligase).  SP-RING 
E3 ligases bind to Ubc9 and SUMO non-covalently via SIM/SBM (SUMO Interacting 
motif/SUMO Binding Motif), functioning as adaptor molecules that act to position the 
SUMO loaded Ubc9 and the substrate protein in a complimentary position for SUMO 
transfer (Wilkinson and Henley, 2010, Meulmeester and Melchior, 2008).   
 
One distinct group of SUMO E3 ligases is the PIAS family proteins (Protein Inhibitor of 
Activated STAT (Signal Transducer and activator of Transcription), which are well 
characterised.  Five of these enzymes  have been found in mammals (PIAS1, PIAS3 and 
the splice variants PIASα, PIASβ and PIASγ (Wilkinson et al., 2010).  Nucleoporin RanBP2 
also functions as SUMO E3 ligase (Pichler et al., 2002) which has many substrates 
including Sp100, HDAC4 and PML (Wilkinson et al., 2010).  Unlike ubiquitination, where 
E3 ligases confer substrate specificity, SUMO-1 conjugation to IκBα and RanGAP1 can 
occur in a purified system only in the presence of SUMO-1, SAE, Ubc9 and the substrate.  
This suggests that E3 ligase may not be required for SUMO conjugation in vitro (Blomster 
et al., 2010, Hay, 2001).   
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Figure 1.2  Schematic diagram representation of SUMO conjugation cascade. 
SUMO moieties are processed by removal of an inhibitory C-terminal extension, known 
as maturation, catalysed by SUMO-specific proteases (belong to enzyme class-
hydrolases).  With the C-terminal carboxyl groups cleaved, SUMO is then attached to ε-
amino group(s) on Lys residues on the target substrate proteins by an active, ATP-
dependent enzymatic cascade.  SUMO is activated by the E1 enzymes SAE2–SAE1 and is 
then transferred to the E2 enzymes, Ubc9.  The target specificity of SUMO may be 
dictated by the presence of a ψKxE/D motif in the substrate that is recognized by the 
E2–SUMO conjugate.  The role of E3 ligases in SUMO cascade is still a debate unlike in 
ubiquitination (represented as ? ).  Deconjugation reactions are mostly catalysed by 
SUMO-specific proteases that cleave catalyse the maturation step of SUMO moieties. 
 
 
Unlike the case for ubiquitination, SUMOylation generally occurs at a well-defined 
consensus sequence.  The SUMO acceptor site has been identified after mapping a 
number of target SUMOylation sequences like RanGAP1, PML, C-Jun and P53 (Rodriguez 
et al., 2001).  The SUMOylation consensus motif has been identified as ‘ψKxD/E’ (ψ is a 
hydrophobic amino acid such as lysine, Isoleucine, Valine or Phenyl alanine, x is any 
amino acid) (Rodriguez et al., 2001).  Nearly 75% of the known substrates are known to 
be SUMO conjugated within this consensus site.  However, some substrates get 
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SUMOylated at lysine residues outside this consensus motif by “atypical” SUMO acceptor 
lysines (Hoege et al., 2002).  Hence, the presence of ‘ψKxD/E’ can be used as a predictor 
but is not a definitive indicator of SUMOylation (Wilkinson et al., 2010).  In addition to the 
covalent SUMO conjugation to an acceptor lysine, recent studies have identified motifs 
on substrates that mediate non covalent interactions with SUMO proteins (Minty et al., 
2000, Hecker et al., 2006).  These motifs are known as SIMs ( SUMO Interacting Motifs) 
which are found to contain a hydrophobic core flanked by acidic residues within the 
general consensus sequence V/I-x-V/I-V/I or V/I-V/I-x-V/I/L, where position two or three 
can be any amino acid (V,I and L are single letter representation of Valine, Isoleucine and 
Leucine respectively) (Song et al., 2004).  Since the present study focuses on the covalent 
SUMO interactions, it has not been possible to detail SIMs in this review. SIMs have been 
reviewed in Song et al. (2005).  
 
Initially on the  basis of immunocytochemical studies, it was suggested that SUMOylation 
occurs primarily in the nucleus or perinuclear space (Scheschonka et al., 2007). 
Subsequently, most of the SUMOylated proteins were found localised in the nucleus 
while the SUMO machinery was found distributed both in the nucleus and cytoplasm.  
Nuclear SUMO conjugates include transcription factors, nuclear pore proteins and 
proteins involved in maintaining genome integrity.  Recent evidence of reported 
SUMOylation of plasma membrane proteins such as ion channels (K+ channel) and GPCRs 
(G-protein-coupled receptors) also suggests the presence of SUMO components at the 
plasma membrane (Scheschonka et al., 2007).   
 
 
1.4.1. Molecular consequences of protein SUMOylation  
Covalent linkage of a 10kDa SUMO protein moiety to the protein substrate may have one 
or more consequences (schematic in Figure 1.3) - (a) SUMOylation may block interaction 
sites on the target protein either by directly competing with the lysine residue which is 
also targeted by acetylation, methylation or acetylation cascade or by stearic hindrance 
caused by the SUMO moiety (Pichler et al., 2002), (b) SUMO conjugation may add 
additional binding surface (sometimes including its own residues) to substrates  therefore  
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attracting new interacting partners in a SUMOylation dependent manner (Matunis et al., 
1996). (c) SUMOylation may cause conformational changes to the target protein 
uncovering previously masked binding sites (Hay, 2001).  The downstream effects of 
protein SUMOylation (in neurons), mediated by the above mechanisms are detailed in the 
next section. 
 
Figure 1.3  Schematic representation of possible molecular consequences of protein 
SUMOylation 
(a) Inhibit interactions: Stearic hindrance caused as a result of covalent attachment of 
nearly 8kDa protein on to the target will result in abolishing protein interaction either 
covalent or ionic.  (b) New interaction surfaces involving SUMO protein:  SUMO moiety 
on the protein may create new surface(s) which facilitate new interactions.  (c) Induce a 
conformational change: A possible conformational change as a result of SUMOylation 
may aid result in new interactions.  
   
Protein SUMOylation is a dynamic, complex and reversible process.  SUMO moieties 
covalently attached to the substrates, are recycled by the action of deSUMOylation 
enzymes.  A single gene family encoding six SUMO specific Cysteine proteases has been 
identified in humans known as Sentrin specific proteases (SENP) (Hay, 2013) . The 
isoforms SENP1-3 and SENP5-7 are the human homologues.  Along with the isopeptidase 
function, they are characterised to have the C terminal hydrolase activity which is 
required for the maturation of pro SUMO proteins.  There are reports of SNEPs 
themselves undergoing post translational modification.  For example, SENP3 is rapidly 
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turned over under normal cellular conditions by ubiquitination.  Extracellular stress 
stimulus causes stabilisation of SNEP3 relocating it from cytoplasm to nucleus.  SNEP3 
rapidly deSUMOylates p300 which regulates transcription of Hif1a, a key regulator of 
stress response (Girdwood et al., 2003).  
 
 
1.4.2.  Protein SUMOylation in CNS 
Protein SUMOylation has proven to be an essential part in the regulation of many 
neuronal cellular pathways.  Although, the SUMOylation pathway was linked to diverse 
neurological functions and disorders, underlying mechanistic details of how SUMO 
conjugation of substrates contributes to health and disease remain largely unknown.  This 
section is a short review to evaluate the role protein SUMOylation in neurobiological 
processes.  
 
The highest levels of Ubc9 expression (SUMO E2 enzyme) and SUMO1 conjugation has 
been detected during early brain development in rodents.  High expression of Ubc9 
reported in dentate gyrus of hippocampus and pyramidal neurons in cerebral cortex 
indicates a possible role of Ubc9 and protein SUMOylation in synaptic signalling and 
plasticity.  Spatio-temporal regulation of SUMOylated substrates and components of 
SUMO cascade machinery during rat brain development implies its crucial role during the 
neurogenesis (Watanabe et al., 2008).  Localisation of SUMO-1 and Ubc9 in Cajal bodies 
(CBs) is another example of SUMO mediated regulation of cellular processes in neurons.  
CBs are small nuclear organelles, which regulate ribonucleo proteins involved in mRNA 
processing (spliceosome machinery).  Neuronal proteins coilin and survival of motor 
neuron protein (SMN), marker proteins of CBs, were described as putative substrates of 
SUMO conjugation (Carvalho et al., 1999).  NR2E3 is a key transcription factor, which 
activates rod specific genes or represses cone specific genes.  This is a key step in 
controlling rod photoreceptor differentiation in the retina.  NR2E3 is SUMOylated in a 
PIAS3 dependent manner.  High expression of PIAS3 is observed in mouse retina during 
retinal development (Blackshaw et al., 2004, Onishi et al., 2009).  MEF2A (Myocyte 
Enhancer Factor 2A) is another example of a transcription factor implicated in synaptic 
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activity whose activity is strictly regulated by acetylation and phosphorylation dependent 
SUMOylation (Shalizi et al., 2006).  It was speculated that SUMOylation may act as switch 
between transcriptional activator and repressor roles of MEF2A (Beg and Scheiffele, 
2006). Leak K+ channels (example: leak K2P1 channel), crucial for neuronal excitability are 
also SUMO modified.  It has been proposed that SUMOylation regulates K2P1 channel 
activity by directly obstructing the channel pore or altering its charge distribution (Plant 
et al., 2005).  GSK3β, a key enzyme in Wnt signalling pathway and a DISC1 binding 
partner, is also a substrate for SUMOylation (Wilkinson et al., 2010).  It is also one of the 
few substrates to get SUMOylated on a lysine residue with in a non-consensus region.  
GSK3β SUMO mutants (non SUMOylable) are unstable and excluded from the nucleus, 
which implies that this modification may be crucial in regulating the enzyme activity (Eun 
Jeoung et al., 2008).  SUMOylation has also been implicated in the pathogenesis of 
Alzheimer’s characterised by progressive dementia.  Neurological hallmarks of 
Alzheimer’s include neuronal plaques of β amyloid and fibrillar plaques composed of 
hyper phosphorylated tau protein, both of which are SUMO substrates (Wilkinson et al., 
2010).  A direct genetic link between the SUMO system and AD has also been 
hypothesised as an SNP (intron 7) on Ubc9 gene has been shown to be associated with AD 
in certain ethnic populations (Ahn et al., 2009).  Likewise, α-synuclein, implicated in 
Parkinson’s disease interacts with SUMO 1 (Pountney et al., 2005).  SUMO protein levels 
in cells also alter under conditions of cellular stress.  Although, SUMO2/3 levels are low 
compared to that of SUMO1, under conditions of oxidative and osmotic stress, SUMO2/3 
conjugation of proteins increases, suggesting that they may act as reserve pools (Martin 
et al., 2007).  SUMO2/3 conjugation is also known to increase in cases of transient global 
cerebral ischemia in mice.  Hence, it was hypothesised that SUMO conjugation may be a 
protective mechanism employed by the cell to down regulate cell surface markers and 
receptors and thereby prevent cell death (Martin et al., 2007).  In addition, SUMO 
proteins are known to be actively transported across the synapse upon neuronal 
stimulation (Paul, 2008).  SUMO E1 and E3 enzymes were found to be in low levels in post 
mortem brain tissue of SCZ patients (Paul, 2008).   
 
Protein aggregation is the hallmark of several psychiatric illnesses such as Alzheimer’s, 
Parkinson’s, amyotrophic lateral sclerosis and Huntington’s disease.  The proteins 
contributing to these diseases Tau, α-synuclein, amyloid precursor protein, SOD1, 
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Huntington and atrophin-1 are SUMO substrates (Krumova and Weishaupt, 2012).  
Although, its yet unknown how protein aggregation contributes to the disease 
mechanism, it is speculated that it is possibly mediated by  SUMOylation as it regulates 
protein solubility and stability (Krumova and Weishaupt, 2012).  To summarize, 
elucidation of SUMOylation mediated regulation of synaptic transmission and neuronal 
differentiation has just started to emerge.  Possible suggested roles include regulation of 
resting membrane potential and synaptic protein-protein interactions.  SUMOylation adds 
complexity to these processes, as they are already known to be modulated by other PTMs 
such as phosphorylation, ubiquitination, and acetylation.   
 
 
1.5. Ubiquitination/Ubiquitylation 
1.5.1. Introduction 
A majority of cellular proteins are tagged by ubiquitin (ubiquitin) via an enzyme cascade 
known as Ubiquitination.  This process is famously known as a prerequisite for targeted 
protein degradation by the proteasome.  Hershko and collegues, using various 
biochemical fractionation and enzymology techniques, discovered that certain proteins 
when added to reticulocyte extract, became covalently tagged to a protein known as 
ubiquitin, and that these Ubiquitinated proteins were gradually destroyed by an ATP-
dependent protease present in the extract (Hershko et al., 1980, Hershko et al., 1979, 
Ciechanover et al., 2012).  This team further identified and characterised the enzymes in 
the ubiquitin cascade and named them as E1 (ubiquitin-activating enzyme), E2 (ubiquitin-
conjugating enzyme) and E3 (ligase).  The other major component of this pathway is the 
ATP dependent protease, which gradually degrades the ubiquitin conjugated protein and 
is now named as the 26S proteasome (Adams, 2003, Baumeister et al., 1998, Braun et al., 
1999, De Mot et al., 1998, Tanaka, 1998).  The ubiquitin moiety, E1, E2, E3 ligases, DUB 
(deubiquitinating enzymes) enzymes and the 26S proteasome collectively constitute the 
UPS pathway. 
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The UPS (Ubiquitin Proteasome System) is involved in controlling many cellular processes 
including protein localisation, transport across membranes, antigen processing and 
maintenance of the stoichiometry in protein-protein complexes.  The UPS pathway 
provides one of the many means through which the cell discards defective, mis-folded, 
non-functional and aggregated  protein (Hershko and Ciechanover, 1998).  Ubiquitin, 
which is a major component of this tightly regulated cascade, acts as signalling messenger 
to regulating the most complex cellular functions.  There has been emerging evidence of 
its involvement in other cellular pathways like gene expression regulation, subcellular 
targeting of proteins, regulation of protein confirmation, and DNA repair (Di Fiore et al., 
2003, Schwartz et al., 1988).  Proteins tagged with a single ubiquitin or ubiquitin chain(s) 
are processed by a multi subunit protease complex, the 26S proteasome.  However, 
ubiquitin itself is spared from the proteasomal action by it release from the substrate by 
the action of specific peptidases known as deubiquitinating enzymes (DUBs), making this 
post translational modification reversible.  Discovery of deubiquitinating enzymes 
supports the theory that free ubiquitin moieties can be recycled by the cell (Matsui et al., 
1982).  They belong to an enzyme class of hydrolases that hydrolyze the isopeptide bond 
between the C-terminal glycine and either the substrate lysine or ubiquitin lysine (if in a 
chain).  Ubiquitin can bind to proteins either covalently or via ionic interactions.  Ubiquitin 
may also be conjugated to target substrate proteins and modulate their function without 
affecting their stability and other non-destructive roles can also be accomplished by non-
covalent interaction with substrate proteins (Finley et al., 1989).    
 
1.5.2. UPS (Ubiquitin Proteasome System): Components and 
pathway 
Components of the UPS system are well conserved from lower to higher eukaryotes and a 
homologous system is absent in prokaryotes.  Ubiquitin is a 76 amino acid protein, 8.3kDa 
in size.  Upon conjugation to the target substrate, ubiquitin may affect their stability, 
localisation, conformation and activity.  The complex surface design of ubiquitin enables it 
to form straight or branched chains of different lengths, which confer great versatility to 
this protein modification.  The name ‘ubiquitin’ can be justified by its omnipresence and 
diverse cellular functions.  Ubiquitin was discovered as a thymus hormone by Goldstein et 
al in 1975 (Goldstein et al., 1975).  However, the exact identity and its extended role  in 
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proteolysis  was elucidated by Avram hershko and colleagues  in 1978 (Hershko et al., 
1980).  It is one of the most conserved proteins known so far and the difference from 
insects to humans is only one amino acid.   
 
Ubiquitin conjugation is an active process, which involves the transfer of an activated 
ubiquitin moiety to the substrate (Etlinger and Goldberg, 1977) as represented in the 
schematic of ubiquitin conjugation cycle (Figure 1.4).  In an ATP dependent step, ubiquitin 
is transferred to an ubiquitin activating enzyme (also known as UAE or E1), to form a thiol 
ester bond between the C terminal glycine (G76) of ubiquitin and the side chain of a 
cystine residue within a highly conserved region with the E1.  Activated ubiquitin is then 
transferred from E1 to the cysteine residue on one of the several ubiquitin conjugating 
enzymes (also known as Ubc or E2).  Ubiquitin is then transferred on to the substrate 
directly or with the help of certain accessory proteins called E3 ligases, depending on the 
class of E2 enzyme involved.   
 
The ubiquitin conjugation enzyme cascade is hierarchical, with the presence of one E1, 
very few characterised E2s and significantly larger number E3s with much more to be 
identified.  Two isoforms of the E1 enzyme (E1a and E1b) have been characterised so far.  
To date, just over 30 genes have identified in E2 class of enzymes.  E2 enzymes were 
discovered to have a conserved Ubc domain (ubiquitin conjugating) of about 150 amino 
acids.  E3 ligases primarily act as substrate recognition machines that act to bring E2s and 
substrates together in the correct conformation to facilitate ubiquitin transfer (Hershko et 
al., 2000). E3 ligases will be discussed in detail in section 1.5.3. 
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Figure 1.4  Pictorial representation of the ubiquitin cascade 
Ubiquitin is activated by ATP mediated covalent binding to ubiquitin-activating enzyme 
(E1) which is then transferred to ubiquitin-conjugating enzyme (E2).  Depending on the 
class of E3 ligase that regulates the substrate (section 1.5.3), Ubiquitin is then 
transferred helps transfer ubiquitin to the target substrate.  This cascade results in the 
attachment of multiple ubiquitin moieties in form of chains which are subsequently 
recognised by the 26S proteasome for degradation and ubiquitin is recycled which is 
mediated by deubiquitinating enzymes (DUBs). 
 
The ubiquitination process relies on formation of an isopeptide bond between the C-
terminal glycine of the ubiquitin and specific lysine(s) on the substrate protein.  Ubiquitin 
itself has 7 lysine residues.  Once a mono ubiquitinated substrate is formed, ubiquitin can 
get self ubiquitinated on one or more of these lysine residues to form poly ubiquitin 
chains either straight or branched in form (Figure 1.5).  Substrates can also be multi, 
mono or poly ubiquitinated at different sites.  Polyubiquitin chains can either be formed 
on the substrate or built on E2 and E3 ligase complexes and transferred to the substrate 
together (Ravid and Hochstrasser, 2007).  The type ubiquitination of a substrate can be 
classified as (1) Mono ubiquitination at a single site (2) multi-ubiquitination at multiple 
sites on the substrate (3) Poly-ubiquitintion with variable length of ubiquitin chains 
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attached at one or more sites on the substrates.  There have been reports of substrates 
carrying nearly over a dozen ubiquitin molecules (Hochstrasser, 2006).  Using peptide 
mapping and site directed mutagenesis studies, K48 and K63 have been identified as the 
sites on Ubiquitin involved in chain formation (Chau et al., 1989).  However, formation of 
chains having both types of the above linkages concomitantly has been reported.  Various 
models have been hypothesised for poly-ubiquitin chain assembly, reviewed in Mark 
Hochstrasser (2006). (Hochstrasser, 2006)).  The fate of the ubiquitinated protein 
depends on the type of the ubiquitin chains conjugated to it (Figure 1.5).  In general, 
proteins tagged with K48 chains are targeted to proteasome and K63 linkage chain are 
degraded by lysosome (Kirkin et al., 2009).  More recent investigations reveal formation 
of other type of linkages, like K3 whose functional outcome still needs to be studied.  
Multi ubiquitin chain assembly, in some cases also requires an E4 class of enzymes, also 
known as E4 chain elongation factors (Hoppe, 2005).  There has also been increasing 
evidence of ubiquitin tagging  to the N terminus of proteins (Ciechanover and Ben-
Saadon, 2004), and the side chains of amino acids like threonine, serine and cysteine 
(Cadwell and Coscoy, 2005, Ishikura et al., 2010).   
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Figure 1.5  Various effects of different types of ubiquitin chain conjugation of substrates 
Type of ubiquitin linkage is designated by the identity of the lysine side chain amino 
group amino group involved in the linkage i.e, Lys6-, Lys11-, Lys27-, Lys29-, Lys33-, 
Lys48-, Lys63-linked, which in turn dictates the fate of the substrate. 
 
Poly-ubiquitinated proteins are targeted to 26S proteasome, a multi enzyme complex 
localised ubiquititiously in the cell (Baumeister et al., 1998, De Mot et al., 1998).  The 26S 
proteasome comprises of a cylindrical 20S subunit (core particle) and a 19S regulatory 
unit (regulatory particle).  This multi-subunit enzyme complex has nearly 64 subunits 
encoded by 32 genes.  To briefly describe the structure of the proteasome, the cylindrical 
core 20S subunit is flanked by the 19S subunit on either side.  The 19S particle in turn has 
a lid which recognises ubiquitinated proteins and the base has nearly 6 ATPases and caps 
the 20S subunit core.  The 19S unit disassembles the ubiquitin chains, unfolds the 
proteins and channels them in to the 20S subunit (Glickman et al., 1998, Braun et al., 
1999).  The 20S core particle has number of polypeptides, which form 4 rings stacked to 
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form the cylindrical core.  The outer two rings comprise of 7 α subunits, complexed with 
the 19S particle and allow unfolded proteins to pass through.  The inner 2 β rings have 3 
active sites, which are categorised based on their substrate specificity as chymotrypsin-
like, trypsin-like, and post-glutamyl peptide hydrolase-like (PGPH) (Adams, 2003).  The 
20S core particle progressively degrades the substrate protein generating short peptides 
of about 3-25 amino acids long (Adams, 2003).  Though the proteins targeted to the 
proteasome are processed in to short peptides,  NFκb is one of few  examples  where 
proteins are only partially processed as a part of signal transduction regulation (Maniatis, 
1999). 
 
 UPS functions can be broadly categorised as follows 
 
1. Regulation of protein half-Life: Enzymes, cell surface receptors, ligands which serve 
regulatory function in various signalling pathways require to be turned on and off to meet 
the cellular needs.  UPS degrades unwanted proteins and maintains the physiological 
levels of the substrates.  Other than phosphorylation, ubiquitination is another PTM that 
is also involved in regulating enzyme activity by labelling them for destruction, for 
example, PDE4 enzymes degrade and maintain intracellular cAMP pools.  These enzymes 
are in turn regulated by ubiquitin conjugation.   
2. Degradation of misfolded proteins: Misfolded proteins are toxic to the cells and are 
degraded by UPS.  Nearly ~30% of newly synthesised polypeptides are degraded via UPS 
(Wittke et al., 2002).  Misfolded proteins forming toxic aggregates form a hallmark of 
neurodegenerative disease such as Alzheimer’s and Parkinson’s disease.  Though the 
exact reason is not yet known, the common cause of protein mis-folding was thought to 
be SNPs and truncations (Selkoe, 2004). 
3. Non proteolytic functions: While there is still a debate lingering around physiological 
consequence of each type of ubiquitin chain formation on the substrate, a number of 
studies are still uncovering new roles of ubiquitin pathway.  Involvement of ubiquitin 
modification in various types of DNA repair, antigen processing and endocytosis during an  
immune response are just a few of many examples illustrating non proteolytic function of 
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ubiquitin in cell signalling (Chen and Sun, 2009).  Ubiquitination and subsequent 
proteasomal degradation of IκB leading to activation of NF-κB signalling pathway 
implicated in DNA repair.   
The following section is a short review on ubiquitin E3 ligases, a crucial component of UPS 
which confers specificity towards its substrates.   
 
1.5.3.  Ubiquitin E3 ligases 
Ubiquitination is temporally and spatially regulated and the complexity is increased by 
the presence of diverse number of E3 ligases.  To date, 600 E3s have been estimated to 
be encoded by the human genome (Bernassola et al., 2008).  The two major classes of E3 
ligases are the RING finger proteins and HECT domain proteins.  The HECT domain forms a 
thioester with ubiquitin before the ubiquitin is transferred to the substrate, while the 
RING domain present in the RING class proteins, provides a docking surface for E2 
enzymes and the target protein facilitating the active transfer of ubiquitin from the 
former to later, as represented in the schematic Figure 1.4 (Pickart, 2001).  Accumulating 
evidence suggests the association of E3 genes with neurogenetic disorders (including 
UBR1 (Johanson–Blizzard syndrome), NHLRC1 (Lafora’s disease)) (Tai and Schuman, 
2008). 
 
1.5.3.1 HECT 
Homologous to E6-AP carboxyl terminus (HECT) class of E3 ligases role has been 
emphasised by the study of tumours caused by HPV virus.  With the help of the viral 
proteins, E6-AP induces the ubiquitination of the tumour suppressor gene p53 (Scheffner 
et al., 1995).  The important characteristic feature of this family of E3’s is a conserved 
stretch of 350 amino acids in their C- terminus called HECT domain, with a cysteine 
residue at the catalytic site.  The HECT class of E3 ligases differ from the RING E3s by 
possessing an intrinsic catalytic site.  HECT E 3s form complexes with E2 enzymes and 
transfer the active ubiquitin to themselves via the cysteine residue within their active site 
forming a ubiquitin-thiolester intermediate.  This class of E3 ligases actively catalyse the 
transfer and  ligation of ubiquitin to the target substrate (Bernassola et al., 2008).  
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Figure 1.6  Schematic representation of mechanism of ubiquitin conjugation by HECT 
and RING class of E3 ligses 
E3 ligases responsible for transferring the ubiquitin from ubiquitin-conjugated E2 to the 
targeted substrates are primarily classified in to two classes.  a. The HECT-domain E3 
ligases transfer the ubiquitin by forming a thioester bond between the E3 ligases and 
the ubiquitin.  Ubiquitin is then transferred again to the substrates.  b. The RING-
domain E3 ligases interact with the Ubiquitin-conjugated E2 which transfers the 
ubiquitin directly to the substrates.  
 
 
1.5.3.2 RING (Really Interesting Gene) E3 ligases 
This is the largest family of E3 ligases, containing hundreds of genes and more being 
uncovered.  The main characteristic feature of this class is the presence of the so called 
RING domain.  The RING domain is a cysteine and histidine rich region forming a cross-
brace accommodating 2 zinc ions (Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-
Cys-X2-Cys, where X is any amino acid)) (Borden and Freemont, 1996, Joazeiro and 
Weissman, 2000).  Initially RING class proteins were believed to be involved in DNA 
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repair, however, the breakthrough in the delineation of their real function came via the 
discovery of a subunit of the  SCF E3 ligase Rbx11 (Kamura et al., 1999, Seol et al., 1999).  
These studies revealed the catalytic role of members of a RING family.  It has been 
suggested that most of the RING class E3 enzymes form a docking platform for the E2 
ligase and the substrate protein and catalyse the transfer of the active Ubiquitin from the 
former to the later without forming an E3 Ubiquitin intermediate with a covalent bond.  
Zheng et al solved the structure of the Cbl-Ubch7 complex, which uncovered a number of 
features of this domain (Zheng et al., 2000).    
 
RING E3 ligases are also regulated by ubiquitination, often by autocatalytic function, 
consequently regulating its enzymatic activity.  For example, Mono ubiquitination of 
Mdm2 (E3 ligase which regulates the activity of p53) by autocatalysis is speculated to be 
critical in inhibiting its activity.  An example, where auto ubiquitination switches on the 
ligase activity of an E3 enzyme is that of Bard1-Brca1 heterodimer (Simons et al., 2006).  
Diverse mutations in Parkin gene, a RING E3 ligase, were reported in a familial form of 
Parkinson's disease known as autosomal recessive juvenile Parkinson's disease (AR-JP) (Yi 
and Ehlers, 2007).  Brca1, a tumour suppressor gene mutated in nearly 90% breast and 
ovarian cancers is an E3 ligase for substrates primarily involved in cell cycle and DNA 
repair.  It forms a heterodimer with another E3 ligase, Bard1 and it has been established 
that this complex formation enhances auto ubiquitination of Brca1, potentially increasing 
the E3 ligase activity of Brca1 (Simons et al., 2006).   
 
RING E3 ligases are known to function as oligomers frequently.  As mentioned above, 
while Brca1-Bard1 is one example another popular example in which these E3 ligases 
function as dimer is that of the formation of heterodimer complex of Mdm2 and MDMX.  
They play a crucial role in constantly regulating the turnover of p53, a tumour suppressor, 
by Ubiquitination.  Wang et al, reported that though Mdm2 alone is able to regulate p53 
levels, it functions more effectively in complex with MDMX forming a heterodimer (Wang 
et al., 2011).  As observed in Traf, c-Cbl and Siah  RING E3 ligases may also form homo 
dimers (Deshaies and Joazeiro, 2009). However, the functional consequence of RING E3 
ligase oligomerisation is not well understood yet.   
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Members of the RING family functioning as multi subunit complexes are discussed in 
detail in the following section. 
 
1.5.3.3 SCF (Skp1 Cullin Fbox) 
These are the well characterised, largest family of RING finger type E3 ligases that form a 
protein complex to bridge the E2 and the substrate.  SCF complexes and their 
components were first discovered during cell cycle studies in yeast.  Sic1 is an inhibitor of 
Cdk, which is required for the G1 to S phase transition.  At the cell cycle checkpoint, Sic1 
degradation is initiated by its phosphorylation by G1 cyclin (Cln)-Cdk kinases and targeted 
by Ubiquitination via the action of a SCF complex  (Schwob et al., 1994).  One well-
characterised mammalian E3 ligase belonging to multi subunit RING E3 ligase family is 
CDL (Cullin dependent ligase).   
 
A member of CDL family, SCFSkp2 quaternary structure has been elucidated which suggests 
that Cullin1 functions as a scaffold protein interacting with all the components of the 
protein complex.  Its N-terminal helical region that adopts a long stalk-like structure and 
interacts with Skp1 and FboxSkp2 while its C terminal domain assumes a globular α/β 
domain which interacts with Rbx1 (Zheng et al., 2002). Cullin proteins are modified by  
NeDDylation, on their C terminus which induces a conformational change in Cullin 
proteins, which inturn leads to activation of the E3 ligase enzyme (NeDDylation  is 
covalent attachment of ubiquitin like NEDD8 protein(s) catalysed by an enzyme cascade 
analogous to ubiquitination) (Duncan et al., 2012).  To date, 7 members of Cullin family 
have been identified and characterised (Marín, 2009). These are Cullin 1, 2, 3, 4A, 4B, 5, 
and 7.  Anomalies in their proteins levels, structure and SNPs have been reported in 
several tumours.  In a comprehensively characterised example of E3 ligase complex Von 
Hippel-Lindau (VHL), Cul2 serves as a scaffold.  Hif1a, a transcription factor regulated by 
cellular oxygen levels, serves as a substrate for the above mentioned complex  (Maxwell 
et al., 1999).  Several mutations in the sequence of VHL have been reported in Von 
Hippel-Lindau disease, primarily characterized by tumours of the eye, brain, spinal cord, 
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kidney, pancreas, and adrenal glands (Lee and Zhou, 2010).  The role of Cul4B in neural 
development has also been reported recently (Liu et al., 2012, Chen et al., 2012).  A study 
by Liu et al in NT2 cells, revealed the regulatory role of cul4B in neural progenitor growth 
and differentiation. 
 
The other component of SCF complex is Rbx protein.  Two homologues identified in 
humans are Rbx1/ROC1/Hrt1 and Rbx2/SAG/ROC2/Hrt2.  In SCFSkp2 , Rbx1 interacts with 
Cullin protein via its N terminus (of Rbx1) and E2 enzyme via the RING domain on its C 
terminus (Zheng et al., 2002).  Rbx1 interacts with all the known Cullin family proteins 
(Ohta et al., 1999).  The function of Rbx1 is to bind and bring the E2 enzyme into close 
proximity with the E3 specific substrate.  Apart from recruiting E2 enzyme, other precise 
physiological functions of Rbx1 in ubiquitination remain largely unknown.  However, it is 
known to function as an E3 ligase for Cullin NEDDylation (a PTM essential for the E3 
activity of SCF) (Megumi et al., 2005). 
 
The other component of SCF complex is Skp1.  Although, there are a number of 
homologues reported in lower eukaryotes, humans have only one functional Skp1 gene.  
Immunoprecipitation studies and yeast 2 hybrid analysis suggest that Skp1 functions as an 
anchor for Cullin and Fbox proteins (Patton et al., 1998).  The human Skp1 was initially 
characterised as a component of a protein complex containing Cyclin A –Cdk2 and Fbox 
Skp2.  This complex Ubiquitinates p27Kip, an inhibitor of CDK, which is a regulatory kinase 
of the cell cycle check point.  Cell cycle is arrested in either G1 or G2 phase in yeast Skp1 
mutants suggesting its role in cell cycle (Piva et al., 2002).  
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Figure 1.7  Schematic of the SCF complex  
SCF (Skp1–Cullin–F-box) complex: Components of SCF complexes include the scaffold 
protein Cullin-1, which interacts with Skp-1 and the F-box proteins at the amino-
terminus.  The C temrinus of Cullin-1 associates with the RING-domain interacting 
molecule Roc1, which in turn interacts with ubiquitin-conjugated E2 enzymes.  
Substrates are recognized through the C-terminus of F-box proteins and Ubiquitin is 
transferred to the substrates from E2.  The interaction between the F-box proteins and 
the substrates may require the phosphorylation of substrates. 
 
1.5.3.4  FBP: Fbox protein  
Fbox was originally identified as a region of homology in proteins such as Cdc4, β-TrCP, 
Met30 which have Trp-Asp repeats (WD repeats) (Bai et al., 1996). Name Fbox, was first 
given by Bai et al, to a motif they identified in Cyclin F (Bai et al., 1996).  As a part of the 
SCF E3 ligase complex (Figure 1.7), the primary function of the Fbox protein is substrate 
recognition and hence the Fbox often confers specificity to the SCF complex with respect 
to substrate selection.   
 
The structure of Fbox proteins has been elucidated and explains their functional role as 
adaptor proteins bringing the substrate in to proximity of the SCF catalytic core.  Usually, 
they have an N terminal Fbox motif and the C terminal substrate recognition domain.  The 
F-box motif consists of approximately 50 amino acids and is crucial for its interaction with 
Skp1. Depending on their composition and structural properties, Fbox proteins are 
classified into the following categories, Fbxl (LRRs, leucine rich repeats, example: Skp2), 
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Fbxw (WD 40 rich, example: Fbxw7 and β-Trcp) and Fbxo (a different or no Fbox, 
example: Cyclin F, Fbxo7) (Cenciarelli et al., 1999).  However, mere presence of Fbox 
motif does not assure of its E3 ligase activity.  For example, Ctf13 forms a part of the 
kinetochore complex along with Skp1 as a component of CBF3 (Centromere DNA-binding 
protein complex) while other components of the SCF complex are absent and there has 
been no reported ubiquitin ligase activity in this complex (Stemmann and Lechner, 1996).   
Certain Fbox proteins are also known to possess other intrinsic enzyme activity such as 
DNA helicase activity of hFbh1 which regulates homologous recombination (Nelson et al., 
2013).  
 
As this family constitutes a structurally diversified group of proteins, their role in wide 
range of cellular processes such as cell division, differentiation, cell survival and apoptosis 
has been proposed.  Dysregulation of Fbox protein-mediated ubiquitination has been 
implicated in many disease pathologies including mood disorders, sleep disorders and 
Parkinson’s disease.  Table 1.1, presents few examples of Fbox proteins, their specific 
substrates and the pathways they regulate.  
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Table 1.1 Examples of Fbox proteins, their substrates and physiological role 
 
Fbox 
protein 
Substrate Function of Substrate Reference 
βTrCP β-catenin Wnt signalling (Petroski, 2008, Maniatis, 
1999) 
βTrCP REST (repressor 
element 1-silencing 
transcription factor) 
Neurogenesis (Stegmüller and Bonni, 
2010) 
Fbxw7  Cyclin E Cell cycle  (Zhang and Koepp, 2006) 
Fbxw7 Notch Neuronal stem cell 
differentiation 
(Grim et al., 2006) 
FBX2 BACE1 
(β-secretase 1) 
amyloid precursor 
protein (APP) 
processing; implied in 
Alzheimer’s disease 
pathology 
(Gong et al., 2010) 
Skp2 Myb Gene transcription (Schulman et al., 2000) 
Fbxl3 CRY1 and CRY2 Circadian rhythm (Siepka et al., 2007) 
Fbxo7 p27 Inhibitor of Cyclin 
dependent kinases; 
Cell cycle regulation 
(Nelson et al., 2013) 
 
Mammalian Fbox protein family is still expanding with the discovery of Fbox function in 
many proteins from time to time.  The following section is a short review on Fbxw7 
protein which has been implicated in control neural stem cell differentiation and brain 
development. 
 
 
1.5.3.5  Fbxw7  
Fbxw7, also known as hCdc4 and SEL10, is a member of the Fbox family, which functions 
as a subunit of SCF complex.  Fbxw7, was identified during a genetic screen for cell cycle 
mutants in yeast (Hartwell et al., 1973).  Cdc4, a yeast homologue of Fbxw7, regulates cell 
cycle by targeting Sic1 for ubiquitination.  Sic1 is an inhibitor of Cdk that is required for 
the G1 to S phase transition.  At the cell cycle checkpoint, Sic1 degradation is initiated by 
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its phosphorylation by G1 cyclin (Cln)-Cdk kinases.  Sic1 is then targeted for ubiquitination 
via the SCFCdc4 complex (Schwob et al., 1994).  
  
Human Fbxw7 spans 200kb on chromosome 4, encoding 3 mRNA transcripts – α, β and γ  
generated as a result of intron splicing.  Each isoform has a unique first exon, followed by 
ten shared exons.  Unique transcriptional control is achieved by separate promoters for 
each isoform.  At the protein level, each isoform shares a unique N terminal region 
followed by common regions (Figure 1.7).  The unique N terminal region has been 
reported to regulate the sub cellular localisation of individual isoforms.  The C terminal 
region is responsible for substrate recognition and promotion of ubiquitination (Bai et al., 
1996).  Isoform specific mutations have been reported in several tumours, implying their 
different roles as tumour suppressors.  One of the well characterised Fbxw7 interactions 
is with Cyclin E.  Three different groups independently identified Fbxw7 as the Fbox E3 
ligase required for Cyclin E proteolysis (Welcker et al., 2003, Orlicky et al., 2003, Hao et 
al., 2007a).  X ray crystallographic studies later followed, elucidating the three 
dimensional structure of SCFFbxw7- Cyclin E complex (Hao et al., 2007a).  
 
 
 
 
Figure 1.8  Schematic of Fbxw7 isoforms 
Three functional domains identified in Fbxw7 and the variable N terminus in the three 
isoforms of Fbxw7. 
 
The proposed functions of Fbxw7 are achieved by a 40 amino acid long Fbox domain 
which associates with Skp1, a D domain  (dimerization domain) through which the 
isoforms dimerize and 8 repeats of WD40, which is the substrate binding domain (Zhang 
and Koepp, 2006).  Tertiary structure of Fbxw7 (Figure 1.9) reveals that the F box domain 
and WD40 domain (Trp-Asp) are linked via an α helical linker.  The Fbox domain 
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comprises of five α helices, designated as α0 to α4.  There are eight copies of the WD40 
motif in Cdc4, altogether.  They form an eight blade β-propeller structure.  However, F 
box proteins such as Met30 and β-TrCP have only 7 blade β- propeller structure in 
contrast to Cdc4, which has 8 α helical extension that link the F box domain of Cdc4 to its 
WD40 domain.  This helical linker comprises of two α helices denoted as α-5 and α-6.  
These 2 helices along with the α3 and α4 of the F box domain, form a stalk positioning the 
WD40 domain at a distance (Figure 1.8 ) (Orlicky et al., 2003).   
 
The elucidation of the tertiary structure of Fbxw7 facilitated development of small 
molecule inhibitors targeting its interaction with relevant substrates (Aghajan et al., 
2010).  Many research groups demonstrated dimerization of Fbxw7 and its homologues is 
mediated by the D domain (Figure 1.8).  Although the significance of this dimerization yet 
remains to be elucidated, it was hypothesised that each SCFFbxw7 complex within the 
dimer recruits its own ubiquitin conjugating enzyme E2, resulting in proper spatial 
orientation between the substrate binding domains of each Fbxw7 monomer and  
increasing the efficiency of ubiquitin conjugation (Welcker and Clurman, 2008).  
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Figure 1.9  The Skp1-Cdc4 CPD complex  
Adapted from Orlicky et al., (2003). 
Ribbons representation of Skp1 (green), the F-box domain (residues 274-319 in red), the 
helical linker region (residues 331-366 in pink) and the WD40 domain of Cdc4 (residues 
367-744 in blue).  The bound Cyclin-E derived CPD peptide is in purple with the 
phosphor threonine moiety shown in ball and stick representation.  Positions of 
disordered loop regions are shown as ribbon breaks.  (b) The WD40 domain of Cdc4.  β-
propeller blades are denoted PB1 to PB8.  Ribbons and CPD peptide are colored as in 
(a).   
 
Analysis of Fbxw7 substrate sequences revealed that they might need to be 
phosphorylated within a conserved sequence for the Fbxw7 to bind.  These phospho-
epitopes are described as Cdc4 phosphodegrons (CPD).  Knockout studies identified 
Fbxw7 as key regulating factor of neuronal stem cell viability and neuronal progenitor 
differentiation (Hoeck et al., 2010b).  It is known to regulate these biological processes by 
regulating the turnover of its substrates such as  AP-1, c-Jun and Notch, all known to be 
involved in neuronal population maintenance and self-renewal (Wang et al., 2012a).  
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As one of the characterised substrate of Fbxw7, Notch plays a crucial role in neuron fate 
and differentiation.  Notch is a transcription factor, which, upon proper extra cellular 
stimulus, is processed and translocated in to the nucleus to regulate the expression of 
genes that induce cell proliferation and prevent differentiation.  Studies on Fbxw7 
conditional knockout mice showed that  Fbxw7 regulated the abundance of Notch 
proteins by ubiquitin mediated proteolysis and thus played a pivotal role in regulating the 
ratio of neurons and glial cells, a process critical in brain development (Matsumoto et al., 
2011).  
 
 
1.5.4. UPS impairment in neurological diseases 
In highly specialised cellular networks like that of neurons, their connectivity at the 
synapse is critical in rapid information transfer in the brain.  With millions of neurons 
forming trillions of synapse, it is challenging to understand how each of these synapses is 
individually modulated to fine-tune neural circuitry.  It is understood that synaptic 
stability and plasticity are maintained through finely co-ordinated intra neuronal 
transport and post translational modification of synaptic proteins.  Ubiquitination is one 
such vital modifications that control synaptic protein homeostasis.  Protein homeostasis 
in post mitotic neurons is susceptible to functional disturbances while its abnormalities 
result in the accumulation of insoluble and aggregated proteins in the cell.  Studies 
evaluating the incorporation of radio labelled amino acids into brain proteins suggest that 
proteins are constantly replenished or up regulated in brain at different developmental 
stages (Cajigas et al., 2010).  Studies implicated the significance of tight and controlled 
regulation of protein turn over in brain to enable normal brain processes (Lin and Man, 
2013).  
 
A few examples which highlight the significance of UPS mediated regulation of proteins 
involved in neuronal signalling are as follows: β-catenin is one of the well-studied 
substrates of the SCF E3 ligase beta βTrcp.  This transcription factor has been shown to 
regulate neural progenitor proliferation (Wang et al., 2004).  Neural secretory proteins 
like Bone morphogenic proteins (BMPs) and Sonic Hedgehog (Shh) are involved in 
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neurogenesis and development signalling pathways.  The downstream effector proteins 
of these regulatory proteins are tightly regulated by the UPS system.  PSD95 (Postsynaptic 
Density protein), an important scaffolding protein involved in localisation of receptors at 
the post synaptic membrane (such as NMDARs : N-methyl-D-aspartate receptor and 
AMPARs: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) are regulated 
by UPS (Mabb and Ehlers, 2010).  Another notable example to demonstrate the 
importance of UPS regulation of signal transduction is that of Notch.  Notch is a 
membrane receptor protein that plays a significant role in neurogenesis in response to 
extra cellular signals (Lathia et al., 2008).  Recent studies discovered that Notch 
degradation is mediated by Fbxw7, thus Fbxw7 action can serve to regulate neuronal 
progenitor differentiation (Matsumoto et al., 2011).   
 
The role UPS has in the cell cycle has been documented in actively dividing cells, however 
not much is known about its role in non-dividing cells like neurons.  Only a few CNS 
disorders involving the UPS, directly or indirectly, are discussed here.  Angelman 
syndrome characterised by mental retardation, epilepsy, ataxia and speech problems was 
the first human mental illness related to a genetic defect (defective UBE3A gene encoding 
E6-AP, a Ubiquitin E3 ligase (Kishino et al., 1997)) in the UPS.  A frame shift mutant form 
of ubiquitin has been reported in patients with Alzheimer’s disease and Downs syndrome 
(van Leeuwen et al., 1998).  The inability of this mutant ubiquitin moiety to undergo 
proteasomal degradation can be one of the possible disease mechanisms in at least one 
of the above disease (Fischer et al., 2003).  Huntington's chorea (HD) is one of the nine 
PolyQ repeat neurodegenerative disorders characterised by the presence of increased tri 
nucleotide repeats of CAG which are translated into long stretches of glutamine residues 
increasing their tendency to aggregate.  A mutant of the Htt protein (encoded by 
Huntigton/Htt gene) is deposited in the form large microscopic inclusion bodies (IB) which 
is the hallmark of HD.  IBs interfere with the proteasome and impair the UPS function.  
Though the exact disease mechanism is not yet elucidated, it is hypothesised the 
impairment of UPS function may disturb the cellular protein dynamics resulting in 
cytotoxicity leading to subsequent cell death (Finkbeiner and Mitra, 2008).  Parkin 
(PRKN2), a ubiquitin E3 ligase and UCHL1, a human DUB enzyme, have been implicated in 
the pathology of  autosomal recessive juvenile Parkinson’s disease (Segref and Hoppe, 
2009).  Spinocerebellar ataxia is caused by a mutant form of ataxin-1, which is resistant to 
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proteasomal degradation (Klimaschewski, 2003).  Micro array analysis of transcripts from 
peripheral blood revealed the UPS as one of the canonical pathway disrupted in SCZ and 
bipolar disorder (Bousman et al., 2010).  Finally, a more recent study performed on post 
mortem brain samples of SCZ patients, uncovered abnormal levels of UPS enzymes and 
protein ubiquitination  (Rubio et al., 2013).  The above-mentioned findings not only 
emphasise the role of dysregulated protein degradation pathways in mental illnesses, but 
also provide scope for new therapeutic drug targets. 
 
 
1.5.5.  UPS as drug target 
UPS became a therapeutic attraction for the first time in 2003 following the approval of 
Bortezomib (Velcade®), a proteasome inhibitor approved by the FDA for the treatment of 
multiple myeloma.  This was followed by the Nobel prize in chemistry awarded to Aaron 
Ciechanover, Avram Hershko and Lewin Rose for their discovery of ubiquitin mediated 
protein degradation in 2004.  Since then, UPS components have become an attractive 
drug targets and number of inhibitors targeting this signalling pathway are being 
developed.  As of 2013 quite a few of them have entered clinical trials.  Examples include 
Proteasome inhibitors - CEP-18770 and MLN-9708, E1 enzyme inhibitor – MLN4924, E3 
enzyme inhibitor – RO5045337 (a Nutlin which antagonises Mdm2-p53 interaction).  Till 
date there is no report of a DUB inhibitor in clinical trials, although there are several 
under preclinical development, reviewed in (Mattern et al., 2012). 
   
The E1 enzyme has been described as a potential therapeutic target for treatment of 
hematologic malignancies (Xu et al., 2010).  Tertiary structure of the E2 has been solved 
and provides insight in to three structural orientations of the catalytic site and the 
interactions with other proteins.  Structure activity relationship studies would help design 
molecules targeting the active site of E2 enzyme.  E2 and E3 enzymes meet the criteria for 
an ideal drug target as they are enzymes, which can be screened for small molecule 
inhibitors or specific antibodies.  Since they are either expressed in low levels or not 
expressed in normal cells, their inhibition may have minimal effect on normal cell growth 
and function, thus minimizing toxic side effects as well as achieving maximal therapeutic 
index.  Different strategies of targeting the E3 ligases would include small molecule 
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inhibitors or peptides that can target E3-E2 interfaces, E3-substrate interfaces or E3 ligase 
catalytic sites.   
 
Proteasome inhibitors, though proven effective as a therapeutic strategy, have associated 
toxicity and side effects due to the non-selective nature of their action (many proteins get 
degraded by the 26S proteasome).  As mentioned earlier, Bortezomib (velcade), was one 
of the first drugs targeting proteasome for treatment of multiple myeloma, however, 
excessive toxicity and drug resistance after prolonged use defined the need for the 
development of new inhibitor classes, which are more specific to the target (Bedford et 
al., 2011).   
 
Ubiquitin Ligases (E3s) provide an alternative and attractive therapeutic target as their 
actions are limited to a handful of protein substrates.  The following scenario serves as a 
best example of E3 ligase as a drug target.  p53 is a tumour suppressor gene and 
transcription factor which regulates cell cycle progression and induces apoptosis 
depending on the stimuli, thus preventing malignant transformation.  In nearly 50% 
tumours p53 is inactivated and altering its activity has been considered as a strategy for 
therapeutic intervention for cancer.  p53 protein levels and activity are maintained under 
strict control by its cognate E3 ligase Mdm2 (murine double minute 2).  Mdm2 binds to 
p53 at its transactivation domains and blocks its activation.  Hence by inhibiting p53-
Mdm2 interaction, stabilizes p53 and activated p53 (Shinohara and Uesugi, 2007) (Ding et 
al., 2013).  X ray crystallographic structure of p53 (15-29) bound to Mdm2 (17-125) 
reveals an interaction between hydrophobic N terminal stretch on Mdm2 and 
amphipathic α helix of p53 peptide (Verkhivker, 2012, Vassilev et al., 2004).  This 
information led to the development of benzodiazephine analogues and polyaromatic 
compounds, which disrupt the above complex.  Several other compounds were later 
identified which disrupt the p53-Mdm2 complex.  These up regulated p53 protein levels, 
activated the p53 pathway and induced cancer cell apoptosis  (Wong et al., 2003).  Other 
examples of irreversible inhibition of E3 ligases are (1) Tetrazole compound (Ro106-9920) 
which blocks ubiquitination of IκBα, (2) Ro106-9920 which reduces the serum levels of 
TNFα and prostaglandins in lung (Wong et al., 2003).  Allosteric inhibitors can also be used 
to block the conformational changes or other post translational modification required for 
the E3 ligase activation.  Compounds with imidazole and benzosulfonamide nuclei 
interfere with Mdm2 ubiquitination of p53 in this manner (Lai et al., 2002).  Virtual ligand 
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screening (VLS) has also been used to screen for compounds with the ability to interfere 
with E3 ligase activity.  In silico based approaches have identified small pockets in the E3 
ligase that are suitable for docking with small molecules that could act as inhibitors.  This 
approach has been used to inhibit Skp2 directed degradation of p27 (Wu et al., 2012). 
 
High-throughput screens are another popular approach in drug discovery.  Multiple steps 
in the ubiquitination cascade can be targeted using this approach.  Inhibitors can interfere 
with kinase activity of the “priming kinase” (required for E3 ligase binding to the 
substrate) or attenuate SCF complex assembly either by interfering with the interaction 
directly or allosterically.  An Inhibitor of the SKp1-Met30 interaction is an example for this 
approach and is selective to the F box domain of Met30 and hence the inhibitor doesn’t 
interfere with the binding of other Skp1 binding F Box proteins (Aghajan et al., 2010). 
 
 
 
1.6. DISC1 as a possible therapeutic target for 
neurological disorders  
 
Various genetic studies have implicated the DISC1 locus to be a predisposing genetic 
factor in major mental illnesses including, SCZ, schizoaffective disorders, bipolar and 
depression (Chubb et al., 2008, Song et al., 2010, Ishizuka et al., 2006).  However, no 
specific allele, mutation or SNPs has been proved to be a risk factor across various 
studies.  As discussed earlier, DISC1 has a conserved nuclear localisation signals (NLS), 
which regulate its cytoplasmic/nuclear distribution.  The nuclear form of DISC1 is 
increased in patients with sporadic SCZ, major depression, and substance alcohol abuse 
(Sawamura et al., 2005b).  This study suggests the importance of the NLS domains on 
DISC1 and proposes it as a putative drug target for the aforementioned diseases.   
Protein aggregates are a hallmark of neurological diseases like Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) and DISC1 also forms aggregates both in vivo and in vitro.  
These aggregates could possibly interfere with the physiological functions of DISC1 and 
disrupting these aggregates can be considered as a potential therapeutic strategy.  
 
cAMP specific PDE4 (phosphodiesterase) enzymes  are potential interacting partners of 
DISC1 which were identified in the yeast 2 hybrid screen (Camargo et al., 2007) PDE are 
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the enzymes, which degrade cAMP, a crucial secondary signalling molecule.  Raised 
cellular levels of cAMP caused the dissociation of DSIC1-PDE4 complex (Murdoch et al., 
2007a).  Of various isoforms of PDE4, PDE4B locus has been identified as a possible risk 
factor for SCZ (Millar et al., 2005).  While genetic variants of PDE4B and PDE4D were 
shown to be directly associated with SCZ (Pickard et al., 2007, Hennah and Porteous, 
2009, Fatemi et al., 2008), DISC1 has been shown to specifically interact with certain 
isoforms of PDE4B and PDE4D and this interaction is modulated by cellular cAMP levels 
(Murdoch et al., 2007).  Hence, the DISC1-PDE4 interaction has gained much attention in 
the studies of pathophysiology of SCZ.   
 
Studies show that shRNA knock- down of DISC1 in adult mice resulted in aberrant 
dendritic morphology and mis-positioning of adult born dentate granule cells (Duan et al., 
2007), abnormalities in axonal targeting  (Faulkner et al., 2008), abnormal development 
of dentate gyrus neurons and dendritic abnormalities and induced mTOR signalling (Zhou 
et al., 2013a).  RNAi mediated knock down of DISC1 in differentiating PC12 cells caused 
significant inhibition of neurite outgrowth and this could be rescued by the co 
transfection of WT DISC1 (Kamiya et al., 2005a). In utero gene transfer of RNAi in mouse 
embryos resulted in reduced neuronal migration and reduced dendritic arborisation of 
cortical neurons (Kamiya et al., 2005b).  In the absence of knockout DISC1 mice, the 
above studies as well as transgenic DISC1 mouse models (reviewed in (Jaaro-Peled, 2009)) 
emphasize the importance of DISC1 in the mechanism behind neurological disease.   
 
As proposed by the neurodevelopmental hypothesis of SCZ, the symptoms of SCZ 
generally tend to appear in late adolescence and it has long been believed that the 
biological events causing the disease may have begun at a much earlier stage (Ayhan et 
al., 2011).  Though other genes have been implicated in SCZ and neurogenesis, such as 
neuregulin-1 and dysbindin, most of the studies were focussed on DISC1 due to its 
increased association in linkage and association studies.  The importance of the Scottish 
translocation has long been a debate for several reasons.  One such reason is that, since 
the translocation is in the middle of an open reading frame, the protein even though 
translated, may be unstable and eventually degraded leading to haploinsufficiency (both 
alleles need to be functional for a wild type functional genotype).  However, to date, 
there is no proof of DISC1 truncated protein being translated.  Truncated DISC1 protein 
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might interfere with function of the wild type protein product from the other allele, 
resulting in total loss of function.  This is known as dominant negative effect.  
 
As discussed earlier, the phosphorylated form of DISC1 interacts with Bardet-Biedl 
Syndrome (BBS) proteins at the centrosome, while non-phosphorylated forms up regulate 
Wnt signalling via interaction with GSK3β which acts as a developmental switch between 
progenitor proliferation to post mitotic neuronal migration (Ishizuka et al., 2011b).  This 
study emphasises the role of DISC1 as a scaffold protein function depends on several 
interacting partners.  One source kinase of the phosphorylation of DISC1 at Ser713 is Cdk5 
(Ishizuka et al., 2011b).  Cdk5 inhibitors CP-668863 and CP-681301, developed by Pfizer 
have been considered as potential drugs to provide neuro protection in Alzheimer’s 
disease (Hikida et al., 2012).  
 
 
1.7. Aims of my Ph.D. 
As detailed in my previous sections, genetic studies implicated DISC1, already associated 
with SCZ and other mood disorders, but also in autism spectrum disorders, attention 
deficit and hyperactivity disorder (ADHD) and Asperger syndrome.  While lymphoblasts 
cell lines of the Scottish family members carrying the translocation were shown to have 
reduced expression of mRNA transcripts, no changes were detected in SCZ patients 
outside this family which suggests the complexity of regulation of DISC1 expression and 
protein processing.  In addition, atypical antipsychotic drugs such as olanzapine and 
risperidone were shown to increase DISC1 transcript levels in mouse frontal cortex and 
hippocampus suggesting that they may exert their effect by modulating DISC1 expression 
(Olincy et al., 2011, Chiba et al., 2006).  Abnormal brain development and function has 
been reported with RNAi mediated knockdown of DISC1 indicating that loss of DISC1 
function is not desirable for appropriate brain development (Maher and LoTurco, 2012, 
Hikida et al., 2012). 
 
To date, little is known about the post translational modifications on DISC1.  
Phosphorylation of DISC1 at Ser713 was shown to function as a molecular switch between 
progenitor proliferation and post mitotic neuronal migration in the developing cortex.  
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From the above evidence it can be proposed that understanding how DISC1 protein levels 
are modulated may hold the key to understand DISC1 associated pathology and uncover 
key targets for therapeutic intervention.  With recent studies implicating the 
dysregulation of ubiquitin and Ubl signalling pathways in schizophrenia, it would be 
interesting to investigate how DISC1 expression is regulated by these signalling pathways 
and how it may contribute to disease development (Altar et al., 2005, Rubio et al., 2013).  
 
Hence through my work I set out to address the following key questions: 
 
1. Is DISC1 a potential SUMO substrate in cells?  What are the key SUMO acceptor sites on 
DISC1?  What is physiological significance of DISC1 SUMOylation?  As a scaffold protein 
with many interacting partners, does SUMOylation effect its protein interactions such as 
DIXDC1 and Ndel1 which have been implicated in neuronal precursor proliferation, 
differentiation and migration.  I addressed these aspects using in vitro peptide array 
technology, UFDS (Ubc9 fusion directed SUMOylation) and Immunoprecipitation in 
chapter 3. 
 
2. In chapter 4, I investigated the ubiquitin modification of DISC1 protein using 
proteasome inhibitor MG132.  Immunoprecipitation, Western blotting and Mass 
spectroscopy studies were used to identify potential lysine moieties which are modified 
by ubiquitin conjugation.  Human Fbox siRNA library screen was performed to identify 
putative Fbox that regulates ubiquitination of DISC1 i.e., Fbxw7. 
 
3. In chapter 5, utilising peptide array approach, I had mapped the crucial interaction sites 
between DISC1 and the Skp1-Fbxw7  followed by a series of optimisation screens via 
which I developed certain disruptor peptides to target DISC1- [Skp1-Fbxw7] complex.  
Lead peptides were shortlisted following their ability to stabilise DISC1 protein levels in 
HEK293 cells.  Neuronal progenitors generated from iPS cells were also explored for their 
potential as cell line models for psychiatric diseases.  
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4. In chapter 6, I discussed my work which involved developing a sensitive in vitro FP 
assay to monitor DISC1- [Skp1-Fbxw7] interaction.  This assay was adapted to perform a 
high throughput chemical library screen to identify small molecules which disrupt this 
complex. 
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2.  
 
Materials and Methods 
 
 
2.1  Materials  
All chemicals used in this study were of analytical grade supplied by Thermo Fisher 
scientific, Invitrogen or SIGMA Aldrich unless otherwise specified.  All peptides used in the 
present chapter were custom made by ProImmune, UK at >85% purity, assessed by Mass 
spectroscopy and HPLC.  Labelled peptides used as tracers in FP assays were tagged with 
FITC (Fluorescein isothiocyanate) on the amino terminal end of the peptides.  All the 
drugs and disruptor peptides were dissolved in dimethly sulfoxide (DMSO) and used at a 
final DMSO concentration of 0.001%. 
 
 
2.2    Molecular Biology Methods 
2.2.1  Transformation of competent cells  
DH5α competent cells (Invitrogen) stored at -80ºC were carefully thawed on ice just 
before use.  1-10 ng of DNA was added to 30 μl of competent cells in a sterile eppendorff 
and incubated on ice for 10 min.  The cells were then heat shocked at 42ºC for 45 sec 
then placed on ice for 2 min.  The cells were then added to 300 μl Luria Broth (LB) media 
(1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract and 170 mM NaCl) and 
incubated at 37ºC for 1 hr with shaking.  50-100 μl of transformation mix was then spread 
on 100 mm petri dishes containing pre poured LB agar plates (L broth with 1.5% (w/v) 
agar) containing appropriate antibiotic (ampicillin, 50 µg/ml, kanamycin 30 µg/ml) using a 
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sterile disposable spreader.  These plates were incubated upside down overnight at 37ºC.  
The growth of bacterial colonies indicated successful cell transformation. 
 
2.2.2   Isolation of plasmid DNA from E coli 
Single colonies were selected from the overnight incubated agar plates  and grown 
overnight in 5 ml LB media containing appropriate antibiotic  in an orbital shaker at 37oC.  
QIAprep Miniprep Kit (Qiagen) was used to isolate smaller amounts of plasmid DNA.  
Alternatively, for a larger volume of bacterial culture, 500 ml LB media supplemented 
with appropriate antibiotic was inoculated with 5ml starter culture grown for about 6-8hr 
and incubated overnight at 37oC.  For large scale plasmid DNA extraction the QIAprep 
Maxiprep kit (Qiagen) was used according to the manufacturer’s instructions.  The 
purified DNA was then eluted with sterile double distilled H20 and stored at 4oC for short 
term storage or -20oC for longer term. 
 
2.2.3  Storage of plasmid DNA 
Overnight incubated bacterial culture was mixed with 30% sterile glycerol solution at 1:1 
ratio to give a final glycerol concentration of 15% in cryovials and snap frozen using dry 
ice and stored at -80°C. 
 
2.2.4  Quantification of DNA concentration 
The concentration of purified DNA was determined using Nanodrop 3300 
spectrophotometer (Thermo Scientific).  Absorbance wavelength was set at 260 nm and 
280 nm and the A260:A280 ratio determines the purity of the nucleic acid extract where a 
value of 1.8 and 2.0 is considered pure for DNA and RNA, respectively.  The ratio of 
A260:A230 ideally should be between 2-2.3 and a lower reading may indicate organic 
solvent contamination in the preparation.  
 
2.2.5  Total RNA extraction 
 The protocols described in this section are described, according to Standard Operating 
Procedure of Pfizer, for the work performed as part of a 10 week placement at Pfizer 
Neuroscience research Unit, Cambridge, MA, USA). 
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Homogenisation: Culture medium was aspirated off culture dishes and 1ml TRIzol (per 
each well of a 6 well culture plate) (Ambion 15596-026) was added. 
Phase Separation: The homogenised samples were incubated for 5 min at RT to allow 
complete dissociation of nucleoprotein complexes.  0.2 volumes of chloroform per 1ml 
TRIzol reagent was then added and vigorously mixed followed by 2-3 min incubation.  The 
samples were centrifuged at no more than 1,000 g for 15 min at 4˚C.  Following 
centrifugation the mixture separates into a lower red phenol chloroform phase (which 
constitutes protein), an interphase and a colourless aqueous phase.  The aqueous phase, 
which exclusively contains the RNA, was carefully transferred to a fresh tube without 
disturbing the other phases. 
RNA Precipitation: RNA in the separated aqueous phase is precipitated by adding 0.5 
volumes of isopropanol per 1 ml of TRIzol reagent used.  The samples are thoroughly 
mixed and incubated for 10 min at RT.  
RNA Wash: The RNA was pelleted by spinning at no more than 10,000 g.  The supernatant 
was removed and the pellet was washed with 1 ml of 75% ethanol.  Samples were then 
centrifuged at no more than 7,500 g for 5 min at 4˚C. 
Redissolving the RNA:  The ethanol was carefully aspirated off, the RNA pellet was air 
dried and re-suspended initially in 100 µl followed by quantification. 
DNase treatment of purified RNA: Purified RNA was further subjected to DNase 
treatment to remove any DNA contamination.  TURBO DNA free kit (Ambion AM1907) 
was used and the DNase treatment was done according to the protocol mentioned in the 
instruction manual. 
RNA precipitations clean up: Re-suspended RNA was re-precipitated to remove any salts 
or organic solvents that may have co-precipitated.  NaCl was added to a final 
concentration of 0.1M followed by the addition of 2.35 volumes of ethanol.  The samples 
were then thoroughly mixed and incubated at -20ºC for >30min or overnight.  The RNA 
was then precipitated at 4˚C by spinning at 10,000 g.  The supernatant was carefully 
aspirated and the RNA pellet was air dried.  The RNA was re-suspended in water and 
stored at -80˚C. 
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2.2.6 cDNA synthesis 
High Capacity RNA to cDNA Kit (Applied Biosystems 4387406) was used according to the 
manufacturer’s instruction manual. 
Reaction was set up as following: 
 
Table 2.1 Standard PCR reaction conditions 
 
 
The cDNA samples were stored at -20C° for subsequent RT-PCR analysis. 
 
2.2.7 TaqMan real-time PCR 
Gene specific pairs of primers and TaqMan probes were designed by Applied Biosystems 
(inventoried TaqMan® gene expression assays). All assays were purchased from Applied 
Biosystems and assay IDs are given in Table 2.3. The relative expression of DISC1, Pan 
FBXW7 and alpha FBXW7 isoform  was assessed in 2 separate cDNA samples from the 
neuronal progenitors generated from all 6 different iPS cell lines. Real-time PCR was 
performed from reverse transcribed cDNA samples using the Platinum Quantitative PCR 
SuperMix-UDG with ROX (Invitrogen) following the manufacturer’s instructions. Briefly, 
100 ng of cDNA were added to a 96-well MicroAmp® Fast Optical Reaction Plate (applied 
Biosystems) with 12.5 μl TaqMan probe mix, 1 μl each of the 10 μM primer pair and 0.25 
μl of 10 μM fluorogenic probe (either gene-specific inventoried assays or endogenous 
reference assays). Thermal cycling and fluorescent monitoring were performed using the 
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ViiA 7 Real Time PCR system. Each PCR amplification was run in quadruplicate using the 
following conditions: initial denaturation at 95°C for 15 sec, followed by a total of 40 
cycles (3 sec at 95°C for denaturation, 30 sec at 60°C for annealing and extension). 
Fluorescence data were collected during the extension step of each cycle. Negative 
controls using RNA as template were also included in all runs to test for the presence of 
genomic DNA contamination.  
 
Table 2.2 Inventoried primer probe sets purchased from Invitrogen 
 
 
Table 2.3: Standard PCR reaction conditions 
 
 
 
 
2.2.8  Transient transfection of plasmid DNA 
Plasmid DNA used in the present study was transiently transfected into Human 
embryonic kidney 293 (HEK 293) cells using Polyfect transfection (Qiagen) according to 
the manufacturer’s instructions.  To describe briefly, cells were plated at a density of  
4x 105 cells per 100 mm dish.  At 50-60% confluency, transfections were performed with 
8μg of circular plasmid DNA using Polyfect transfection reagent according to the 
manufacturer's instructions.  The assay was scaled down for smaller culture dishes 
following the instruction manual.  Cells were incubated for at least 48 hr for sufficient 
protein expression. 
 
Component Per Reaction 
Master Mix 5 µl 
Taqman Assay 0.5 µl 
Water 1.5 µl 
cDNA (5 ng/µl) 3 µl 
Total volume  10 µl 
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2.2.9  si RNA transfection – Fbox siRNA library screen 
ON Target PLUS siRNA library for Fbox (G-105625-05) was purchased from Dharmacon, 
Thermofisher Scientific.  HEK293 cells were plated at a density of 3 x 103 cells/ well in 6-
well plates.  24 hr after incubation, the cells were transfected with control nonspecific 
siRNA or the test siRNA from the above library at a final concentration of 25 nM/each well 
using DharmaFECT  (Dharmacon - Thermo Scientific) according to the manufacturer’s 
protocol.  The cells were incubated for 64 hr at 37°C in a CO2 incubator.  Gene expression 
knockdown was analysed by performing Western blotting. 
 
2.3  Cell culture 
All cell culture procedures were carried out in a Class II hoods using standard aseptic 
techniques and sterile instruments.  All culture reagents were supplied by Sigma.  The 
tissue culture flasks, dishes, and pipettes were supplied by Corning.  All cultures were 
examined regularly under a phase contrast inverted microscope (Leitz Diavert, Germany). 
 
2.3.1  HEK293 cells  
The HEK293 cells were used for the present study.  These cells were maintained in growth 
media containing DMEM (SIGMA) supplemented with 10% foetal bovine serum, 2 mM L-
glutamine, 100 U/μg penicillin-streptomycin at 37°C in a humidified atmosphere of 5% 
CO2.  The cells were passaged at about 80% confluency.  For cell passage, growth medium 
was aspirated and the cells were washed in sterile phosphate buffer saline (PBS) to 
remove traces of media.  The PBS was then aspirated off and the cells were treated with 
2mL trypsin-EDTA solution per 75 cm2 culture flask of cells to dissociate cell monolayer.  
Growth medium was added to quench the trypsin-EDTA solution and cells were collected 
by centrifugation at 10,000 g for 2 min at room temperature.  The supernatant was 
removed without disturbing the cell pellet which was then re-suspended in appropriate 
fresh growth media and re-plated according to the requirement.  For cryopreserving the 
cells, the cell pellet was re-suspended in 10% dimethyl sulfoxide (DMSO) containing 
growth medium and stored at -80˚C. 
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2.3.2  iPS cell culture and neuronal progenitor differentiation 
All the protocols described in this section were according to the SOP (standard operating 
procedure) followed at Pfizer Neuroscience Research Unit, Cambridge, USA. 
 
2.3.2.1 iPSc generation and culture  
All the iPS cells (except Detroit 551 cell line) used in the present study were generated by 
Chiang et al (Chiang et al., 2011).  Detroit 551 iPS cell line was generated by Dr.Sandra 
Engle, Pfizer Inc.  Detroit 551 fibroblasts were obtained from ATCC (CCL-110) and 
maintained in Knockout DMEM (Life Technologies 10829-018) with 15% FBS (Life 
Technologies), 1x Nonessential amino acids (Life Technologies 11140-050), 2 mM L-
glutamine (Life Technologies 25030-081), 1x Gentamicin (Life Technologies 15710-072), 
0.1 mM β-mercaptoethanol (Sigma M-7522).  The cells were reprogrammed with 
individual lentiviruses expressing c-Myc, KLF4, SOX2, Oct3/4, Nanog, and LIN28 using 
standard techniques (Takahashi, Okita et al. 2007).  One colony, Detroit 551-3, with ES-
like morphology, high expression of pluripotency markers (e.g. Oct3/4, TRA-1-60, TRA-1-
81, SSEA4), a normal karyotype, a normal karyotype and the ability to form all 3 germ 
layers in a teratoma assay was used in all subsequent experiments.  The cells were 
maintained on mitomycin C (Sigma M0503)-treated mouse embryonic fibroblasts (MEF) 
and grown in hPSC media [DMEM/F12 (Life Technologies 11330-057), 20% Knockout 
serum replacement (Life Technologies, 10828-028), 2 mM L-glutamine (Life Technologies 
25030-081), 1x Gentamicin (Life Technologies 15710-072), 0.1 mM β-mercaptoethanol 
(Sigma M-7522), FGF2 (Life Technologies PHG0263)].  Cells were enzymatically passaged 
using 1 mg/ml Dispase (Life Technologies 17105-0410) to every 4-6 days to fresh MEF. 
 
2.3.2.2 Neuronal Progenitor differentiation 
Neuronal differentiation protocol was adapted from the protocol of (Pankratz et al., 
2007).  Embryoid body formation was induced on the first day, assigned as day 0.  Culture 
media was removed from the appropriate culture dishes with iPS cell colonies and 
washed with warm (37°C) DMEM-F12 media.  1ml Dispase (Invitrogen- 17105-041) was 
added per p100 culture plate and incubated for 37°C for 2-5 min until the edges of the 
cell colony start curling up.  Disapase was aspirated off and washed with DMEM-F12 
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media.  Using Stempro EZPassage (Invitrogen 23181-010) the colonies were gently broken 
until they were dissociated from the plate.  The iPS cell colonies were transferred from 
half of the p100 dish to 100 mm non coated, non-treated, non-adhesive cell culture dish 
with hPSC media [DMEM/F12 (Life Technologies 11330-057), 20% Knockout serum 
replacement (Life Technologies, 10828-028), 2 mM L-glutamine (Life Technologies 25030-
081), 1x Gentamicin (Life Technologies 15710-072), 0.1 mM β-mercaptoethanol (Sigma 
M-7522), FGF2 (Life Technologies PHG0263)], to promote preferential adhesion between 
cells over adhesion to the culture dish.  
 
On day 2, the embryoid bodies were collected by centrifugation in appropriate centrifuge 
tubes at 500 g for 5 min at RT. Supernatant was discarded while extreme care is taken not 
to disturb the pellet which was re-suspended in 10 ml of GABA differentiation media [50% 
Neurobasal Media (Life Technologies 21103-0490), 50% DMEM/F12 (Life Technologies 
10565-018), 0.5x N2, 0.5x B27 (Life Technologies 17504-044), 1 mM L-glutamine (Life 
Technologies 25030-081), 1x Gentamicin (Life Technologies 15710-072), 10µM SB431542,  
0.2µM LDN-193189 (StemGent 04-0074), 20ng/ml FGF8b (R&D Systems 423-F8-025), Shh 
(R&D Systems 1845-SH-025/CF), 10 ng/ml FGF2 (Invitrogen PHG0263)], supplemented 
with ROCK inhibitor (10 µM) and transferred to cell culture plates pre-coated with 
matrigel.  Cell culture dishes were coated with matrigel according to manufacturer’s 
instructions (BD Matrigel matrix- 354277).  Fresh GABA Media change was done from day 
4 to day 10. 
 
Cells were passaged on day 10 by aspirating the media and washing 3 times with PBS.  1 
ml of accutase (Invitrogen A1110501) was used to gently lift the cell off the dish.  Equal 
volume of DMEM-F12 media was added to neutralise the enzyme activity and the cells 
were collected by gently pipetting the suspension and centrifuged at 1000 g for 5 min at 
RT. Supernatant was disposed and the cell pellet was re-suspended in GABA media 
supplemented with 10µM ROCK inhibitor and plated in 1:1 ratio on pre coated POL 
coated plates (20 µg/ml poly-L-ornithine hydrobromide (Sigma P3655)/ 5 µg/ml natural 
mouse laminin (Life Technologies 23017-015) (POL)-coated plates).  
 
Fresh media change was performed every day with GABA media.  Confluency and 
morphology of the cells was microscopically observed on a daily basis to detect unwanted 
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differentiation.  Cells can be passaged using the protocol described above depending on 
the confluency after day 15.  From this point onwards neuronal progenitors can be 
maintained and expanded as required in NP media [50% Neurobasal Media (Life 
Technologies 21103-0490), 50% DMEM/F12 (Life Technologies 10565-018), 0.5x N2, 0.5x 
B27 (Life Technologies 17504-044), 1 mM L-glutamine (Life Technologies 25030-081), 1x 
Gentamicin (Life Technologies 15710-072), 10ng/ml EGF (R&D Systems 236-EG), 10ng/ml 
FGF2 (Invitrogen PHG0263)].  Cells were maintained in appropriate dishes or multi well 
plates as required at 1.62 x 105 per cm2 area of the culture vessel. 
 
2.3.3  Preparation of Cell Lysates 
Cells were briefly washed with PBS and then lysed in to ice cold cell lysis buffer 20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 10mM DTT 
with Roche protease inhibitor, phosSTOP (Roche, 04906837001), 2mM NEM (N-
ethylmaleimide).  The cell suspension was then incubated on an end-over-end rotor at 
4°C to ensure proper cell lysis and then centrifuged at 13,000 g for 10 min at 4°C.  The 
protein concentration in the supernatant was analysed by Bradford method (Bradford, 
1976). 
 
2.4    Protein techniques 
2.4.1  Co-Immunoprecipitation 
Cell lysates were adjusted to equal protein amount (1 μg/μl) using cell lysis buffer. Cell 
lysates normalised for the protein concentration were incubated with mouse IgG 
(Millipore, 12487) Protein A agarose beads (life technologies, 15918-014) for 2 hr at 4°C.  
Agarose beads were collected after a brief centrifugation and the collected supernatant 
was added with HA tagged agarose (SIGMA; A2095) washed 3 times in cell lysis buffer and 
the final volume is adjusted to 750 µl and incubated over night at 4°C.  The beads were 
precipitated and washed three times to remove non-specifically bound proteins.  Immune 
complexes were eluted from the beads by boiling them in SDS loading buffer.  The 
complexes were analysed on SDS PAGE.  Tagged agarose beads used in the present study 
include: Flag (Sigma), HA (Sigma), V5 (Abcam), IgG (Sigma). 
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2.4.2  Denaturing Co-Immunoprecipitation 
Cells were scraped in to cell lysis buffer with 1% SDS (Sodium Dodecyl Sulphate, an 
anionic detergent) and boiled for 5 min at 95°C.  Bovine pancreatic DNase 1 (EMD_BIO-
260913) was added to degrade the DNA and prevent the lysate from becoming viscous. 
The lysates were then spun down at 13000 g for 10 min to precipitate cell debris.  Lysates 
normalized for protein concentration were then diluted with the cell lysis buffer to a 
make final SDS concentration to 0.1%.  Immunoprecipitation was carried out as explained 
in previous section. 
 
2.4.3  SDS-PAGE 
Polyacrylamide gel electrophoresis (PAGE) was carried out to separate proteins based on 
their molecular weight.  SDS (Sodium Dodecyl Sulphate) is an anionic detergent which 
imparts uniform negative charge to the polypeptide backbone.  The cell lysates were 
boiled in  5x SDS loading buffer (10% SDS, 300 mM Tris-HCl, pH 7.2, 0.05% bromophenol 
blue, 50% glycerol, 10% β-mercaptoethanol) at 95°C for 5 min and were then loaded on 
to NuPAGE precast 4-12% gels in MOPS buffer along with  pre-stained protein marker 
(Bio-Rad).  Protein samples were resolved on the gel according to the manufacturer’s 
instruction manual. 
 
2.4.4  Western blotting  
The resolved proteins on NuPAGE gel were electrotansfered onto nitrocellulose 
membranes (Whatman GmbH) in 1X transfer buffer with 20% methanol for 2 hr at 27 V or 
overnight at 11 V.  The membrane was then blocked in 5% (w/v) non-fat dry milk (Marvel) 
in TBST (25 mM Tris-HCl; pH 7.6, 100 mM NaCl, 0.5% Tween 20) for 1 hr at room 
temperature or 4°C over night.  Membranes were then probed with specific primary 
antibodies at appropriate dilutions (Table 2.4) in 1% (w/v) marvel in TBST solution and 
incubated for 2 hr at room temperature or overnight at 4˚C.  The membranes were 
washed thrice for 15 min each in TBST.  Membranes are then probed with appropriate 
horseradish peroxide (HRP) conjugated anti-immunoglobulin G (IgG) secondary antibody 
(Table 2.5) diluted 1:5000 in 1% milk/TBST solution for 1 hr at room temperature.  
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Membranes were then washed 3 times for 10 min.  Chemiluminescence (ECL) Western 
blotting Substrate (Thermo Scientific) was used for detecting the HRP conjugates on the 
membrane. Chemiluminescent images of immune detected bands were recorded on blue-
light sensitive autoradiography X-ray films which were then developed using the Kodak® 
X-Omat Model 2000 processor.  Band intensities were quantified using image J (Girish and 
Vijayalakshmi, 2004). 
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Table 2.4  List of primary and secondary antibodies, their source and working dilutions. 
 
Primary Antibody Supplier Part number Host animal Dilution 
HA Santa Cruz sc-7392 Mouse 1:2000 
Penta His HRP Qiagen 34460 Mouse 1:2000 
Ubiquitin Lys 48 Millipore 05-1307 Rabbit 1:2000 
Ubiquitin Lys 63 eBioscience 14-6077-82 Mouse 1:1000 
FK2 (Pan mono and 
poly  ubiquitin chains) 
Enzo life sciences BML-PW8810-
0500 
Mouse 1:3000 
His HRP conjugated 
(Kit)  
Qiagen 34460  Mouse 1:2000 
Fbxw7 Abcam ab12292 Rabbit 1:1000 
c-Myc Santa Cruz Sc-764 Rabbit 1:2000 
Myc tag Cell Signalling  Mouse 1:1000 
α-Tubulin Sigma Aldrich T5168 Mouse 1:10,000 
GAPDH Merck Millipore AB2302 Mouse 1:20,000 
Alpha hDISC1 Gift from Prof. 
Takayama, 
University of 
Tokyo 
 Rabbit 1:1000 
(over night 
incubation) 
GFP Santa Cruz Sc-9996 Mouse 1:3000 
Flag HRP conjugated Sigma  Mouse 1:5000 
V5-HRP Invitrogen R961-25 Mouse 1:5000 
Ubc9 Santa cruz Sc-1-759 Rabbit 1:2000 
Cyclin E Cell signaling 4129 Mouse 1:2000 
Notch1 Cell signaling 3608 Rabbit 1:2000 
c-Jun Cell signaling 9165 Rabbit 1:2000 
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Table 2.5  List of secondary antibodies, their source and working dilutions. 
 
Secondary Antibodies Supplier Part number Dilution  
Mouse IgG - HRP GE healthcare NXA931 1:5000 
Rabbit IgG-HRP Sigma Aldrich A6154 1:5000 
IRDye 800CW Donkey anti-Mouse IgG  Licor 926-32212 1:10,000 
IRDye 800CW Donkey anti-Rabbit IgG Licor 926-32213 1:10,000 
 
 
2.4.5  SPOT synthesis of peptides – Mapping DISC1-FBXW7 
binding sites 
Peptide arrays were generated in- house by SPOT synthesis on the AutoSpot-Robot ASS 
222 (Intavis Bioanalytical Instruments).  Principle behind this technique is the spotting of 
25-mer peptides on a cellulose membrane.  These peptide arrays can be used to identify 
protein interaction motifs by overlaying with purified proteins.  It can also be used to 
perform in vitro assays like phosphorylation, SUMOylation etc.  Either domain within a 
protein or the full length protein can be spotted as overlapping 25-mer (for in vitro 
SUMOylation assay – section 2.4.6) or shorter peptides, each shifted by five amino acids 
to increase the reliability of the screen.  
 
To elucidate DISC1-Fbxw7 interaction, peptide library was generated constituting DISC1 
phosphodegron motif  C191-G-P-E-V-P-P-T-P-P-G-S-H-S-A-F-T-S-S-F-S-F-I-R-L215 , full length, 
N terminal truncations, C terminal truncation, with phospho Thr and phospho Ser at 198 
and 202 positions respectively.  This library was spotted (linked covalently) on to 
microscope glass slides.  Arrays were stored dry at -20°C prior to use.  The slides were 
washed in 1xTBST for 1 minute followed by blocking with 5% PhosphoBLOCKER (AKR-103, 
CELL BIOLABS INC.) in TBST (w/v) (150 mM NaCl, 0.1% Tween20, 20 mM Tris-HCl and pH 
7.5) for 1hr at room temperature to block non-specific binding.  The array was then 
incubated with 1μg/ml of purified, recombinant SCFFbw7 complex (Millipore, 23-030) in 1% 
PhosphoBLOCKER solution in TBST at 4°C overnight. Follwonig day, the array was washed 
3 times for 10 minutes in TBST and incubated with His-HRP antibody at 1 in 2000 dilution 
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in 1% blocking solution for 2 hours at room temperature.  After a further 3 washes the 
array was  exposed to ECL and film (as in section 2.4.4). 
 
 
Figure 2.1  Schematic of peptide array workflow 
Adapted from (Katz et al., 2011). 
 
2.4.6  In vitro SUMOylation of hDISC1 peptide array 
Human DISC1 (hDISC1) peptide array was pre-blocked in 5% (w/v) BSA (bovine serum 
albumin, SIGMA) in TBST for 1hr at room temperature with gentle rocking.  This was 
followed by a brief washing in TBST for 5 min.  SUMO kit (Enzo life sciences, UW8955) was 
used to SUMOylate hDISC1 peptide array.  This kit contains purified recombinant His 
tagged human SUMO1, SUMO2, SUMO3 proteins, active E1, E2 enzymes, ATP (required 
co factor for SUMO conjugation).  A reaction mixture was prepared with all the above kit 
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components and made up to 2ml with sterile PBS (phosphate buffered saline).  The array 
was incubated at 30°C for 60 min and then washed in TBST, 3 times for 5 min each.  This 
was followed by probing with His HRP conjugated antibody at appropriate dilution 
mentioned for 2hr at room temperature followed by 3 times, 5 min washes with TBST.  
The array was ECL detected as explained in section 2.4.4. 
 
2.4.7  Immunocytochemistry 
All immunocytochemistry studies were performed at Pfizer NRU, Cambridge, MA, USA, as 
a part of 10 week placement (discussed in chapter 5).  iPS cell colonies and neuronal 
progenitors (NPs) were stained for relevant markers for characterisation.  NPs were 
plated at 100 cells per cm2 area of 35mm MatTek dishes (Invitrogen).  Cells were fixed 
with 4% paraformaldehyde followed by three washes with TBS (Tris-buffered saline; 
150mM NaCl, 20 mM Tris, pH 7.4).  Cells were permeabilised by incubating with 0.2% 
Triton dissolved in TBS.  Cells were blocked for 1 hour with blocking solution (10% donkey 
serum, 4% BSA in TBS).  The primary antibody was diluted in antibody diluent (Dako, 
S0809) to required concentration (dilutions were represented in the Table 2.6 and 2.7).  
50 μl of diluted primary antibody was added to the coverslip for 2 hr or overnight 
incubation at 4°C.  The dishes were washed thrice with TBS.  The fluorescent antibody 
(Alexa 594-conjugated antibody or Alexa 488-conjugated antibody, depending on the 
primary antibody choice, was diluted at 1:200 using diluent and added to the dish for 1 
hour (this procedure was repeated if a second fluorescent probe was needed).  The 
coverslips were washed 5 times with TBS before mounting a cover slip with 
Immunomount (sandon). Cells were visualized using the Zeiss LSM 710 confocal 
microscope (Zeiss, Oberkochken, Germany).  
 
Table 2.6  List of Stem cell marker antibodies used to characterise the iPS cell lines 
 
Marker Localisation Host animal Dilution Source 
Oct4A Nuclear Anti rabbit  1 : 800  Cell signalling, 2890  
Tra-1-81 Surface Anti mouse 1:1000 Cell signalling, 4745S 
Nanog Nuclear Anti goat 1:100 Millipore, MABD24 
SSEA4 Surface Anti mouse 1:100 Millipore, MABD43034 
DAPI Nuclear   Invitrogen 
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Table 2.7  List of Neuronal Progenitor cell marker antibodies used to characterise the NPs 
generated from the iPS cell lines  
 
Marker Localisation Host animal Dilution Source 
Nestin Filament Anti Mouse 1:200 Millipore, MAB5326 
SOX-2 TF (nuclear) Anti goat 1:100 Santa cruz, SC-17319 
Pax6 Nuclear Anti Rabbit 1:300 Covance, PRB-278P 
 
 
2.4.8  Mass Spectroscopy sample preparation 
 
Figure 2.2  Schematic of Mass Spectrometry (MS) technique.  
Figure adapted from (Steen and Mann, 2004) 
 
Mass spectrometry is a powerful technique used to quantify unknown compounds, 
identify sample composition and characterise structure of various molecules such as 
proteins.  In the present study, MS studies were performed to detect the following: (1) 
DISC1-SUMO conjugates and the corresponding acceptor lysine residues (2) DISC1-
ubiquitin conjugates, type of ubiquitin chains and the acceptor lysine residues.  HEK293 
cells were transiently transfected with relevant constructs using Polyfect transfection 
reagent.  48hr post transfection, cell cultures were treated with MG132 at 10 µM final 
concentration (where ever applicable) before proceeding to cell lysis and subsequent co-
Immunoprecipitation (described in chapter 4 and 5 for DISC1 SUMOylation and DISC1 
ubiquitination respectively).  Flag tagged agarose beads or 14F2 (DISC1 antibody 1) were 
used as bait to detect DISC1-ubiquitin and DISC1 –SUMO conjugates respectively.  
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Immunoprecipitate complexes were separated using SDS PAGE on bis tris acrylamide gel.  
The gel was then stained with Colloidal blue stain, Invitrogen (part number: LC6025) 
according to manufacturer’s instructions.  This was followed by gel de-staining in ultra-
pure double distilled water over night.  Relevant bands of interest (as indicated in the 
respective results chapter 3 and 4) were then excised under sterile conditions.  The Mass 
spectroscopy analysis of the samples was out sourced to M.W. Keck Facility-Mass 
Spectrometry and Protein Chemistry Services Yale University, Connecticut, USA.  In brief, 
the proteins in the excised gel bands were subjected to double digestion with Glu-C (a 
serine protease which cleaves at the C-terminus of glutamic acid and aspartic acid 
residues) and trypsin (a serine protease which primarily cleaves proteins and peptides at 
the C terminal side of lysine and arginine).  Protein digests were analysed using Thermo 
Scientific LTQ-Orbitrap XL mass spectrometer.   
 
The MS spectra were searched using the Mascot algorithm for MS spectra data (Hirosawa 
et al., 1993).  MASCOT software search engine identifies proteins by comparing the MS 
data to peptide sequence databases.  This program cleaves the protein in silico depending 
on the cleavage enzyme used in MS and determines the theoretical mass of each peptide.  
Each peptide is then scored based on the probability of a match between the sample 
peptides and the protein database.  The score is a measure of the reliability of 
identification i.e., the number of peptides identified for each protein/peptide is 
proportional to the MASCOT score for that protein /peptide.  For details more details on 
MASCOT score, refer to http://www.matrixscience.com/home.html. 
 
 
2.4.9  Fluorescence polarization (FP) assay 
Purified ‘His6-tagged Fbw7 (residues 263-707)-Skp1’ protein complex was a kind gift from 
Bing Hao, Structural Biology Program, Memorial Sloan-Kettering Cancer Centre, New York, 
USA.  All the peptides used in the present study were custom made by Proimmune, UK.  
FP assays were performed in 384-well black, low-binding, round-bottomed plate (Sigma 
Aldrich) and read in Mithras LB 940 Multimode microplate Reader.  Saturation 
experiments were performed to determine the Kd values of fluorescently labelled traces 
(peptides)  with Skp1-Fbxw7 protein complex using 0.1 µM each of the peptides and serial 
dilutions of Skp1-Fbxw7 (example: 0.1 µM – 50 µM) in assay buffer PBS to produce a total 
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reaction volume of 10 µL.  Each assay plate was covered with adhesive aluminium foil 
before reading polarization values using 485 nm and 535 nm excitation and emission 
wavelengths with Mithras plate reader.  
 
Competitive FP binding assays were performed with 5 µL total volume of the fluorescent 
tracer (final concentration in the well - 0.1 µM) and Skp1-Fbxw7 complex (final 
concentration in the well 0.4 µM) was pipetted in each well in quadruplicates.  Disruptor 
peptide or compound was titrated in a dose dependent manner using no fewer than 6 
concentrations.  Compounds and the disruptor peptides were serially diluted to minimise 
pipetting errors.  For every assay negative controls were performed with the Skp1-Fbxw7 
complex.  The output reading was obtained as mP units (milli polarisation units).  mP 
values were plotted against log concentration of the protein complex (for binding assays) 
and compound/disruptor peptides (competition curves).  The principle of this assay and 
the Z′-factor for the competitive FP assay is further elucidated in chapter 6. 
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3.  
 
DISC1 is a potential SUMOylation target 
 
 
3.1  Introduction  
While the complex pathophysiology of schizophrenia remains unclear, a number of recent 
molecular studies have uncovered interesting new insights, which are crucial to the 
understanding of the disease mechanism.  Since its discovery, the DISC1 gene has been 
found to be associated with a range of psychiatric illnesses such as SCZ, bipolar disorder, 
major depression and autism (Hashimoto et al., 2006, Song et al., 2010).  Several groups 
have independently reported that genetic variations in DISC1 can be associated with 
abnormal brain function and structure, along with impaired cognitive functions (Carless et 
al., 2011, Singh et al., 2011, Nakata et al., 2009, Zhang et al., 2006).  Further to this, 
considerable effort has been put into understanding how DISC1 exerts its physiological 
function by studying its localisation and interacting partners.  DISC1 has been shown to be 
localised in various sub cellular compartments such as mitochondria  (Park et al., 2010) 
and the centrosome (Miyoshi et al., 2004) and altered localisation was reported to be 
associated with disease phenotypes.   
 
Independent studies have reported associations between SNPs (single Nucleotide 
polymorphisms) within the DISC1 locus and various clinical and morphological brain 
phenotypes in patients with SCZ (Lipska et al., 2006b, Hashimoto et al., 2006).  One such 
SNP, S704C, was identified in individuals with reduced hippocampal grey matter and was 
also identified in SCZ patients with positive symptoms (Leliveld et al., 2009, Singh et al., 
2011).  These studies suggest a role for the S704C allele in regulating human brain 
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morphology and function.  Other DISC1 variants such as L607F and R264Q have been 
reported in both healthy individuals and in SCZ patients, and are known to affect cortical 
morphology, though the exact mechanism by which these SNPs affect the brain 
morphology is as yet unclear.  It is interesting to note that no DISC1 mutations were 
observed  in certain  cases of chronic mental disorders (Leliveld et al., 2008).  Hence, in 
this scenario it’s unclear how a healthy DISC1 gene contributes to the disease aetiology.  
It may be hypothesised that post-translational modifications of DISC1 could be a reason 
for the wild type and the mutant DISC1 proteins becoming dysfunctional in these 
respective scenarios contributing to the pathophysiology of the disease. 
 
 
3.1.1  Evidence of DISC1 aggregation contributing to impaired 
neuronal function   
Carsten Korth and colleagues have conducted extensive studies of DISC1 aggregates in 
various cell lines (Figure 3.1).  They reported the presence of DISC1 in detergent insoluble 
fraction prepared from post mortem brain tissue of individuals with chronic psychiatric 
illness including SCZ (Korth, 2012).  Studies in neuroblastoma cells demonstrate that the 
100kDa DISC1 isoform can aggregate and that the resulting  insoluble fraction fails to 
interact with Ndel1, a well characterised DISC1 interacting partner (Leliveld et al., 2008).   
DISC1 aggregation also influences the selection of the scaffold’s interacting partners.  For 
example, DISC1 aggregates have a reduced ability to interact with Ndel1 (Leliveld et al., 
2008) while they co-recruit soluble fractions of Dysbindin (Ottis et al., 2011).  DISC1 
aggregation was also found to be influenced by cellular stress (such as hydrogen 
peroxide) and disease polymorphisms.  DISC1 Ser704Cys variant was shown to have an 
increased propensity to form aggregates (Korth, 2012).   
 
DISC1 aggregates are also cell-invasive, a scenario mirrored  in other psychiatric 
aggregation illnesses with proteins such as  α-synuclein and polyglutamine  (Bader et al., 
2012).  Independent studies by Kittler et al, reported the recruitment of GFP-DISC1 
aggregates to aggresomes and subsequent degradation by the autophagy pathway.  
Microscopic studies show  GFP-DISC1 co-localised with autophagy markers such as  LC3 
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(microtubule-associated protein light chain 3) in COS-7 cells and primary neuronal 
cultures (Atkin et al., 2012).  In COS7 cells, over-expressed GFP DISC1 co-recruits 
endogenous DISC1 from soluble fractions under physiological stress.  Mitochondrial 
transport and neuronal function is also be impaired due to increased DISC1 aggregation 
(Atkin et al., 2012).  This may be attributed to yet unknown conformational changes in the 
protein, which in turn may be influenced by post-translational modification events.   
 
 
Figure 3.1  Laser scanning confocal microscopy of DISC1 aggregates in neuroblastoma 
cells.  
Figure taken from Korth et al. (2012).  Mouse neuroblastoma cells (CAD cells) 
permanently transfected with monomeric red fluorescent protein (red) and transiently 
transfected with untagged, full length DISC1, stained with α-DISC1 mAb 14F2 and a 
secondary FITC-labelled antibody (green) and DAPI stained nucleus (blue). Scale : 10 µm   
   
Furthermore characterisation of these DISC1 aggregates led to the identification of a 
distinct oligomerization domain which lies towards the C-terminus (amino acids 640-854).  
Genetic variants within this region such as S704 and C704 were reported to disrupt this 
oligomerization of the DISC1 (Bader et al., 2012, Leliveld et al., 2009).  It is also interesting 
to note that this C terminal oligomerization domain on DISC1 corresponds to the 
fragment lost in the Scottish translocation, and therefore it may have an underlying and 
crucial role in the disease mechanism.  
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3.1.2  SUMOylation dependent regulation of protein aggregation 
in chronic mental disease  
As discussed in chapter 1, post translational modifications such as phosphorylation and 
SUMOylation have long been implicated in a number of neurodegenerative disorders, 
including Alzheimer’s  and Parkinson’s diseases (Bence et al., 2001).  SUMOylation is a 
post-translational modification characterised by the covalent conjugation of a small 
ubiquitin like modifier (SUMO) to the target protein.  The SUMO pathway is detailed in 
section 1.4.  The functional role of the SUMO pathway was emphasised by Ubc9 (SUMO 
E2 enzyme) knockdown studies, which show that this pathway is crucial for eukaryotic cell 
viability (Anderson et al., 2009).  Studies on the role of SUMOylation in the central and 
peripheral nervous system reveal a wide array of mechanisms by which this PTM can 
contribute to the neuropathology of various diseases.  Members of the SUMO cascade 
regulate the activity of several signalling molecules contributing to cerebellar 
development.  One such example is MEF2A, whose activity has been shown to be 
repressed by SUMOylation at K403 leading to post synaptic granule neuron 
differentiation (Martin et al., 2007).  Diseases such as NIID (Neuronal intranuclear 
inclusion disease) are characterised by neuronal intra-nuclear inclusions (NIIs) carrying 
SUMO-1 and SUMO substrates such as PML (promyelocytic leukaemia protein), RanGAP1 
and HDAC4 (histone deacetylase 4) (Takahashi-Fujigasaki et al., 2006). 
 
Emerging evidence describes SUMOylation as a powerful regulator of many signal 
transduction pathways and gene expression cascades, with a majority of SUMOylated 
substrates localised in the nucleus.  As previously discussed (in section 1.4.1), the 
functional consequences of SUMOylation of a substrate may include altered sub-cellular 
and sub-nuclear localization, altered gene expression, as well as cross-regulation with 
other post-translational modifications, such as ubiquitination.  Such consequences are 
often attained at the molecular levels via the alternation of protein - protein interactions 
of the SUMO conjugated protein, by altered protein conformation, inhibition of an 
existing binding site or the creation of a new binding site for the interacting proteins.    
Pathological protein aggregates formed as a result of altered protein folding, stability or 
targeting have been identified as a hallmark of many neurodegenerative disorders such as 
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Parkinson’s disease (aggregates of α-Synuclein constituting Lewy bodies) and Huntington 
Disease (aggregates of Htt protein).  However, recent studies have shown that deficiency 
of a SUMO acceptor lysine in α-synuclein renders the Lewy bodies more toxic than the 
wild type sequence (Krumova et al., 2011).  Although, in some instances the converse was 
true, where it was observed that SUMOylation reduced aggregation of mutant 
Huntington protein and ataxin-7.  There are also reports of SUMOylation dependent 
enhancement of aggregate formation, as seen in super oxide dismutase 1 (SOD1), a 
causative factor of  ALS (Amyotrophic lateral sclerosis, a motor neuron disease) (Krumova 
and Weishaupt, 2012). Progressive ataxia and dementia have also been demonstrated to 
be associated with insoluble protein aggregates, showing strong immune reactivity for 
SUMO1 (Martin et al., 2007). 
 
 
3.2  Experimental aims  
DISC1 has repeatedly been implicated as a candidate for susceptibility to SCZ and other 
chronic mental disorders, and such studies have also shed light on the role of DISC1 in 
neuronal development.  Formation of DISC1 aggregates and reports of cell invasion by 
these aggregates have provided proof of DISC1 mediated pathophysiology in mental 
illnesses.  However, the exact mechanistic relation of DISC1 to these diseases remains 
unclear.   
 
As several other aggregation prone proteins were known to be SUMO conjugated and 
SUMOylation has been strongly implicated in several so called ‘aggregopathies’ such as 
Parkinson’s disease, Huntington’s disease, it was hypothesised that SUMOylation may 
play a role in regulating the formation of DISC1 aggregates.   
 
My aims in the present section were: 
1. To determine whether DISC1 is a substrate for SUMO conjugation.  
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2. To identify SUMO acceptor lysines (K) on DISC1.  
3. To analyse the significance of my findings in light of what has already been published 
and to explore the future perspectives.    
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3.3  Results 
3.3.1  DISC1 is a putative SUMOylation target 
SUMOylation usually occurs on a lysine residue entrenched in a core consensus motif 
ψKxE/D (where ψ is a branched hydrophobic and x is any amino acid).  Ubc9 (the SUMO 
E2 enzyme) directly recognises this consensus motif and covalently bonds the SUMO 
residue to the lysine residue within this motif (Bernier-Villamor et al., 2002).  To add to 
the complexity of this system, certain SUMO substrates also contain SUMO Interacting 
Motifs (SIMs) which allow substrates to interact non-covalently with SUMO moieties 
(Meulmeester and Melchior, 2008).  The SUMOplot™ Analysis Program designed by 
Abgent to predict putative SUMO consensus sequences was used to determine if DISC1 
possessed SUMO consensus sequences.  The SUMOplot Analysis Program predicts and 
assigns probability scores to sites where SUMOylation may occur in a given protein.  The 
SUMOplot™ score system is based on the following criteria: direct amino acid match to 
SUMO consensus sequence, and substitution of the consensus amino acid residues with 
amino acid residues exhibiting similar hydrophobicity.  The results of the analysis 
suggested putative SUMO consensus sequences present within DISC1 (Figure 3.2). 
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Figure 3.2  SUMOPlot analysis of DISC1 protein sequence 
Human DISC1 Protein sequence (NCBI accession number NP_061132.2) was analysed 
using the free software SUMOplotTM developed by Abgent.  Link to SUMOPlot 
algorithm: (http://www.abgent.com/SUMOplot).  Lysine residues (K) with a higher 
score have a higher probability of undergoing SUMO conjugation.  
  
 SUMOplot software predicted 7 potential SUMO acceptor lysine residues on DISC1 
protein with varying probabilities (Figure 3.2).  K643 was predicted with high confidence 
score as it falls within a strict consensus ψKxE/D.  Other sites were sub-optimal in this 
regard and received lower scores. 
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3.3.2  DISC1 peptide array is selectively SUMOylated in vitro 
Although search engine software such as SUMOplot is useful in identifying the SUMO 
consensus sites on substrates, follow-up experiments are necessary to validate the sites.  
Novel peptide array technology has been employed in number of studies to characterise 
post-translational modifications such as Ubiquitination and SUMOylation.  This approach 
has been used to detect SUMO sites in substrates such as PDE4D5 (Li et al., 2010).  A 
study by K. Schwamborn and group describes a method by which peptide array 
technology can be employed to identify SUMO target (Schwamborn et al., 2008).  Peptide 
arrays of overlapping 25-mer peptides sequentially shifted by five amino acids and 
spanning the entire indicated DISC1 protein sequence (in Figure 3.1) were incubated with 
SUMOylation assay mixture and this was followed by the detection of conjugated SUMO 
with anti His antibody (to detect His-tagged SUMO moieties).  Dark spots represent 
positive areas of SUMO conjugation, while clear spots are negative for the modiﬁcation 
by SUMO (Figure 3.3).  While no spots were detected on a control array that contained  
the SUMOylation assay without the E2 ligase Ubc9, there were putative SUMO 
conjugation sites identified on the test array (Figure 3.3). 
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Figure 3.3  In vitro SUMOylation of DISC1 peptide array 
Upper panel: In vitro SUMOylation of peptide arrays of DISC1 protein.  Putative 
SUMOylation sites appear as dark spots, identified are highlighted in boxes numbered 
1,2,3.  Bottom panel: Corresponding peptide sequences of the spots.  Putative SUMO 
consensus site within the peptides are highlighted in red (K643, K743, K768).   
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Figure 3.4   Alanine substitution peptide arrays of the positive hits from in vitro peptide 
array analysis  
In vitro SUMOylation assay on alanine scanning peptide array of the peptides identified 
in Figure 3.3.  This peptide array library consisted of  peptides with SUMO consensus 
site sequentialy substituted with Alanine.  In vitro SUMOylation assay was carried out 
on these peptide array libraries and probed with His tag antibody (to detect His tagged 
SUMO moeities) (described in section 2.4.6).  Positive interaction appears as dark spot. 
SUMO consensus site moities were substituted with alanine are indicated in bold letters 
while each alanine substitution within this consensus is highlighted in red.  
 
 
 
Putative SUMO conjugation sites identified in initial DISC1 peptide array screen were 
further characterised by mutational analysis.  Positive peptides identified were re-
synthesised with sequential mutation of each amino acid to alanine and in vitro 
SUMOylation was carried out (Figure 3.4).  In sequences corresponding to spot 127 and 
146, replacing the residues within the consensus motif with alanine abolished the SUMO 
conjugation of those peptides.  However, in peptides corresponding to spot 154, replacing 
the motif with alanine had no or very little effect on SUMO conjugation indicating that 
the initial observation of positive SUMO attachment may be considered as an artifact.  
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While SUMO prediction algorithms and in vitro peptide array screens are extremely useful 
in identifying putative SUMOylation substrates, they are essentially artificial screening 
tools that require validation to account for their limitations.  It has been reported that 
this motif is found in over a third of all characterised proteins, which leads to the real 
possibility of identifying false positives using the SUMO prediction software (Song et al., 
2005).  Many other proteins with the characterised consensus motif are not SUMO 
targets, while many other proteins are SUMOylated at sites other than the consensus 
motif.  Hence, a range of biochemical validations are required before any physiological 
importance can be attributed to the modification. 
 
 
3.3.3   DISC1 is SUMOylated in HEK293 cells 
3.3.3.1 Ubc9 and PIAS E3 ligases enhance DISC1 SUMOylation 
SUMOylation is catalysed by Ubc9, an E2 conjugating enzyme and the E3 ligase, PIAS 
(PIAS1, PIAS3, PIASy).  Over expression of the SUMO E2 and E3 enzymes are known to 
enhance SUMO conjugation of certain substrates, such as  Smad4 (Lee et al., 2003).  The 
effect of co expression of the above mentioned SUMO E2 and E3 enzymes on DISC1 
SUMOylation was therefore investigated.  Figure 3.5 depicts the co-expression of Flag-
DISC1 with Ubc9, SUMO1/2 and various isoforms of PIAS (1/3/y).  Over expression of 
SUMO with the E2 and E3 ligase results in the retardation of the electrophoretic 
migration of Flag-DISC1 compared to that co-expressed with empty vector.  This suggests 
that DISC1 has been modified by SUMOylation.   
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Figure 3.5   Enhancement of DISC1 SUMOylation by SUMO modification enzymes 
HEK293 cells were transfected with Flag-DISC1, SUMO-1, or SUMO-2 in the presence of 
Ubc9 and PIAS (1, 3, y isoforms).  Cells were lysed in denaturing conditions and 
subjected to immunoblot analysis.  Anti-Flag antibody was used to analyse DISC1 
expression and alpha tubulin antibody was used as loading control.  Slow migrating 
DISC1 bands were indicated as SUMO modified DISC1 species.   
 
 
3.3.3.2  UFDS method based detection of DISC1-SUMO conjugates 
Most post translational modifications, although covalent in nature, are a two-way process 
whereby there is an adding step (example: phosphorylation by a kinase) followed by a 
subtraction step (example: dephosphorylation by a phosphatase).  This “on” and “off” 
switch allows downstream physiological changes to be transient, allowing  cells to return 
to their quiescent state in readiness for another functional event.  In this way, 
SUMOylation is regulated by SUMO conjugating enzymes (UbC9) and SUMO specific 
proteases which cleave off the SUMO moiety from the target protein i.e., DeSUMOylation 
enzymes.  As SUMOylation requires energy and is switched on following certain cellular 
signals, only a small fraction of cellular proteins are SUMOylated under steady state 
conditions (Hay, 2013).  As a result of this, the detection of SUMOylated proteins is 
notoriously tricky using conventional biochemical methods.  Basal levels of SUMO 
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modified and unmodified proteins are strictly maintained under the control of SUMO E3 
ligases and DeSUMOylating enzymes.  One confounding factor was that specific SUMO 
protease inhibitors were unavailable at the time of this study to stabilise the SUMO 
conjugated substrates for easy biochemical analysis.  In order to overcome these 
technical limitations,  the SUMOylation of DISC1 by a novel Ubc9 fusion–directed 
SUMOylation (UFDS) method described in Jakobs et al. (2007) was chosen to investigate 
DISC1 basal SUMOylation levels.  This study highlights enhanced SUMOylation of p53 and 
STAT1 when they were expressed as Ubc9 fusion proteins (p53-Ubc9 and STAT1-Ubc9).  
The principle behind the UFDS method is that substrates undergo SUMO conjugation 
even in the absence of SUMO E3 ligase when Ubc9 (SUMO E2 enzyme) is bought in to 
close proximity of a substrate by fusing it to the said substrate Figure 3.6).  This study 
provided a novel method to study the SUMOylation of substrates in a cellular context.   
 
To determine whether DISC1 is SUMOylated in cells, DISC1 was cloned in to plasmids that 
generate the fusion proteins with Ubc9 at the C-terminus (represented as WT DISC1-
Ubc9, DISC1 K643A-Ubc9, DISC1 Ubc9 C93S for WT, putative SUMO dead DISC1 mutant 
and Ubc9 dead mutant respectively).  HEK293 cells were transfected with the above 
vector together with GFP-SUMO1.  Use of GFP tagged SUMO1 facilitates the identification 
of SUMOylated DISC1 species because of increased molecular weight of the SUMO 
conjugate that can easily be detected as a more pronounced band-shift on a Western 
blot.  Over-expressed GFP was used as a negative control.  The protein extracts were 
analysed by immunoblot analysis, probing with a DISC1 antibody.  The gels revealed a 
number of slow migrating, higher molecular weight proteins (Figure 3.7) in the lysates of 
cells that overexpressed the DISC1-Ubc9 fusion and GFP-SUMO1.  These bands 
representing SUMOylated forms of DISC1 were not detected in the absence of GFP-
SUMO1 or where the fusions contained a catalytically dead Ubc9 (C93S) (DISC1 Ubc9 
C93S serves as a dominant negative since the cysteine residue at the active site of Ubc9 is 
mutated to Serine which abolishes SUMO-1 conjugating ability (Jakobs et al., 2007)).  
Interestingly, the DISC1 alanine mutant (K643A), whereby the DISC1 SUMO consensus site 
identified by algorithms and peptide array (section 3.3.1 and 3.3.2) was mutated, showed 
diminished SUMOylation suggesting that this is a definite SUMO site, but other sites must 
also exist. 
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Figure 3.6  Schematic representation of UFDS (Ubc9 Fusion Directed SUMOylation) 
method  
Adapted from (Jakobs et al., 2007).  SUMO E3 ligase- dependent SUMO(s) conjugation 
occurs when SUMO E2 enzyme Ubc9 is brought in close proximity to the substrate by a 
SUMO E3 ligase.  UFDS method bypasses the requirement of SUMO E3 enzyme by fusing 
a SUMOylation substrate (DISC1 WT/ K643A in the present study) to the SUMO 
conjugating enzyme Ubc9.   
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Figure 3.7  Ubc9 Fusion Directed SUMOylation (UFDS) of human DISC1 in Hek293 cell 
line 
The expression plasmids for DISC1-Ubc9, DISC1 (K643R)-Ubc9, DISC1-Ubc9 (C93S) were 
transfected into HEK293 cells either alone or together with the GFP-SUMO1 expression 
plasmid as indicated.  After 48 hr, the fusion proteins in the protein extracts were 
detected by Western blotting using a DISC1 antibody (Upper panel), GFP antibody 
(middle panel) and alpha tubulin (lower panel).  DISC1-Ubc9 proteins (WT and K643A 
mutant) DISC1-Ubc9 C93S mutant and their corresponding GFP-SUMO1 conjugates are 
indicated. 
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Figure 3.8  Validation of DISC1-SUMO species using two antibody approach 
The expression plasmids for DISC1-Ubc9, DISC1-Ubc9 (C93S) were co-transfected into 
HEK293 cells either with the GFP-SUMO1 or GFP expression (negative control)  plasmid 
as indicated.  After 48 h, immunoprecipittion was performed with a DISC1 raised 
against a specific epitope on DISC1 and immunobloted with another DISC1 antibody 
raised against a different epitope to the former DISC1 antibody.  Top panel: IP antibody 
: 14F2 , WB antibody: 14F2, Bottm panel:  IP antibody : 14F2, WB antibody : alpha 
DISC1.  IP was performed with an IgG antibody as a negative control.  DISC1-Ubc9, 
DISC1-Ubc9 C93S mutant and their corresponding GFP-SUMO1 conjugates are indicated. 
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By using the UFDS method, we established, for the first time, the novel post translational 
modification on DISC1, SUMOylation.  DISC1-Ubc9 fusion proteins were observed to be 
migrating at about 125kDa.  Co expression of these constructs with GFP-SUMO1 resulted 
in the appearance of high molecular bands on the immunoblots, which correspond to the 
DISC1–Ubc9 SUMO1 conjugates.  DISC1-Ubc9 C93S (DISC1 fusion with the catalytically 
inert form of UBC9) is completely devoid of these bands.  This observation confirms the 
specificity of SUMO conjugation.  A high molecular weight band was observed when 
DISC1-Ubc9 alone was overexpressed.  This could likely be a result of endogenous SUMO 
conjugation of the overexpressed DISC1 Ubc9 fusion construct (Figure 3.7).  
 
To validate the high molecular weight bands appearing in the immunoblots as SUMO 
DISC1 conjugates, immunoprecipitation was performed using UFDS lysates.  DISC1 
immunoprecipitation was performed using 14F2 (DISC1 antibody 1) and the immune 
complexes were probed with alpha DISC1 antibody (DISC1 antibody 2).  The presence of 
DISC1 – SUMO conjugates in both the immunoblots rules out the possibility of non-
specific DISC1 bands (Figure 3.8).   
 
The kinetics of SUMO conjugation on DISC1K643A Ubc9 mutant were also studied.  K643 
site was identified as a putative SUMO acceptor site on DISC1 in in vitro SUMOylation 
studies.  Ideally, alanine mutant at K643 should abolish the SUMO conjugation.  However, 
this was not the case, DISC1 SUMO conjugate bands can still be seen when an Alanine 
mutant at K643 was overexpressed with GFP SUMO-1, which indicates the presence of 
other potential SUMO acceptor lysine residues on DISC1 as predicted by SUMOPlot 
software (figure 3.7).  Hence, a mass spectrophotometry approach was employed to 
uncover potential SUMO acceptor sites on DISC1 as detailed in section 3.3.4.   
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3.3.4  Mass Spectroscopy studies to validate SUMO modification 
of DISC1 protein in vitro 
Identification of the type and site of post translational modification on a substrate of 
interest is a crucial step towards understanding the physiological role of the specific 
modification.  Consideration of the field of protein phosphorylation is a good example.  
Mapping of the site of phosphorylation and identification of candidate kinases has 
enormously contributed to our understanding of numerous signal transduction pathways.  
Mass spectroscopy (MS) is an advanced powerful tool, used to characterise proteins and 
peptides.  Hence, I took a MS approach to further validate DISC1 as a SUMO substrate and 
identify the SUMO acceptor lysines. 
 
To ensure maximal amounts of SUMOylated DISC1, once again the UFDS approach 
described in the previous section was used.  DISC1-Ubc9 was co-expressed with GFP-
SUMO1 in HEK293 cells.  48hr post transfection, cell lysates were prepared under 
denaturing conditions and DISC1 was immunoprecipitated using 14F2 (DISC1 antibody 1) 
antibody.  DISC1 immuno complexes were subjected to SDS-PAGE separation.  SDS-PAGE 
gels were stained with Colloidal Blue (Invitrogen) and bands were excised at indicated 
molecular weights in Figure 3.9, upper panel.  Western blot analysis from the same 
samples and subsequent probing with α-DISC1 (antibody 2) - Figure 3.9 (lower panel) 
ensured the fidelity of the immunoprecipitations in isolation of DISC1. 
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Figure 3.9  Preparation of mass spectroscopy samples for the detection of DISC1 
SUMOylation 
The expression plasmids for DISC1-Ubc9, DISC1(K643A)-Ubc9, DISC1-Ubc9 (C93S) were 
co-transfected into HEK293 cells together with the GFP-SUMO1 or GFP expression 
plasmid as indicated.  Immunoprecipitation was performed with a DISC1 antibody 
1(14F2) or IgG antibody (negative control).  Top panel: Immunoprecipitate complexes 
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were separated by PAGE technique and coomassie stained.  The number of bands 
indicated in the Figure (lane 5, highlighted in red) have been excised from the stained 
gel and stored for further analysis. Bottom Panel:  5µl of each sample have been 
analysed by Western blotting and probed with anti DISC1 antibody to confirm the 
presence of DISC1-SUMO conjugates.  DISC1-Ubc9 proteins (WT and K643A mutant) 
DISC1-Ubc9 C93S mutant and their corresponding GFP-SUMO1 conjugates are indicated.  
 
 
 
Table 3.1  Summary of DISC1- SUMOylation Mass Spectroscopy studies  
 
 
The above table depicts the prescence of DISC1 at two different molecular weights which 
correspond to post translationaly modified (PTM) DISC1 species in the respective samples 
Column 1 represents the lane number followed by the sample number assigned in Figure 
3.9. Example: 5.4 represents lane 5 and sample 4.  Column 2 is the precise molecular 
weight on the gel at which the band has been excised. Column 3 represents the peptide 
identified in the respective sample with the SUMO conjugated lysine highlighted in red. 
Column 4 is the position of lysine residue identified to be SUMO conjugated in the 
sample.  Column 5 is the type of SUMO modification detected and column 6 is the 
MASCOT score, which was found not to be significant (MASCOT score explained in section 
2.4.8).   
 
MS studies positively detected DISC1 peptides at molecular weights higher than 125 kDa 
(additive molecular weight of DISC1-Ubc9) indicating potential DISC1-SUMO conjugation.  
SUMO343 represents the molecular mass (~343 Da) of the peptide ‘QTGG’ generated from 
SUMO1 after GluC digestion (specific for Carboxyl side of Glutamate residue).  K788 was 
identified as a putative SUMO acceptor lysine.  However, the percentage peptide 
coverage within the samples analysed was too low indicating high contamination or poor 
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sample quality.  Although DISC1 peptides were detected in the other samples, the 
confidence scoring was too low to be considered.  (The principle of Mass spectroscopy 
techniques is explained in section 2.4.8). 
 
 
3.3.5  Consequences of DISC1 SUMOylation – effect on its protein 
interactions  
SUMO modification of substrates has many physiological consequences.  Since SUMO 
proteins are about 10kDa size proteins, covalently conjugated to its substrate, this bulky 
modification may either cause stearic hindrance thereby interfering with protein – 
protein interactions or create additional binding surface on the substrate and promote or 
strengthen protein interactions (Jentsch and Psakhye, 2013).  Hence, we made an 
attempt to understand the effect of SUMO modification on DISC1, on its protein 
interactions.  DISC1 is known to bind many proteins involved in several  critical signalling 
pathways reviewed in (Bradshaw and Porteous, 2010).  Out of all these interacting 
partners we were particularly interested in two crucial interactors – nuclear distribution 
protein nudE-like 1 (Ndel1) and dishevelled axin domain containing 1 (DIXDC1) for the 
following reasons:  1. Ndel1, a component of the dynein motor protein complex interacts 
with DISC1 at the centrosome and mediates neurite outgrowth, migration and cortical 
development (Ozeki et al., 2003a, Morris et al., 2003).  2. DISC1 interaction with DIXDC1 
was shown to mediate embryonic neural progenitor proliferation and neuronal migration 
(reviewed in section1.2.3) (Bradshaw and Porteous, 2010, Singh et al., 2010). 
 
To investigate the effect of SUMO conjugation of DISC1 on its interaction with the above 
mentioned proteins, we employed the UFDS method to enhance DISC1 SUMOylation 
while co-expressing DISC1 binding partner of interest in HEK293 cells.  
Immunoprecipitation was performed using an antibody specific for the tag on the 
interacting partner as bait, followed by Western blot analysis of the immnuoprecipitate 
complexes by probing for DISC1 antibody, to examine if the binding partner precipitated 
only with unSUMOylated DISC1-Ubc9 or SUMOylated DISC1-Ubc9 or both. 
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Figure 3.10a  DIXDC1 may interact only with unSUMOylated DISC1  
Western blot analysis of DIXDC1 and DISC1 co-immunoprecipitation (Figure legend in 
next page under Figure 3.10b).  
This work was performed by Elizabeth M Cannell, Gardiner Laboratory, University of 
Glasgow.   
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Figure 3.10b  Ndel1 interacts with both SUMOylated and unSUMOylated DISC1 
Western blot analysis of Ndel1 and DISC1 co-immunoprecipitation assay.  Following 
overexpression of indicated constructs in HEK293 cells, lysate was incubated with the 
indicated antibody.  Mouse IgG antibody was use in the negative control IP.  The first 
three lanes of the blots are cell lysate, while the next three lanes were loaded with 
proteins isolated by the immunoprecipitation assay by mouse IgG and last three lanes 
with those isolated with Myc antibody (tag on DIXDC1 and Nudel1).  Top panel: blots 
probed with DISC1 Ab and bottom panel: blots probed with Myc antibody.   
 This work was performed by Elizabeth M Cannell, Gardiner Laboratory, University of 
Glasgow. 
 
 
Co-imunoprecipitation experiments revealed that SUMO conjugation of DISC1 may 
interfere and abolish its interaction with DIXDC1.  As it can seen in Figure 3.10a, the high 
molecular weight DISC1-Ubc9 – SUMO conjugates  are absent in both the test IP and 
negative control IP lanes (highlighted in  box, Figure 3.10a).  However, these results were 
inconclusive.  Since, the SUMOylated DISC1-Ubc9 bands (bands above 100kDa) were faint 
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in the input lanes (first three lanes) it could be possible that the SUMO DISC1-Ubc9 levels 
in the immunoprecipitates were too low to be detected.  More experimental repeats are 
needed to ascertain this, which was not within the scope of this project.   
Similar experiments with Ndel1 revealed that SUMOylation of DISC1 does not alter its 
interaction with Ndel1 (Figure 3.10b) and the slow migrating, high molecular weight 
DISC1-Ubc9-SUMO bands are present in the test IP lane but not the negative control lane 
(highlighted with red box Figure 3.10b).   
 
 
3.4  Discussion 
3.4.1  DISC1 is modified by SUMO1 
It has been established through the last two decades that post-translational modifications 
(individually or co-operatively) regulate many signal transduction pathways (Prabakaran 
et al., 2012).  SUMOylation is one such kind of modification that is increasingly garnering 
interest in the field of chronic mental disease research due to its role in protein 
aggregation and solubility, a hallmark feature of many neurological disorders (Krumova 
and Weishaupt, 2013, Krumova and Weishaupt, 2012). 
 
It has been established here that there is a novel post translational modification on DISC1 
in the form SUMOylation.  DISC1 could be covalently modified by SUMO1 conjugation at 
one or more site, as the SUMOplot algorithm identified number of putative consensus 
SUMOylation motifs on DISC1 (Figure 3.2).  In vitro peptide array studies identified three 
of the predicted motifs K643, K768 and K743 (Figure 3.3, 3.4).  However, Alanine 
substitution scans of the putative sites identified in the initial peptide array screen 
validated only two of those motifs, K643 and K743 (Figure 3.4).  My preliminary studies 
focused on the characterisation of the K643 site as it was predicted to be more likely to 
be SUMO conjugated implied by highest score of 0.93 in the SUMOplot algorithm, while it 
is also conserved in mouse and human.  However, mutational studies on DISC1 K643R-
Ubc9 conjugate reduced but did not completely abolish SUMO modification.  This may be 
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because of the presence of more than one SUMO acceptor site as predicted by SUMOplot 
algorithm.   
 
Studies show that the mere presence of consensus Lys residues in the SUMO motif is 
often not sufficient for recognition by the SUMO conjugation machinery, there are other 
criteria such as the presence of downstream acidic patches or pre-existing 
phosphorylation (Yang et al., 2006).  If the lysine residues are embedded in stable 
structural helices, it may not be recognised by the SUMO conjugating enzyme, Ubc9.  
However, it is important to note that certain substrates are SUMOylated at a non-
consensus lysine residue, for example, human E2-25K (Pichler et al., 2005).  If this is the 
case, it is difficult to predict such random sites.  The UFDS method has proved to be 
useful in efficient SUMOylation of DISC1 in my cell line model and this represents the first 
reliable indication that DISC1 can be SUMOylated in vitro.   
 
Mass spectroscopy, was also used in the present study to verify DISC1 as a SUMO 
substrate and identify the site of post translational modification.  DISC1-Ubc9 migrates at 
about 125kDa on SDS-PAGE; however, as expected, the MS study detected DISC1 
peptides in samples excised at molecular weights greater than 125kDa indicative the 
putative post translational modification by SUMO.  Though all modifications could not be 
identified, SUMO343 modification was detected at K788 (SUMO343 refers to the molecular 
weight of the putative adduct, 343.1492 Da molecular weight corresponds to the peptide 
‘QTGG’ remaining after GluC cleavage of a SUMO1-modified lysine). Only one SUMO 
acceptor lysine was identified in the MS studies while several bands are observed in UFDS 
methods based immunoblots.  From the MS spectral data it was evident that the sample 
quality was not optimal.  Absolute identification of SUMOylation sites on substrates has 
always been challenging due to the reversible dynamic nature of SUMOylation (achieved 
by the action of SUMO conjugation and deSUMOylating/SUMO protease enzymes in cells) 
which deteriorates the sample quality.  SUMO1 forms chains less efficiently in vitro since 
it lacks the internal SUMOylation site which is present in SUMO 2 and SUMO 3 (Vertegaal, 
2007).  Also, successful detection of SUMO sites depends on the sensitivity of mass 
spectrometer which can retrieve less abundant SUMOylated peptides from the MS 
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samples (Knuesel et al., 2005).  Unfortunately technical and biological repeats for MS 
studies were not feasible in this project due to time constraints and budgetary concerns.  
 
It is also important to note that just as any other post translational modification, 
SUMOylation is spatio temporally regulated which confers additional levels of regulation 
(Loriol et al., 2012).  It may be triggered by a physiological stimulus or other pre-existing 
post translational modification such as phosphorylation as seen in case of c-Jun and p53 
SUMOylation (which require a phosphorylation event) (Muller et al., 2000).  With no 
knowledge of the above stimuli nor the tertiary structure of DISC1, it would be difficult to 
induce enough SUMOylation in cells to generate high quality samples for MS, which may 
generate more information on this modification.  However, my work provides a number 
of different avenues of biochemical proof that the SUMO conjugation of DISC1 occurs in 
vitro. 
 
3.4.2  Significance of DISC1 as a SUMO substrate 
Over the past few decades, there have been very few developments in psychiatric drug 
development and most of the newer antipsychotics and anti-depressants have been 
reported to cause severe side effects.  The increasing characterisation and appreciation of 
the DISC1 interactome is a factor that may provide novel opportunities to discover new 
classes of brain function altering drugs (Hikida et al., 2012, Soares et al., 2011). 
 
Demonstration of the SUMO conjugation of DISC1 opens up new opportunities to explore 
its physiological functions.  DISC1 is known as a scaffold protein with no reported 
enzymatic activity.  Several of its interactions have been studied and known to influence 
various neuronal signalling pathways (Bradshaw and Porteous, 2010, Chubb et al., 2008).  
One of the molecular consequences of SUMO conjugation of a substrate is a 
conformational change leading to altered protein- protein interaction.  Hence my studies 
may prove useful in developing further understanding how DISC1 interactions are 
modulated. 
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SUMO and other post translational modifications are known to regulate many aspects of 
substrate proteins.  Phosphorylation of DISC1 orchestrates neuronal progenitor cell 
migration and proliferation in mice (Ishizuka et al., 2011c).  Some substrate proteins 
require a pre-existing phosphorylation to induce SUMO conjugation as seen in regulation 
of heat shock factor HSFb and MEF2 (Hietakangas et al., 2006).  SUMOylation and 
ubiquitination are also known to cross-talk via regulation of each other’s respective 
enzymatic cascade.  This type of regulation is quite evident in E2-25K, an E2 enzyme , 
which loses its ubiquitin conjugating ability upon SUMOylation (Pichler et al., 2005).  The 
next chapter investigates another novel modification crucial in regulating DISC1 protein 
turn over: ubiquitination.   
 
Post translational modification by SUMO conjugation has been shown to influence 
subcellular localisation of substrates such as RanGAP (a small GTPase activating protein).  
While SUMO-RanGAP is co-localised with the nuclear pore complex, its unmodified 
counterpart is predominantly cytoplasmic (Matunis et al., 1996).  DISC1 is hypothesised to 
exert its function by interaction with specific proteins in discrete sub cellular 
compartments.  For example, DISC1 is known to interact with NudE-like (NUDEL/NDEL1) 
at the centrosome and activating transcription factor 4 (ATF4)/CREB2 in the nucleus 
(Kamiya et al., 2005a, Morris et al., 2003).  A 75kDa DISC1 isoform has been reported to 
be specifically enriched in the nucleus in brain autopsies of patients with sporadic 
schizophrenia and major depression as well as substance and alcohol abuse (Sawamura et 
al., 2005a) suggesting its role in the pathophysiology of these major mental illnesses. 
Hence, it would be interesting to investigate the role of SUMO conjugation on sub cellular 
targeting of DISC1.  
 
In an attempt to develop a fly model expressing human DISC1, Akira Sawa and colleagues 
have shown that DISC1 appears in a punctate pattern co-localised with PML protein, a 
core component of PML nuclear bodies (Sawamura et al., 2008).  Another study has 
shown that SUMO1 conjugation of PML protein is necessary for formation of PML bodies 
(Zhong et al., 2000).  Hence, it would be interesting to investigate if DISC1 aggregation is 
regulated by SUMO modification.   
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In this project, the effect of SUMO modification of DISC1 on its interacting partner profile 
was explored (section 3.3.5).  Of the two binding proteins chosen, DIXDC1 was likely to be 
interacting with non SUMOylated DISC1 although the results were inconclusive and 
require further characterisation.  DISC1 functionally interacts with DIXDC1 and regulates 
neuronal progenitor proliferation during early brain development  by modulating  Wnt-
GSK3β/β-catenin pathway (Singh et al., 2010).  Their role in neuronal migration was 
suggested to occur through a pathway independent of Wnt/β-catenin signalling (Singh et 
al., 2010).  If SUMOylation of  DISC1  indeed abolishes  its interaction with DIXDC1, it is 
likely that this PTM on DISC1 may be a  crucial event during early brain development and 
is influenced by DIXDC1-DISC1 complex formation.    
 
Another interacting partner studied in this context is Nudel1, is a Cysteine protease 
(endo-oligopeptidase A (EOPA)) whose activity is inhibited by DISC1 interaction in in vitro 
assays (Hayashi et al., 2005).  Nudel also regulates neuronal differentiation of PC12 cell 
line (Ozeki et al., 2003a).  Co-immunoprecipitation experiments show that Nudel1 
interacts with both SUMOylated and non SUMOylated DISC1.  However, these 
experiments are only qualitative and do not provide any information on the strength of 
binding or interaction.  Presence of SUMO Interacting Motifs (SIMs) on proteins increases 
their binding affinity  to proteins which are covalently conjugated to SUMO proteins, 
which is one of the possible consequence of protein SUMOylation  (Jentsch and Psakhye, 
2013).    
 
Co-immunoprecipitation experiments performed in rodent brain lysates have shown that 
binding occurs between the C terminal region (fragment spanning from 596 to 852 
residues) of DISC1 and region between the calponin homology domain and the coiled-coil 
domain of DIXDC1 (Singh et al., 2010).  Ndel1 interacts with the C-terminal domain of 
DISC1 (residues 727-854) (Ozeki et al., 2003a, Soares et al., 2011).  As stated earlier, the 
binding sites for DIXDC1 and Nudel1 on DISC1 overlap.  It has been suggested that Cdk5 
mediated phosphorylation on DIXDC1 results in the formation of  DISC1/DIXDC11/Ndel1 
complex which is indispensable in neuronal migration (Singh et al., 2010).  Taking this in 
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to account, it is likely that SUMO conjugation of DISC1 may act as a trigger between 
neuronal progenitor proliferation and migration and this event mimics the 
phosphorylation event on DISC1 which acts as a molecular switch between proliferation 
of mitotic progenitor cells enabling the migration of post-mitotic neurons.  Putative 
truncated protein in the DISC1 translocation in the Scottish pedigree (TrDISC1) lacks the 
binding site for both these proteins as well as the identified SUMO acceptor lysine (K643 
and K788). Hence, it is likely that this PTM on DISC1 influences various physiological 
events possibly mediated by its interactions with various proteins.   
Given the role SUMOylation in CNS related disease pathways (reviewed in section 1.4.2) it 
can be considered as an attractive target for therapeutic intervention.  For example the 
increase in overall protein SUMOylation observed in neurons is a neuroprotective 
response (Loftus et al., 2009) while SUMO-1 expression has been shown to rapidly 
increase during hypoxia (Shao et al., 2004).  It would be interesting to investigate if SUMO 
conjugation of DISC1 has such a role to play in the disease mechanism of DISC1 associated 
psychiatric illnesses.   
To this end, future work should  1. Unequivocally identify the SUMO sites on DISC1  2. Use 
site directed mutagenesis to block the SUMO acceptor sites  3.analysis of the aggregation 
and cellular location of Wt vs mutant SUMO-null DISC1.  Interesting insights into the 
functionality of the SUMOylation of DISC1 in animal models could be gleaned by 
generating transgenic mice carrying DISC1 mutations at SUMO conjugation sites. 
 
3.5  Chapter summary   
In summation, my work presented in this chapter uncovers a novel post translational 
modification on DISC1 in the form of SUMOylation.  In vitro SUMOylation of DISC1 
peptide array identified K643 as a potential acceptor lysine.  SUMOylation of arginine 
mutant at K643 site on DISC1 was attenuated using the UFDS method suggesting that this 
site as a principle SUMO conjugation site on DISC1.  However, this site could not be 
verified using MS studies due to poor sample quality.  Our co-immnoprecipitation studies 
also suggest that SUMO modification of DISC1 may abolish its binding with DIXDC1, while 
its interaction with Nudel1 remained unaffected. 
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4.  
 
Proteasomal regulation of human DISC1 
protein 
 
 
 
4.1  Introduction  
Gene expression studies carried out on the post-mortem brain tissue of subjects with SCZ 
has provided insight in to possible involvement of ubiquitin proteasome system  
dysregulation in the SCZ disease mechanism.  A number of studies used cDNA microarrays 
to evaluate the profile of differential gene expression in these samples vs control.  
Consequently, Ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinating 
enzyme with predominant expression in CNS (known to be associated with neurological 
disorders such as AD and PD) and PSMC6 (proteasome 26S subunit, ATPase, 6 encodes 
one of the catalytic subunits of the 20S subunit of the proteasome) are two candidate 
genes that were signiﬁcantly down-regulated in subjects with SCZ (Altar et al., 2005, 
Vawter et al., 2001).  Another study used a blood based micro-array approach to screen 
for the gene expression patterns from SCZ and BD patients belonging to two different 
ethnic groups and in doing so, identified a number of UPS genes to be dysregulated 
(Bousman et al., 2010).  Various other reports of  altered gene expression of UPS 
components in SCZ and Bipolar disorder (Middleton et al., 2002) garnered my interest. 
 
The functional role of DISC1 in neuronal development was initially investigated by 
delineating its interacting partners using a yeast 2 hybrid screen (Millar et al., 2003, Ozeki 
et al., 2003b).  Key proteins involved in neuronal development, neuron migration and 
synaptic signalling have been identified in these screens.  These studies emphasise the 
functional significance of DISC1 in brain development and strengthen its role in disease 
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mechanisms of psychiatric illnesses such as SCZ and certain mood disorders (Hashimoto 
et al., 2006).  The  effects of DISC1 knockdown has been studied using various methods.  
In utero  gene transfer was used to transiently knockdown DISC1 in mouse models to 
understand  its role in growth and maturation of the brain (Niwa et al., 2010).  This study 
used GFP tagged DISC1 shRNA, which was injected in to the pre frontal cortex of mice 
brain at E14.  This resulted in morphological abnormalities in postnatal meso cortical 
dopaminergic maturation, in turn, resulting in several behavioural abnormalities in 
adulthood (Niwa et al., 2010).  shRNA mediated DISC1 knockdown in cortical precursor 
cells in ventricular zone, abolished the  migration of cells in to the cortical plate (Kamiya 
et al., 2005b).  
 
Various independent studies focused on the functional consequences of the truncated 
form of DISC1 protein (Millar et al., 2000c)) and revealed its dominant negative role.  Over 
expressed C-terminal truncated DISC1 (TrDISC1, amino acids 1-597) has been shown to 
interfere with the wild type protein product of the functional allele affecting its function, 
subcellular localisation and microtubular dynamics (Ozeki et al., 2003a, Kamiya et al., 
2005b).  However, it should be noted that TrDISC1 protein has not been detected in cells.  
Apart from the Scottish pedigree, several other groups independently reported many 
other SNPs within the DISC1 locus in various ethnic groups to be associated with chronic 
mental illnesses (Zhang et al., 2006, Saetre et al., 2008, Callicott et al., 2005).  Exonic 
polymorphisms such as S704 and C704 have been implicated in SCZ and major depression 
respectively (Leliveld et al., 2009, Song et al., 2010).  However, the effect of these SNPs or 
truncations on the protein confirmation or stability has not been investigated. 
 
The hallmark of many psychiatric illnesses is pathological aggregation of defective or 
mutant proteins resulting in dysregulation of key signalling pathways, ultimately leading 
to chronic neurological disorders such as  Alzheimer’s disease, Creutzfeldt-Jakob’s 
disease, Parkinson’s disease and Huntington’s disease (Leliveld et al., 2009).  A study of  
DISC1 dimerisation and oligomerisation, revealed interesting leads regarding the 
pathological role of DISC1 (Leliveld et al., 2009). The presence of sarkosyl (detergent) 
insoluble DISC1 aggregates in the brains of a sub set of cases with mental disease can be 
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triggered by subtle conformational changes and possibly yet unknown posttranslational 
modifications (Leliveld et al., 2008).  These putative post translational modifications in 
turn might abolish or create new interacting partners leading to loss or gain in function.   
 
In spite of the increasing evidence that DISC1 is a key susceptibility factor in SCZ, not 
much is known about its turnover/half-life and whether its regulatory mechanisms at the 
protein level depend on its cycling synthesis or degradation.  Very few studies 
investigated the levels of DISC1 at the transcript and protein level.  Increased DISC1 
transcript levels were reported in peripheral blood mononuclear cells of patients with 
schizophrenia.  In an effort to identify a suitable biomarker for SCZ, the above study 
compared the transcript levels of various DISC1 isoforms in blood samples of patients 
experiencing psychosis, to those samples collected after neuroleptic doses of haloperidol 
was administered.  A predominant decrease in DISC1 transcript levels was reported  
following the treatment, suggesting a strong association of DISC1 levels to the disease 
mechanism (Olincy et al., 2011).  Another study used immunostaining techniques to 
investigate the effect of epileptic seizures on DISC1 levels in adult rats (Fournier et al., 
2009).  Electrically induced epileptic seizures significantly reduced DISC1 immunolabeling 
within the dentate gyrus, while the width of the granule cell layers remained the same 
between the control and induced (Fournier et al., 2009).  This study by Fournier and 
collegues suggests the crucial role of DISC1 levels in cytoarchitectural abnormalities of the 
dentate gyrus observed in some SCZ subjects (Arnold, 1999). 
 
Approximately 10-20% cellular proteins are short lived, with a half-life less than 3 hours. 
Studies using proteasomal inhibitors show that up to 90% cellular proteins are degraded 
by UPS (Lee and Goldberg, 1998).  Ubiquitinated substrates are short lived and it is 
challenging to capture the signal of ubiquitinated protein of interest using conventional 
biochemical techniques.  Proteasome inhibitors, hence, are very useful to stabilise cellular 
levels of modified proteins.  Proteins, whose turnover is regulated by UPS, should 
accumulate, in a ubiquitin-conjugated form, upon proteasome inhibition.  My initial 
experiments were concerned with investigating the consequences of inhibiting the 
proteasome on DISC1 and studying the dynamics of DISC1 ubiquitination (L isoform).  
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Commonly used proteasome inhibitors are Lactacystin, Epoxomicin and MG132.  
Lactacystin, a β lactone, is a natural microbial product which exerts its inhibitory action by 
undergoing partial hydrolysis forming clasto-lactacystin, which interacts with proteasome 
(Dick et al., 1996).  Epoxomicin, an α1, β1 – epoxy-ketone tetrapeptide, is also a natural 
bacterial product which inhibits chymotrypsin-like, trypsin-like, and peptidyl glutamyl 
peptide-hydrolyzing (PGPH) activities of the proteasome.  Epoximicin is 80 fold more 
potent than lactacystin (Meng et al., 1999).  MG132, a peptide aldehyde, has been chosen 
in the present study as it is inexpensive compared to the others.  Its structure and 
mechanism of action is explained in the following section.  
 
 
4.1.1  MG132- Structure, Mechanism of action 
MG132 is one of the first groups of proteasome inhibitors to be synthesised that belong 
to the class of peptide aldehydes.  These inhibitors were developed on the basis of 
substrate specificity (Lee and Goldberg, 1998).  MG132 (Carbobenzoxy-Leu-Leu-leucinal) 
is structurally a substrate analogue which inhibits the chymotrypsin like activity in the 20S 
subunit of the proteasome.  It is a cell permeable small molecule, which exerts it 
inhibitory function by the formation of a transition state analogue.  However, the 
proteolytic enzyme activity is gradually restored by the hydrolysis of the covalent bond 
between MG132 and the enzyme complex, hence the inhibition is reversible.  Its IC50 is 
0.1μM for chymotryptic activity of the proteasome and its Ki is 4nM.  MG132 also induces 
neurite outgrowth in rat PC12 cell line (Obin et al., 1999). 
 
Figure 4.1  Chemical structure of Proteasome inhibitor MG132  
Carbobenzoxy-Leu-Leu-leucinal.  
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4.2  Experimental aims  
DISC1 has already been established as a susceptibility factor in SCZ and other related 
illnesses.  Increasing evidence also suggests dysregulation of the UPS pathway in various 
psychiatric disorders.  Reduced DISC1 protein levels observed in tissue collected from 
subjects with SCZ may be a part of the actual disease mechanism which is not yet 
understood  (Lipska et al., 2006a) . 
 
Hence I set out to investigate the following in this chapter: 
 
1. To determine whether DISC1 protein levels are regulated by the ubiquitin proteasome 
system (UPS). 
2. To identify E3 ligase components of the UPS system that mediates DISC1 
ubiquitination. 
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4.3  Results 
4.3.1 Proteasomal regulation of DISC1 protein in HEK293 cell line 
HEK293 cells are derived from Human Embryonic Kidney cells by transformation with 
sheared adenovirus 5 DNA.  Their ease of culture, maintenance, transfection and 
transduction made them a popular choice of cell line for various studies.  Regardless of 
their origin, HEK293 cells exhibit a number of neuronal characteristics such as expressing 
all sub units of neuroﬁlament proteins, neuron specific enolase and Tau (Campbell et al., 
2005).  They also express functional ion gated calcium potassium channels (He and 
Soderlund, 2010). In spite of the availability of neuroblastoma cell line SH-SY5Y, HEK293 
cells were chosen for my study for the following reasons: higher detectable DISC1 protein 
levels and ease of transfection in HEK293 cells over SH-SY5Y cells.  
 
My Initial experiments involved investigating the effect of proteasomal inhibition on 
DISC1 endogenous levels (Figure 4.2) and overexpressed HA - DISC1 (Figure 4.3) using 
Western blotting techniques.  MG132 transiently increased DISC1 protein levels in a time 
dependent manner in first two hours at the indicated concentration.  However, after 3hr 
treatment there was a significant reduction of DISC1 protein levels to below the levels 
seen at time = zero.  MG132 time courses with cells transfected with HA DISC1 were 
restricted to 5hr (Figure 4.3) as an increase in cell death was observed beyond that point.  
This may be attributed to the possible non proteasomal enzyme inhibition effect  of 
MG132 on lysosomal cysteine protease and calpine inhibition (Lee and Goldberg, 1998). 
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Figure 4.2  Proteasome inhibition transiently stabilises endogenous DISC1 levels in 
HEK293 cell line. 
Top panel: HEK293 cell cultures were treated with MG132 at 10µM concentration for 
indicated time points and endogenous DISC1 protein levels were analysed by Western 
blotting technique using Anti DISC1 antibody.  Anti GAPDH antibody was used as a 
loading control.  Bottom panel: Densitometric analysis of the amount of DISC1 protein 
normalised to GAPDH expression levels.  Data is represented as ± S.E.M. of three 
biological repeats. Statistical significances between control (time = 0) and a time point 
was calculated using one way analysis of variance (ANOVA). *P < 0.05 values were 
considered significant. 
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Figure 4.3  Proteasome inhibition transiently stabilises over expressed DISC1 levels in 
He293 cell line. 
Top panel:  HEK293 cell cultures were transiently transfected with HA (haemagglutinin)- 
DISC1.  48hr post incubation Ubiquitination cell cultures were treated with MG132 at 10 
µM concentration for indicated time points and DISC1 protein levels were analysed by 
Western blotting technique with anti HA antibody.  Anti GAPDH antibody was used as a 
loading control.  Bottom panel: Densitometric analysis of the amount of DISC1 protein 
normalised to GAPDH expression levels.  Data is represented as ± S.E.M. of three 
biological repeats.  Statistical significances between control (time = 0) and a time point 
was calculated using one way analysis of variance (ANOVA). *P < 0.05 values were 
considered significant.  
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4.3.2  Ubiquitin chain formation on DISC1 protein – K48 and K63 
linked ubiquitin chains detected 
To determine whether DISC1 is a substrate for ubiquitination, HA - DISC1 was 
overexpressed with HA - ubiquitin or an empty vector which served as a negative control.  
48 hours post transfection, cells were treated with MG132 or DMSO (vehicle) at 10µM for 
3hr.  The cell lysates were evaluated using a Western blotting technique.  Probing with 
DISC1 antibody shows the presence of high molecular weight, slow migrating DISC1 
species in the samples co expressing ubiquitin (Figure 4.4).  Proteasome inhibition retains 
the high molecular weight DISC1 bands which correspond to the ubiquitinated DISC1 
protein, likely to be carrying one or many type of ubiquitin chains.  These high molecular 
weight bands are absent in the samples of HA - DISC1 co expressed with an empty vector 
i.e., absence of ubiquitin (Figure 4.4.). 
 
 
 
Figure 4.4  Immunoblots showing DISC1-ubiquitin conjugates from HEK293 cell lysate. 
 HA-DISC1 was overexpressed with an empty vector or HA-ubiquitin.  Samples were 
treated with DMSO or MG132 at a concentration of 10µM for 3hr.  Cells were lysed 
under denaturing conditions (described in materials and methods)  and analysed for the 
presence of DISC1-ubiquitin conjugates using Western blotting technique.  Anti-DISC1 
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antibody was used to detect DISC1 (unmodified and ubiquitin conjugated) and anti-
tubulin antibody was used as loading control. 
 
The ubiquitination of DISC1 was further confirmed by immunoprecipitation experiments 
where endogenous DISC1 was purified from HEK293 treated with MG132 or DMSO 
(vehicle) at 10µM concentration for 3hr.  Immunoprecipitation was performed using 
DISC1 antibody as bait and the immunoprecipitate complexes were analysed for the 
presence ubiquitin chains by probing with a pan ubiquitin antibody or K48, K63 type 
ubiquitin linkage specific antibodies (Figure 4.5).  Similar experiments to detect 
ubiquitination of over expressed HA tagged DISC1 were also performed.  
Immunoprecipitation of over expressed HA tagged DISC1 from HEK293 cells was carried 
out using HA tag specific antibody (Figure 4.6). 
 
Figure 4.5   Detection of endogenous DISC1 – Ubiquitin conjugates in HEK293 cells under 
denaturing conditions. 
Immunoblot analysis of DISC1-Ubiqutin conjugates after immunoprecipitation of 
endogenous DISC1 from HEK293 cell lysate.  HEK293 cells cultures were treated with 
DMSO or MG132 at a concentration of 10µM for 3hr.  Cells were lysed under denaturing 
conditions and immunprecipitation was performed using anti DISC1 antibody or rabbit 
IgG (described in materials and methods).  Captured immunoprecipitate complexes 
were analysed by Western blotting technique.  Left panel: Anti Ubiquitin and anti DISC1 
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antibodies were used.  Immunoprecipitate complexes were also analysed with ubiquitin 
chain type specific antibody – middle panel:  anti K48 linked Ubiquitin chain type 
specific antibody and right panel: anti K63 type Ubiquitin chain specific antibody.  
 
 
Figure 4.6  Immunoblot analysis of overexpressed human DISC1-Ubiqutin conjugates in 
HEK293 cell lysate under denaturing conditions: 
(a) HA - DISC1 was overexpressed in HEK293 cells and treated with 10µM DMSO or 
MG132 for 3hr.  Cells were lysed under denaturing conditions and immunprecipitation 
was performed using HA - agarose beads or mouse Ig G - agarose beads (negative 
control).  Captured immunoprecipitate complexes were analysed by Western blotting 
technique (described in materials and methods).  Left panel: Anti ubiquitin and anti 
DISC1 antibodies were used.  Immunoprecipitate complexes were also analysed with 
ubiquitin chain type specific antibody; middle panel:  anti K48 linked ubiquitin chain 
type specific antibody and right panel: anti K63 type ubiquitin chain specific antibody.  
 
The biochemical experiments performed in this section confirm that DISC1 undergoes 
covalent modification with ubiquitin which can be observed as high molecular weight, 
slow migrating DISC1-ubiquitin conjugates observed as a smear at molecular weights 
above that of native DISC1 (~100kDa).  Pretreatment of cells with proteasome inhibitor 
MG132 prior to cell lysis led to significant enrichment of ubiquitin conjugates in the 
sample, which can be seen as increased ubiquitin conjugate bands in the immunoblots.  
As discussed in Chapter 1, ubiquitin is reversible and mediated by the action of de-
ubiquitylating enzymes (DUBs) which rapidly deconjugate ubiquitin from the substrates 
and recycle ubiquitin.  The action of these enzymes hampers the detection and reliable 
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characterisation of protein ubiquitination.  One strategy that has been efficiently 
employed was purifying the protein-ubiquitin conjugates under denaturing conditions i.e, 
use of strong detergents and heat.  Protein denaturation rapidly destroys enzyme activity 
by disrupting protein secondary and tertiary structure  by destroying  hydrogen bonding, 
salt bridges and disulphide bonds while the backbone peptide bond  and other covalent 
modifications remains intact (Ciechanover and Iwai, 2004).  This strategy was successfully 
employed in the present study which allowed efficient detection of post translation 
medication on DISC1 and also aids further biophysical studies discussed in the next 
section.   
 
 
4.3.3 DISC1 ubiquitination - Mass spectroscopy evidence 
Identification of ubiquitin modification sites on a substrate protein is crucial to the 
facilitation of understanding the physiological role of ubiquitination in the context of that 
protein.  All PTMs direct specific functional consequences for the target protein.  Most 
often, ubiquitin receptor lysine residue(s) on the target is/are identified by site directed 
mutagenesis experiments which block ubiquitination.  Recent advances in technology 
have enabled the use of Mass spectroscopy techniques to not only identify the target 
lysine residue which undergoes the PTM but also the type of ubiquitin chain associated 
with it.  In this study, Flag DISC1 and HA Ubiquitin were co expressed in HEK293 cells 
followed by MG132 treatment and cell lysis after 48hr incubation.  Immunoprecipitate 
complexes were collected using Flag tagged agarose beads as bait.  Materials and 
methods section 2.4.8 describes the protocol for the immunoprecipitation and 
subsequent sample preparation for the Mass spectroscopy studies. 
Mass spectroscopy samples were analysed at Yale School of Medicine, USA. 
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Figure 4.7  Preparation of Samples for mass spectroscopy studies to detect human 
DISC1 Ubiquitination in HEK293 cells. 
Flag DISC1-HA Ubiquitin complexes overexpressed in HEK293 cell line were 
immunoprecipitated using Flag tagged agarose beads.  Untransfected HEK293 cell lysate 
was used as a negative control.  Bands were excised from a colloidal blue stained PAGE 
gel as indicated in this Figure (top panel) and analysed by mass spectroscopy.  Small 
fraction of sample was analysed by Western blotting to analyse the efficiency of the 
transfections (bottom panel).  
 
 
107 
 
Table 4.1  Summary of Mass Spectroscopy studies to detect DISC1-ubiquitin conjugates  
 
 
The above Table implies the prescence of DISC1 at various  molecular weights which correspond to native DISC1 and post translationally modified 
(PTM) DISC1 species (Column 1 and 2). Column 3- DISC1 peptides identified in the corresponding samples.  Column 4 and 5 indicate the percentage 
of DISC1 peptide detected in resepective samples  and the PTMs identified in corresponding  samples. Lysine residues which undergo PTM are 
represented in bold letters. Column 5- GlyGly indicate Ubiquitination modification on the indicated lysine residue.The sample highlighted in green 
has been identified to have the highest MASCOT score of 30 of all the samples screened. A higher MASCOT score indicates a more confident match 
of all the samples analysed. Mass spectroscopy principle, sample preparation protocol was explained in materials and methods section 2.4.8.  
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The mass spectroscopy studies on DISC1 Ubiquitnation  can be summarised as follows: 
DISC1- ubiquitin conjugates  were detected at various molecular weights above 100kDa 
(the weight at which native DISC1 migrates).  These conjugates were represented as 
glycine-glycine-lysine linkages (GlyGly(K)) in Table 4.1.  
Six lysine residues were identified to be carrying  G-G-K modification with variable 
MASCOT scores.  MASCOT scores were generated using a software package from Matrix 
Science (www.matrixscience.com) that interprets mass spectral data into protein 
identities.  Mascot compares the spectral data to a database of known proteins and 
scores based on confidence of the match. 
Lysine 372 residue was chosen for subsequent work as it was predicted to be the site with 
higher probability of ubiquitin modification implied by its highest MASCOT score of 30 
(Table 4.1). 
 
 
4.3.4  Analysis of ubiquitination kinetics of the DISC1 K372R 
mutant (site identified in the Mass spectroscopy studies)  
V5 tagged DISC1 lysine to arginine mutant at position 372 (K) was generated and 
evaluated for ubiquitination at basal levels and in the presence of the proteasome 
inhibitor MG132.  Lysine to arginine substitution mutants are ideal in this situation to 
retain the net negative charge on the R group (side chain of the amino acid).  
Immunoprecipitation studies were performed by over expressing V5 tagged DISC1 WT 
and K372R mutant, to analyse the pattern of ubiquitin chain formation in response to 
proteasomal inhibition.  V5 tag antibody was used as bait to immunoprecipitate the 
DISC1-ubiquitin protein conjugates.  
  
 109 
 
 
 
Figure 4.8  Comparative analysis of Ubiquitination of human DISC1 Ubiquitination 
mutant K372R  to that of wild type DISC1.  
Wild type V5-DISC1 and K372R V5-DISC1 constructs were overexpressed in HEK293 
cells.  48hr post transfection, cultures were treated with MG132 at 10 µM concentration 
for indicated time points.  Immunoprecipitation was performed on the cell lysates using 
V5 tag antibody as bait.  The first lane in all the blots in untransfected HEK293 cell 
lysate used as negative control.  Top panel : Anti ubiquitin antibody.  Middle panel: V5 
tag antidoy (DISC1).  Lower panel: anti V5 tag antibody (DISC1) for input which is the 
positive control . Graph indicates the statistical representation of densitometric analysis 
of the amount of DISC1-ubiquitin protein conjugates normalised to unconjugated DISC1 
expression levels.  Data is represented as ± S.E.M. of three biological repeats.  
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Interestingly, I discovered that the degradation rate of  the  V5-DISC1 K372R mutant  
(represented by the smeary pattern in Figure 4.8, top panel) was reduced compared to 
that of the WT.  This suggests that the K372 site is a bona fide ubiquitination site but 
there are one or more other sites on DISC1 that get modified in this way.  This notion is 
supported by the mass spectroscopy studies which suggest up to five sites.  This sort of 
site specific ubiquitination dependent regulation of a substrate has been reported for 
other proteins, for example HMGR (3-hydroxy-3-methylglutaryl coenzyme A reductase).  
Though this  enzyme has several lysine residues which serve as ubiquitin acceptors, 
mutational studies show that K248 acts as a primary ubiquitin acceptor site (Doolman et 
al., 2004). 
 
4.3.5  Identification of E3 ligase regulating DISC1 ubiquitination – 
High Throughput Screen for Fbox proteins 
Fbox proteins were initially characterised as components of SCF ubiquitin E3 ligase 
complexes, which help catalyse the transfer of ubiquitin moiety from the E2 enzyme to 
the substrate.  The Fbox protein is the variable component of the SCF complex where 
substrate specific Fbox proteins are recruited as a consequence of specific post 
translational modification such as phosphorylation or SUMOylation (ubiquitination 
cascade is reviewed in section 1.5).  My hypothesis highlights the significance of 
identifying the putative Fbox protein which regulates DISC1 half-life.  
 
siRNA technology is a widely popular tool which can be used to silence target gene 
expression.  siRNA oligonucleotides can be either introduced to cells by transfection or  
can be generated within the cell by introducing plasmids which encode shRNAs (short 
hairpin) which function as precursors of siRNA.  siRNA screening has been widely used to 
investigate the functional role of various proteins and genes.  siRNA libraries to screen for 
specific components such as kinases, E3 ligases and DUBs have now been generated and 
validated by number of commercial companies and are available in various formats. 
One such library has been used in the present study to identify crucial E3 ligases that may 
catalyse ubiquitination of DISC1.  To identify the Fbox protein (substrate recognising 
component of SCF complex) I used a genome wide screen using siRNA approach.  ON-
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TARGETplus® siRNA Library (Dharmacon) to all known human Fbox proteins was screened 
to serve this purpose.  This library consists of 96 siRNA pools (four duplexes each) 
designed to reduce potential off target effects.  Owing to the higher transfection 
efficiency and detectable basal DISC1 protein levels, HEK293 cells were used in the 
screen.  HEK293 cell cultures were transfected with the siRNA following manufacturer’s 
instructions (materials and methods, section 2.2.9).  48hr post transfection, cell lysates 
were analysed for DISC1 protein levels using the Western blotting technique.  Anti GAPDH 
antibody was used as a loading control.  The siRNA knockdown of the putative Fbox for 
DISC1 should reduce DISC1 ubiquitination, leading to its stabilisation.  Increased amounts 
(vs control) of DISC1 protein can be screened by using Western blots.  Putative hits were 
shortlisted following densitometric quantification of the DISC1 protein bands.  These hits 
were rescreened to eliminate possible technical artifacts.  Representative blots of the 
screen are shown in Figure 4.9 (high throughput screen) and Figure 4.10  (secondary 
screen).  The complete screen (immunoblots) can be found in the appendix of this thesis. 
 
This screen was followed by validation experiments, where the siRNA knockdown was 
confirmed by the analysis of the protein levels of another known substrate of Fbxw7, c-
Myc (Figure 4.11). Gratifyingly, siRNA oligos that down regulated Fbxw7 expression also 
upregulated the protein levels of DISC1 and c-Myc concomitantly, suggesting that Fbxw7 
is indeed involved in DISC1 degradation. 
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Figure 4.9  Fbox siRNA screen to identify putative Fbox protein that regulates DISC1 
ubiquitination – Primary screen 
HEK293 cells were transfected with siRNAs targeting the indicated transcripts.  Non 
targetting siRNA was used as a negative control.  Upper panel:  Anti DISC1 antibody was 
used.  Anti GAPDH antibody was used as a loading control.  Lower panel: Densitometric 
analysis of the amount of DISC1 protein is normalised to GAPDH expression levels. 
Putative hit has been identified (Fbxw7) for further analysis, indicated with ‘*’.  
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Figure 4.10  Validation of Fbox siRNA screen hit - Secondary Screen  
Putative shortlisted Fbox proteins were rescreened.  Upper panel:  Anti DISC1 antibody 
was used.  Anti GAPDH antibody was used as a loading control. Lower panel: 
Densitometric analysis of the amount of DISC1 protein is normalised to GAPDH 
expression levels.  Complete information about Fbox siRNA screen with Figures is 
detailed in appendix.  From the above screen, Fbxw7 was identified as a putative hit as 
its knock down consistently stabilised DISC1 protein levels.  
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Figure 4.11  siRNA knockdown of Fbxw7 stabilises DISC1 and known substrate, c-Myc – 
Tertiary screen 
HEK293 cell cultures were individually transfected with 4 different siRNA (which 
constitute the SMART Pool used in the Fbox library screen) targeting different regions 
on Fbxw7 transcript.  DISC1 (protein of interest), Fbxw7 and c-Myc (known Fbxw7 
substrate) and GAPDH (loading control) expression levels were evaluated using anti 
DISC1, anti Fbxw7, anti c-Myc and anti GAPDH antibodies respectively.  
 
 
4.3.6 Fbxw7/Cdc4 – A Novel interacting partner of DISC1  
The siRNA screen detailed earlier provided us with a valuable putative novel interacting 
partner and E3 ligase for DISC1, Fbxw7.  Most of the literature discusses Fbxw7 as a 
popular cancer drug target and it is interesting to note that many of the characterised 
Fbxw7 substrates are oncogenes such as c-Myc and c-Jun (Tu et al., 2012, Wang et al., 
2012b).  Very few studies were conducted to understand the physiological role of Fbxw7 
protein in brain.  Mice with brain region specific knockdown of Fbxw7 were generated 
and studies show that Fbxw7 is crucial in regulating neural stem differentiation (Hoeck et 
al., 2010a).  Histological studies on mice with cerebellum specific Fbxw7 deletion revealed 
reduced Purkinje cell density and  a smaller sized cerebellum at P2 (Jandke et al., 2011). 
Immunohistochemical studies show DISC1 staining of cerebellum, predominantly in 
Purkinje cells (Schurov et al., 2004a).  Fbxw7 was also implicated in the regulation of 
neural stem cell differentiation via the Notch signalling pathway (Hoeck et al., 2010a).  
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Hence, we found Fbxw7 to be an interesting putative E3 ligase protein to investigate 
further. 
 
To validate the results of the Fbxw7 siRNA screen further, biochemical studies were 
carried out to validate the novel interaction.  Co-immunoprecipitation (co-IP) experiments 
were carried out to isolate a complex of Fbxw7 and DISC1.  Due to the unavailability of a 
suitable Fbxw7 antibody, the putative interacting partners were overexpressed in HEK293 
cells.  Initially, Flag - Fbxw7 and GFP, V5 - DISC1 were co transfected respectively in 2 
different sets of experiments (Figure 4.12 a and b).  Using Flag antibody as bait, Flag 
Fbxw7 immunoprecipitate complexes were collected and analysed for the presence of 
GFP DISC1 or V5 DISC1.  Figure 4.12 a, 4.12b; show that DISC1 and Fbxw7 co-IP.  This 
interaction was also validated by performing reciprocal co-IP, i.e., overexpressing Flag 
DISC1 and untagged - Fbxw7 followed by immunoprecipitation of Flag DISC1 and probing 
for the presence of Fbxw7 (Figure 4.12c).  Control co-IP experiments were carried out in 
parallel using IgG antibody which precipitates neither of the interacting partners in all the 
three different sets of experiments (Figure 4.12).  
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Figure 4.12   Immunoblots showing  association of Fbxw7 and DISC1 
Representative immunoblot of DISC1-Fbxw7 co-IP.  Lysates of HEK293 cells co- 
expressing - Fbxw7 and DISC1 were immunoprecipitated on to Flag tagged agarose 
beads.  (a) Flag - Fbxw7 and GFP - DISC1 : IP antibody-Flag.  (b) Flag - Fbxw7 and V5 - 
DISC1: IP antibody Flag.  (c) Untagged- Fbxw7 and Flag - DISC1 : IP antibody Flag.  First 
lanes in all the blots are 8% input which correspond to the 8% of cell lysate from which 
the immunoprecipitation was performed (positive control).  Second lane represents IP 
with IgG antibody which serves as a negative control. Third lane represents IP carried 
out with Flag tagged agarose beads.  This work was carried out by Dr. Jon P Day, 
Gardiner Laboratory, University of Glasgow. 
 
Next, we examined the ability of Fbxw7 to regulate DISC1 protein levels under conditions 
of translation inhibitor to determine whether Fbxw7 could affect the turnover of DISC1.  
Cyclohexamide (CHX) is a reversible protein translation inhibitor which exerts its function 
by blocking the translation elongation step.  Flag DISC1 and Fbxw7 were overexpressed in 
HEK293 cells following by treatment with CHX or DMSO (vehicle) at 50µg/ml 
concentration for indicated time points and cell lysates were tested using immunoblots.   
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Figure 4.13  Effect of Fbxw7 over-expression on the stability of Flag-DISC1 
Flag - DISC1 was co transfected in HEK293 cells with untagged Fbxw7 or an empty 
vector (negative control).  Cells were treated with Cyclohexamide (CHX) at indicated 
concentration and time and cell lysates are analysed by Western blotting technique 
using anti DISC1, Fbxw7 antibodies.  Ku70 and GAPDH protein expression levels serve as 
loading controls as they are stable under Cyclohexamide treatment.  n=2 
This work was carried out by Dr. Jon P Day, Gardiner Laboratory, University of Glasgow. 
 
The decrease in DISC1 levels, induced by CHX, was exacerbated following Fbxw7 
expression, as suggested by preliminary studies (Baillie laboratory).  This implies that the 
E3 ligase complex with Fbxw7 promoted the degradation of DISC1.  Other proteins which 
are known for their stability under CHX treatment (Ku70 and GAPDH) were unaffected by 
either CHX treatment or Fbxw7 expression.  These data further validate my hypothesis 
that Fbxw7 is the E3 ligase for DISC1 (Figure 4.14).  These data were supported by the 
observation that both proteins co-purify in DISC1 immunoprecipitations (Figure 4.12).  
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Figure 4.14   Schematic of proposed Fbxw7 (SCFFbxw7) mediated ubiquitin conjugation of 
DISC1.  
From my study, with the results we have so far I hypothesise that Fbxw7 is the Fbox 
component of the SCF complex (Skp1, Cullin, RBX1 and Fbox) that orchestrates the 
ubiquitin transfer from the E2 enzyme to a specific lysine residue on the DISC1 protein.  
 
 
4.3.7  Fbxw7 - DISC1 interaction is mediated by Cdc4 
phosphodegron (CPD) 
Substrate degradation by SCFFbxw7  E3 ligase complexes is triggered by a phosphorylation 
event within a conserved motif known as a CPD (Cdc4 phosphodegron)  which physically 
interacts with Fbxw7 (Orlicky et al., 2003).  Substrates such as Cyclin E  can have more 
than one CPD, though they have variable affinities towards SCF binding (Nash et al., 
2001).  Screening of the DISC1 protein sequence revealed the presence of a putative CPD.  
Comparison of the DISC1 CPD shows a close resemblance with that of other known 
characterised Fbxw7 substrates (Figure 4.15).  The DISC1 CPD and its interaction with 
Fbxw7 were further characterised using structure based studies, detailed in chapter 5. 
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Figure 4.15  SCFFbxw7 substrates with Cdc4 conserved CPD motif, consensus sequence 
and putative DISC1 CPD.  
Boxed sequences represent Threonine and Serine residues which upon phosphorylation 
recruits the SCF complex for ubiquitination.  ϕ indicates any amino acid. 
 
In order to probe the putative interaction between DISC1 CPD consensus and the SCF 
Fbxw7 complex, we utilised peptide array technology which is a core technique within the 
Baillie lab.  Peptide libraries consisting of 25-mer peptides containing the DISC1 CPD (with 
and without phosphorylation on the Thr 198 and and Ser 202 residues) were synthesised 
along with a series of amino acid truncations from C terminal and N terminal ends of the 
peptide.  Purified His tagged Skp1-Fbxw7 complex was overlaid onto the peptide arrays 
and areas of positive interaction were detected with an anti-His antibody (Figure 4.16). 
Gratifyingly, robust interaction between the Skp1-Fbxw7 complex and DISC1 CPD 
consensus was detected.  Various characteristics of the interaction site were disclosed 
through these studies.  First, dual phosphorylation within the CPD (Thr198 and Ser 202) 
increases the interaction with the E3 ligase in vitro.  Secondly, additional binding sites 
may be provided by the residues at the amino terminal to the CPD such as Valine and 
Proline.  Finally, a strong in vitro interaction was achieved by the smallest peptide 
(showing positive interaction), a 7-mer  ‘P-pT-P-P-G-pS-H’  (spot 31 in Figure 4.16) which 
is hypothesised to be the minimal interacting surface on DISC1 CPD for successful 
association with the E3 ligase  (Figure 4.16). 
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Figure 4.16  Peptide array analysis of DISC1 – SCFFbxw7  interaction through the CPD motif  
on DISC1.  
A DISC1 peptide library consisting of CPD motif and sequentially truncated N terminal 
and C terminal CPD peptides were spotted on a membrane and analysed for SKp1-
Fbxw7 binding using recombinant protein complex.  Peptide array analysis is described 
in materials and methods section 2.5.  His tag antibody was used to probe for the 
interaction.  Lanes 1 – Negative Control, probed with antibody only, 2- Coomassie 
stained array showing the presence of peptides, 3- long exposure of the test array 
which was overlaid with SCFFbxw7 protein followed probing with His tag antibody.  4- 
shorter exposure of the above test array. Peptides showing a strong positive interaction 
were highlighted in red, with arrows marked to the corresponding spots.  
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4.4  Discussion 
4.4.1  Proteasomal regulation of DISC1 protein  
The two main proteolytic pathways of mammalian cells, the lysosomal pathway and the 
UPS, play an important role in maintaining cellular homeostasis of proteins.  The role of 
UPS in neurological disorders has been reviewed in section 1.5.4.  Earlier studies have 
proposed immunocytochemical staining for ubiquitin and its conjugates as a marker for 
neuro-degeneration (Lowe et al., 1988).  These were later identified as ubiquitin rich 
inclusion bodies (IBs) enriched with deposits of ubiquitin conjugated misfolded proteins.  
These accumulated proteins may lead to cellular stress and subsequent cell death.  IBs are 
a hallmark of neurodegenerative illnesses such as Alzheimer’s disease.  Although so far 
there has been no report of IB formation by DISC1 protein, DISC1 aggregate formation 
has been widely reported in various cell types (Atkin et al., 2012).  The role of these 
aggregates in DISC1 associated diseases still remains unclear. 
  
My study focused on how DISC1, a putative susceptibility factor of SCZ, is regulated in 
cells, i.e. what controls the protein levels of DISC1?  Initial studies involved 
characterisation of DISC1 degradation kinetics in the presence of the 26S proteasome 
inhibitor, MG132.  DISC1 was shown to be stabilised and ubiquitin conjugated upon 
inhibition of its proteasomal degradation.  Mass spectroscopy analysis further 
strengthened my suggested hypothesis that ubiquitin conjugation directs DISC1 
proteasomal targeting.   
My biochemical studies show the presence of K48 and K63 type ubiquitin chains on 
DISC1. Antibodies which detect other types of ubiquitin chains (such as K3, K11) were 
unavailable at the time of this study.  Conjugated K48 linked ubiquitin chains are believed 
to be the signal for proteasome degradation, while conjugation of K63 linked ubiquitin 
chains is known to serve non proteolytic roles such as such as gene expression regulation 
and inflammatory responses (Xu et al., 2009).  Tetra ubiquitin has been identified as a 
minimum (shortest) signal required for proteasomal targeting (Ciechanover and Ben-
Saadon, 2004).  It has been suggested that specific receptors on the 19S complex of the 
26S proteasome have the potential to recognise the poly ubiquitin chain assembly formed 
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by K48 linkage.  It has also been proposed that longer ubiquitin chain length may increase 
the residence time of the substrate. However, the exact mechanism by which the length 
of ubiquitin chain influences the fate of ubiquitinated substrate has been a long standing 
debate (Ciechanover and Ben-Saadon, 2004).  A Variety of linkages, inter linkages 
between chains and lengths which in turn assume various confirmations were all known 
to contribute to the complexity and specificity of the ubiquitination of a substrate and 
dictate the physiological response (Fushman and Wilkinson, 2011).  Though the Mass 
spectroscopy studies performed in the present study uncovered a putative ubiquitination 
site on human DISC1 (K372), the type of ubiquitin chains nor the length could not be 
verified due to the moderate quality of the samples.  More investigation to uncover the 
type of ubiquitin chains would be useful in understanding the physiological consequences 
of chain formation on DISC1.  Technical and biological replicates of Mass spectroscopy 
studies would be useful, but were not within the scope of this project.   
 
The immunoprecipitation data on ubiquitination of DISC1 K372R mutant suggest reduced 
ubiquitin conjugation, if not completely abolished.  This can be attributed to the fact that 
substrates might have one or more ubiquitination targeted lysines.  Ubiquitin conjugation 
at different lysines on a substrate may be spatio temporally regulated as well as having 
different physiological responses (Grabbe et al., 2011).  Other experimental studies which 
may be useful in the further characterising ubiquitination of DISC1 are ones involving 
expression of an ubiquitin ‘lysineless’ mutant (Ubiquitin(K0)), in which all the seven lysine 
residues are mutated to arginine residues.  This mutant terminates ubiquitin chain 
formation, and therefore stabilises the substrate preventing its proteasomal targeting.  
These mutants should alter the pattern of slow migrating bands on a Western blot as a 
result of less ubiquitination or shorter chain formation.  Lysine at specific sites on 
ubiquitin can also be mutated to arginines such as K48R or K63R.  Overexpressing such 
mutants would validate the type of chain formed on the substrate protein.  
 
As discussed earlier, the extreme short life of ubiquitin modified substrates due to the 
reversible nature of the modification (deubiquitination catalysed by DUBs) poses several 
challenges in biochemical and biophysical characterisation of ubiquitin conjugated 
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substrates. Although cysteine protease inhibitors (example: Iodoactemide and NEM – N-
ethyl maleimide) have been widely  used  to inhibit DUBs, they were shown  to interfere 
with mass spectroscopy studies (Nielsen et al., 2008).  Recent studies have focused on 
developing strategies to overcome this issue and facilitate a more reliable detection and 
characterisation of the protein ubiquitination.  Tandem-repeated ubiquitin-binding 
entities (TUBEs) are an example which was developed based on ubiquitin-associated 
(UBA) domains.  TUBEs specifically recognize, interact and thereby protect the tetra 
ubiquitin by interacting with a higher affinity than individual UBA domains (present on 
DUBs).  TUBEs therefore function as molecular traps and were described as valuable tools 
for studying PTMs (Hjerpe et al., 2009).  
 
As discussed earlier, many studies have shown that loss of DISC1 expression (RNAi 
knockdown of DISC1) results in abnormal brain development and function (Niwa et al., 
2010, Faulkner et al., 2008, Young-Pearse et al., 2010).  Retroviral mediated shRNA 
knockdown of DISC1 shows that it is a key factor regulating neuronal maturation in adult 
brain (Faulkner et al., 2008).  DISC1 knockdown studies in Zebra fish have revealed 
abnormal oligodendrocyte and cerebellar neuronal development.  RNAi mediated loss of 
DISC1 expression has also affected neurite outgrowth in PC12 cells (Miyoshi et al., 2003b).  
All these studies show that the loss of DISC1 function may be critical in the underlying 
pathophysiology of DISC1 associated psychiatric illnesses.  I see this uncovered novel PTM 
on DISC1 as initial step towards understanding these disease mechanisms, and more 
investigation and characterisation of this modification would provide more avenues for 
therapeutic intervention.   
 
4.4.2  Fbxw7 dependent degradation of DISC1 
My screening studies uncovered a novel interacting partner for DISC1 i.e., Fbxw7.  It is 
interesting to note that none of the yeast 2 hybrid screens on DISC1 have identified 
protein as a candidate interacting partner (Camargo et al., 2007).  This may be attributed 
to the transient nature of the DISC1-Fbxw7 interaction - many of the interactions that 
characterise ubiquitination are extremely short lived. It may also be that a prior post 
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translational modification such as phosphorylation is required for this interaction, as 
suggested by my study. 
 
Literature mining revealed that Fbxw7 is mutated in several different types of cancers and 
its inactivation leads to chromosomal instability (Jandke et al., 2011, Rajagopalan et al., 
2004).  Recent studies have implicated Fbxw7 role in stem cell differentiation.  Fbxw7 
sustains hematopoietic stem cell quiescence and regulates their differentiation by 
regulating transcription factors Notch, c-Jun and mTOR (Reavie et al., 2010, Iriuchishima 
et al., 2011).  Fbxw7 is crucial in neuronal stem cell maintenance and differentiation in 
brain and is known to exert this function by controlling the abundance of Notch proteins 
(Hoeck et al., 2010a, Matsumoto et al., 2011).  Fbxw7 has been reviewed in section 
1.5.3.5.   
 
Several Fbox proteins recognise a short motif within a substrate which upon 
phosphorylation facilitates recognition and interaction by Fbox protein, known as CPDs 
(Ye et al., 2004).  Many of these proteins have been crystallised with their respective 
phosphopeptides.  While some substrates have only one CPD, many other substrates such 
as Sic1 and Cln2 have multiple degrons dispersed across the protein sequence.  My 
peptide array studies involving sequential truncation from the C terminal and N terminal 
ends of the DISC1 CPD also identified the minimal interacting region of Fbxw7 on DISC1 
within the CPD (Figure 4.16).  As discussed earlier, as in the case of most of the other 
Fbxw7 substrates, a phosphorylation event followed by an isomerisation might be crucial 
in triggering this interaction (Zhang and Koepp, 2006, Hao et al., 2007b).  Hence, peptide 
array studies were used to further validate this hypothesis of Fbxw7 mediated DISC1 
ubiquitination.  As seen in Figure 4.16, SKp1-Fbxw7 complex specifically shows strong 
interaction with DISC1 CPD peptides carrying dual phosphorylation (Thr198and Ser202).  
This is an important finding which aligns with the observations made by other research 
groups in other known Fbxw7 substrates.  As can be seen in Figure 4.15, DISC1 CPD 
consensus has a close similarity with Cyclin E’s CPD motif.  Cyclin E (regulates cell cycle 
transition from G1 to S phase) is a well characterised Fbxw7 substrate whose degradation 
is triggered by phosphorylation within multiple degron motifs (Orlicky et al., 2003, Ye et 
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al., 2004).  In vitro studies employing Cyclin E CPD peptides and site directed mutagenesis 
studies have identified doubly phosphorylated degron (Thr380/Ser384) as a high affinity 
motif and singly phosphorylated degron (Thr62) as a lower affinity motif.  More studies are 
to follow in the next section to further characterise the DISC1 CPD motif.  Interestingly 
the identified CPD is not conserved in mouse and Rat DISC1 homologues (Figure 4.15).  
 
Another noteworthy aspect of Fbxw7 is its isoform specific regulation of its substrates 
(Grim et al., 2008). As reviewed in section 1.5.3.5, three splice variants of Fbxw7 have 
been characterised – α, β and γ isoforms, which vary at their amino terminal end.  Fbw7-α 
is predominantly  nuclear; Fbw7-β is cytoplasmic; and Fbw7-γ is reported to be localised 
in the nucleolus (Zhang and Koepp, 2006).  Their differential localisation may also dictate 
their isoform specific physiological role (Welcker et al., 2004).  For example, it has been 
demonstrated that p53 is regulated by the cytoplasmic β isoform (Galli et al., 2010), The 
nucleolar pool of Fbxw7-γ regulates c-Myc (Welcker et al., 2004) and different degrons 
with in Cyclin E were shown to differentially interact with  three Fbxw7 isoforms (Zhang 
and Koepp, 2006).  The Fbxw7 siRNA used in the Fbox screen was designed to target a 
common region for all the three isoforms.  Fbxw7-γ isoform is absent in brain tissue 
(embryonic and adult), β isoform is moderately expressed, while the α isoform is the most 
abundant and ubiquitously expressed isoform of Fbxw7. α isoform is abundant  in 
neuronal stem cells and progenitors ((Hoeck et al., 2010a) (Akhoondi et al., 2010, Grim et 
al., 2008) and HEK293 cells (cell line used in  the present study).  Hence I chose to 
investigate the Fbxw7-α isoform interaction with DISC1 by performing 
Immunoprecipitation studies.  However, the involvement of the other isoforms 
involvement in DISC1 regulation may not be ruled out and requires further investigation.  
Positive interaction between FBXW-α isoform and DISC1 may also suggest that DISC1 
could be localised in the nucleus, supporting its known centrosomal association (Morris et 
al., 2003).  
 
 The following studies may shed light on the Fbxw7 and DISC1 interaction, and were not 
within the scope of the present study: 
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1. Investigating DISC1 – Fbxw7 interaction studies (immunoprecipitation, pull down 
assays, immunostaining techniques) and  Isoform specific knockdown of Fbxw7 and its 
effect on DISC1 ubiquitination would be useful in understanding if this interaction is 
isoform specific. 
 
2. The developmental expression profile of DISC1 protein in mice reveals that the 100kDa 
form peaks at E13.5 and P35, which corresponds to periods of active neurogenesis, 
supporting its role in active brain development (Lipska et al., 2006a).  In humans, the 
expression is predominant in hippocampus, while the expression is stronger in dentate 
gyrus in early childhood and gradually rapidly declines with age into adulthood (Lipska et 
al., 2006b).  Fbxw7 has also been implicated in cerebellar development and neuronal 
stem cell differentiation.  However, the expression profile of Fbxw7 in human brain has 
not been explored yet.  It would be intriguing to investigate any expression based inverse 
correlation between these two proteins in normal subjects and psychiatric patients in the 
context of my study showing that DISC1 levels are regulated by Fbxw7.  This also supports 
the neurodevelopmental hypothesis of SCZ.  
 
3. GSK3β has been known to be functionally associated with Fbxw7 (source kinase for its 
substrates).  GSK3β is a crucial interacting partner of DISC1 and studies in zebraﬁsh, 
mouse model systems and mammalian cell lines show that DISC1 variants (A83V, R264Q, 
and L607F) could not activate Wnt/GSK3β signalling.  In this context, it would be 
interesting to assess the potential of GSK3β to directly phosphorylate DISC1 within the 
CPD.  However, this might prove challenging, as in general, a priming phosphorylation 
event is required for GSK3β to phosphorylate its substrates.  
 
4. It would be also interesting to investigate how DISC1 common variants and t (1; 11) 
translocation (truncated DISC1) affect DISC1 stability in cells, which may explain the 
molecular consequences of the underlying disease mechanism.  
 
 127 
 
 
4.5 Chapter summary 
To summarise this chapter’s results, I have provided novel and previously undiscovered 
information on the regulation of DISC1 turnover in HEK293 cells.  The data presented in 
this chapter indicate that DISC1 protein levels are regulated by ubiquitin mediated 
proteasomal degradation.  Mass spectroscopy studies identified K372 as a potential 
acceptor site while my biochemical data suggest the presence of more acceptor lysine 
residues at other sites.  This is a novel PTM identified on DISC1 and we speculate that this 
modification has a potential role in the DISC1 pathway.  I also propose that DISC1 
ubiquitination may play a role in the mechanism of all DISC1 associated 
neurodegenerative illnesses, as seen in Alzheimer’s and Parkinson’s diseases where UPS 
dysfunction has been reported.  My studies also uncovered Fbxw7 as a novel interacting 
partner of DISC1 which regulates DISC1 protein levels by catalysing its ubiquitination as a 
functional SCF component.    
 
In the following chapter, my studies focused on targeting this newly uncovered PPI 
(protein- protein interaction) with inhibitors to modulate DISC1 protein levels, exploring a 
new avenue for therapeutic intervention. 
  
 128 
 
5.  
 
Development of disruptor peptide to 
modulate DISC1-SCFFbxw7 complex 
interaction 
 
 
5.1 Introduction 
Association studies, linkage studies and mouse models support DISC1 as one of the most 
promising candidate susceptibility factors for SCZ and other major mental illnesses 
(reviewed in detail in (Chubb et al., 2008)).  Transgenic mice expressing a truncated 
dominant-negative form of DISC1 (Tr DISC1), displayed several anatomical and 
behavioural abnormalities consistent with those observed in patients with SCZ (Hikida et 
al., 2007, Clapcote et al., 2007, Koike et al., 2006).  It has been hypothesised that DISC1 
SNPs and mutations such as that of the Scottish C terminal truncation may lead to loss of 
DISC1 function, which may directly or indirectly contribute to the pathophysiology of 
psychiatric illnesses.  It has been difficult to study human DISC1 protein as the DISC1 
protein levels in the lymphoblasts collected from the patients of the Scottish pedigree 
were shown to be too low to be detected by Western blotting technique.  These low 
protein levels may be attributed to the instability or haploinsufficiency of TrDISC1 (Millar 
et al., 2005b, Sawa and Snyder, 2005).   
 
To date, there is no evidence that the DISC1 truncated protein (TrDISC1) is translated in 
lymphocytes in which the translocation has been identified (Scottish translocation) (Millar 
et al., 2000b).  However, there are a few hypotheses for how DISC1 mutation can result in 
psychiatric disease.  Firstly, it has been hypothesized that the translated protein product 
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might not be stable and is rapidly degraded (Millar et al., 2005b).  In a different scenario, 
the truncated protein may be stable but may interfere with the function of the wild type 
protein product from the other allele, resulting in loss of function known as a dominant 
negative effect.  Secondly, another hypothesis suggests that the DISC1 truncation could 
result in haploinsufficiency (definition of haploinsufficiency- both alleles need to be 
functional for a wild type functional genotype for a particular gene) (Thomson et al., 
2005).  My proposed project aims to address the DISC1 haploinsufficiency hypothesis and 
uncover the disease mechanisms involved.   
 
Since DISC1 is ubiquitinated and the E3 ligase component Fbxw7 is crucial in regulating 
DISC1 protein levels, I hypothesize that a disruptor peptide/small molecule targeting the 
binding sites of DISC1 and Fbxw7 would abolish their interaction thus interfering with 
DISC1 ubiquitination and increasing its stability.  I propose that the identified and mapped 
novel protein-protein interaction site could be a future drug target for SCZ and other 
associated psychiatric illnesses with underlying DISC1 mutations.  
 
5.1.1  Protein – protein interactions (PPI) as drug targets  
The present drug market is mostly full of competitive small molecule inhibitors of various 
enzymes, receptors and ion channels, and over the years the number of targets has 
dwindled, whilst the developmental costs have soared.  Protein-Protein interfaces of 
large molecular complexes have become attractive drug targets as they have an added 
advantage of extra specificity and can be easily identified through biochemical co-
purification (Arkin and Wells, 2004, Chène, 2006).  Until recent years, they have been 
considered to be ‘undruggable’ and complex targets.  With drugs belonging to this new 
class already on the market such as Tirofiban and Maraviroc and many others advancing 
in clinical trials, there has been increasing scope to exploit this new class of drug targets 
(Vlieghe et al., 2010).  In essence, PPI inhibitors represent the next generation of drugs 
and more of their kind are en route to the market in the near future.  PPIs are involved in 
a wide array of disease pathways that have become attractive drug targets lately, and the 
ongoing elucidation of the human interactome is opening up avenues in this field of drug 
discovery.  The human interactome has been estimated to have approximately 650,000 
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interactions, providing an excellent source to develop novel targets for therapeutic drug 
development (Chène, 2006, White et al., 2008).  Having overcome initial technical hurdles 
and experimental difficulties for characterising PPI drug targets, this class of therapeutic 
intervention has gathered considerable pace.  
  
5.1.2  DISC1 – Fbxw7 interaction as a drug target 
It is estimated that nearly 80% of cellular proteins undergo irreversible ubiquitin 
conjugated proteolysis by mediation of substrate specific ubiquitin E3 ligases, in response 
to specific stimuli (Bernassola et al., 2010, Varshavsky, 1997).  Most of the characterised 
E3 ligases are modular protein complexes constituting a core scaffold unit with switchable 
substrate targeting subunit (Joazeiro and Weissman, 2000, Kipreos and Pagano, 2000).  
Cullin RING ligase (CRL) ligases, also known as SCF (Skp1-Cullin-Fbox) complexes, are the 
best characterised complexes which have such architecture (reviewed in 1.5.3.3).  The 
crucial substrate recognition component of the SCF type E3 ligases is the Fbox protein 
(Skowyra et al., 1997).  To date, only 69 human Fbox proteins have their multiple specific 
target substrates identified and it is hypothesised that there are a number of other Fbox 
proteins whose substrates are yet to be identified.  One Fbox protein which has been 
implicated in the brain is Fbxw7, which plays a significant role in neural stem cell 
differentiation (Matsumoto et al., 2011, Wang et al., 2012a).  Cultured neurospheres 
lacking Fbxw7 showed decreased neurogenesis and increased accumulation of cells 
expressing radial glial markers (Hoeck et al., 2010a).  From the above studies, the role of 
Fbxw7 in neuronal proliferation and maturation is evident, though the precise mechanism 
is not elucidated yet.   
 
The present study so far uncovered a novel interacting partner of DISC1, Fbxw7, which 
directly interacts and modulates DISC1 protein levels.  This finding is highly significant in 
the wake of recent reports which identify dysregulation of ubiquitin in neurodegenerative 
diseases, such as Parkinson’s disease, where α-synuclein rich Lewy bodies stain positive 
for ubiquitin and have been associated with dementia (Al-Mansoori et al., 2013).  Since 
‘haploinsufiency’ of DISC1 was one of the proposed disease mechanism of SCZ and other 
associated chronic mental illnesses (Hikida et al., 2012), the DISC1-Fbxw7 interaction is 
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considered by our group to be a novel druggable target, and my strategy was to stabilise 
DISC1 protein levels by disrupting the above complex and hence abolishing its subsequent 
ubiquitination. 
 
5.2  Experimental aims 
 
 
Figure 5.1 Schematic of the proposed hypothesis addressed in the present chapter 
DISC1 is ubiquitinated and the E3 ligase component Fbxw7 is crucial is regulating DISC1 
protein levels.  A disruptor peptide targeting the binding sites of DISC1 and Fbxw7 
would abolish their interaction interfering with DISC1 ubiquitination and increasing its 
stability. 
 
I propose that the identified and mapped novel protein-protein interaction site could be a 
future drug target for DISC1 associated mental illnesses.  The developed disruptor peptide 
has the potential for development into DISC1 - associated neuropsychological disorder 
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drug treatment and a valuable tool to probe still uncovered functional roles of DISC1 in 
various signalling pathways and disease mechanisms. 
 
5.3 Results 
5.3.1  Peptide array based screening and optimisation of the 
putative disruptor peptide to increase its activity, specificity 
and stability 
DISC1-Fbxw7  interaction was elucidated by peptide array fine mapping studies in chapter 
4, and the precise CPD (Cdc4 Phosphodegron) motif on DISC1 protein was identified.  In 
agreement with other Fbxw7 substrates, Fbxw7 interacts with DISC1 through a preceding 
phosphorylation event by a yet unknown kinase on a short and well defined motif.  The 
shortest DISC1 CPD motif identified in the peptide array screens was similar to other 
known Fbxw7 substrates and was selected for further development as a tool to disrupt 
the protein complex.  
 
 
Figure 5.2  Designated amino acid positions on the 7-mer peptide identified and 
shortlisted for developing a disruptor peptide.  
This peptide will be termed as ‘peptide T’ from here on.  pT and pS refer to 
phosphothreonine and phosphoserine respectively.  The remaining amino acids were 
given single letter amino acid representation.  
 
Peptide arrays have been considered a powerful tool not only to identify and characterise 
protein interactions but also to develop peptide ligands.  In the present study, in-depth 
structure activity relationship studies (SAR) of peptides were performed in order to 
facilitate development of a lead peptide disruptor. 
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Criteria considered while optimising and developing the disruptor peptide were as 
follows: 
1. Most of the naturally occurring amino acids are L isomers and the cellular proteases are 
specific to peptide bonds linking L amino acids.  Therefore, substitution with D isomers of 
the amino acids increases the stability of the peptide in cells.  Peptides flanked by non-
natural amino acids also resist proteolysis by exopeptidases. 
2. Since side chains of the amino acids play a crucial role in the specificity of enzyme – 
substrate complex formation, amino acids with capped or modified side chains serve as 
better substitutes, as they evade proteolysis. 
3. When the amino acids are substituted, it is important to maintain the overall charge to 
mimic the natural peptide, so that the disruptor will act as a peptidomimetic with a higher 
affinity towards Fbxw7 interaction than that of the natural peptide (DISC1 CPD).  
Phosphomimetic amino acids such as Glu and Asp retain the charge while replacing the 
phosphorylated residues pT and pS.  
4. These substitution studies also provide information on the role of each amino acid 
residue and whether the side chains participate in the interaction.  Substitution with Ala, 
which has a methyl group as its side chain, eliminates side chain interactions while the 
peptide backbone confirmation is retained.  
5. Pro with a cyclic side chain containing a nitrogen as a backbone atom, restricts protein 
confirmation and makes it  preferential for inducing β turns in polypeptides sheets 
(MacArthur and Thornton, 1991).  Hence, the amino acid substitutions considered should 
have a similar backbone while they meet all the above criteria, such as the non-natural 
amino acids - Pip, Tic, Sar.  
6. Shifting the amino group on the peptide back bone, from the α carbon to the β carbon, 
increases the length of the peptide backbone and increases their stability, since β peptide 
bonds are non-natural.  
7. While considering substitutions for His at P7 in the native peptide, amino acids such as 
lys and the non-natural amino acid ornithine were considered to retain the negative 
charge.  With an imidazole ring in its side chain and its ability to exist in protonated and 
de protonated forms depending on the pH, His is known to be crucial in protein 
 134 
 
interactions.  Replacement with neutral amino acids (no charge on the side chain) such as 
Trp, Phe, Lys would determine if the side chain of His functions as a charge donor or is 
involved in pi-stacking  (non covalent interactions between aromatic rings in proximity) 
which  is crucial for the interaction under study.   
 
Table 5.1 Recommended amino acid substitutions for disruptor peptide optimisation  
 
 
Non natural amino acids and those with capped/modified side chains are given 3 letter 
representation. mE – N methyl Glutamic acid, mE – N methyl Aspartic acid, Sar – 
Sarcosine, L-β-homoalanine, Pip - (S)-N-Fmoc-piperidine-2-carboxylic acid, Tic-N-FMOC-
L-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid.  Lower case and Upper case single 
letter represents the D and L enantiomers of the amino acids respectively.  Amino acid 
(used in the optimisation experiments) structures can be found in the appendix.  Based 
on the criteria discussed previously, the above recommendations were considered for 
developing the disruptor peptide for DISC1-Fbxw7 interaction.  Amino acids highlighted 
in red were only considered as the rest of the amino acids were not available at the 
time of this study. The above recommendations were suggested by Dr Jeffrey Walton, 
University of Edinburgh.  
 
To explore the interaction between the DISC1 CPD peptide and Fbxw7, and to develop 
shorter peptides with improved pharmacological properties,  a peptide library was 
generated containing modified peptides (with substitutions described in Table 5.1). An 
array produced with this library was screened for interaction with SCFFbxw7 (Figure 5.3 (a)).  
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Spot intensity was quantified and represented statistically by normalising it to the 
intensity of the control/native peptide (peptide T) (Figure 5.3 (b), (c)). 
 
 
 
Figure 5.3 (a) Peptide array studies to optimise and increase peptide stability and 
efficacy 
A substitution peptide library was generated by substituting amino acids of the core 
sequence at various positions, as suggested in Table 5.1 above.  The peptide library was 
spotted on a cellulose membrane and incubated with SCFFbxw7 protein complex and 
probed for His tag with an anti His antibody, which is on the Skp1 component of the 
complex.  Dark spots indicated positive interaction.  The left panel represents the first 
round optimisation while the right indicates the second round.  The peptides sequences 
selected in each round for further optimisations were highlited in red and the 
sequences were mentioned below the peptide array scans. Control spots were 
hightlighted in green.  Replicate spots were omitted from the list. Control spots (control 
peptide  P-pT-P-P-G-S-H) highlighted in green. 
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Figure 5.3 (b), (c) Optimisation to increase the efficacy of the disruptor peptide to 
modulate DISC1-SCFFbxw7 interaction 
(b) and (c) - Each spot intensity from the peptide arrays from Figure 5.3a was quantified 
using Image J and statistically represented as percentage intensity over that of the 
control spot (native DISC1 CPD peptide, Figure 5.2).  Representative data from n=3.  
Values plotted as mean +/- S.E.M. 
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After the second optimisation round, peptides showing stronger positive interaction were 
identified and shortlisted (Figure 5.3a).   
 
 
5.3.2  Stabilisation of endogenous DISC1 protein by the lead 
peptides in HEK293 cells  
Subsequently, four peptides were selected for further investigation (Figure 5.4) based on 
the following criteria: (a) Peptides with Gly were selected because Gly at P1 retains the β 
turn while it replaces Pro in the natural peptide; (b) peptides with non-natural 
phosphomimetics at  P2 and P4 were selected as they maintain the charge while they 
increase the stability of the peptide.  From close observation of the sequence of the 
peptides, it was evident that the lead peptides selected were phosphomimetic in nature.  
This also strengthened the proposed hypothesis, which states that the phosphorylation 
within the DISC1 CPD triggers its association with Fbxw7 (as seen in other known Fbxw7 
substrates).  Previous work in our lab demonstrated that a stearate group facilitates 
peptide transport across the cell membrane, owing to its hydrophobic nature (Meng et 
al., 2009).  N terminal stearated peptides (Figure 5.4) were custom made by Think 
Peptides®, ProImmune Ltd., UK.  The peptides were synthesised using FMoc chemistry and 
purified to > 85% for further cell based testing.  Peptides were quality tested using Mass 
spectroscopy and HPLC to confirm the mass and purity, respectively.   
 
Figure 5.4 Optimised putative disruptor peptides selected for testing in cell lines.  
Peptide sequence is represented from N terminal to the C terminal.  St indicates 
stearated group at the N terminal end of the peptide.   
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The lead peptides obtained in lyophilised form were carefully resuspended in DMSO, 
aliquoted and stored at -20°C.  The next step in the study was to determine whether the 
cell permeable stearated 7mer lead peptides stabilise/increase endogenous DISC1 protein 
levels in HEK293 cells.  Initial studies included technical optimisations such as monitoring 
any possible cell toxicity, concentration of peptide, and the time of peptide treatment.  
HEK293 cells were treated with the stearated peptides at 100µM concentration for 3hr 
and cell lysates were analysed for changes in DISC1 protein levels by performing Western 
blotting.  
 
 
Figure 5.5  Preliminary  screen of the lead peptides in HEK293 cells for DISC1 protein 
stabilisation.  
Top panel: Immunoblot analysis of lysates from HEK293 cells treated with 100µM 
peptide for 3hr.  DISC1 expression levels was analysed using anti DISC1 antibody and 
GAPDH antibody was used to probe for GAPDH expression which served as a loading 
control. Lower panel: Immune band intensities were quantified by densitometry and 
are presented as fold change in DISC1 expression normalised to GAPDH. S.E.M. of three 
biological repeats.  Statistical significances between control peptide and each test 
peptide was calculated using one way analysis of variance (ANOVA). *P < 0.05 values 
were considered significant.  
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My preliminary  peptide treatments have suggested that only peptide 139 and 142 
treatment have stabilised DISC1 protein levels (Increased band intensity over control, 
determined by densitometric quantification of the blots) in HEK293 cells over control 
peptide treatments (Figure 5.5). 
 
 
5.3.3  Application of peptides to cell lines resulted in stabilised 
endogenous DISC1 protein levels in a dose dependent 
manner  
Peptides 139 and 142, now considered as ‘lead peptides’, were utilized to perform dose 
response experiments to determine the dose dependent effect of the peptides on DISC1 
stabilisation in HEK293 cells.  Cells were treated with the peptides at indicated 
concentrations for 3hr and cell lysates were subjected to Western blot analysis.  To 
increase the accuracy of the Western blot quantification, the Licor Odyssey infrared 
imaging system which offers a wider linear dynamic range was used.  This imaging system 
uses secondary antibodies conjugated with infrared fluorophores (Table 2.5), while the 
primary antibodies remains the same as used in chemiluminescent detection.  As evident 
from Figure 5.6, DISC1 levels increased with increasing concentration of the test peptides.  
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Figure 5.6 Lead peptides stabilised DISC1 protein levels in HEK293 cells in a dose 
dependent manner. 
 Peptides 132 and 149 were applied to HEK293 cells with a range of increasing 
concentrations and the cell lysates were subjected to immuno blot analysis.  DISC1 and 
GAPDH were detected by probing with anti DISC1 and GAPDH antibodies respectively.  
DISC1 immuno band intensities were quantified by densitometry and presented as fold 
change in DISC1 expression normalised to GAPDH intensities and plotted on a 
logarithmic scale with peptide concentration on the X axis and band intensities on the Y 
axis.  Data shown represent the mean ± SEM of 3 separate experiments.   
This work was performed by Dr.Christina Elliot, Gardiner Laboratory, University of 
Glasgow. 
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5.3.4  The lead peptides specifically stabilised DISC1 while the 
other known Fbxw7 substrates protein levels remained 
unaltered  
The most important factor to be considered in drug development is specificity.  While the  
DISC1 –Fbxw7 complex is being considered as a drug target in my study, it should be 
noted that the interaction is via a consensus motif known as CPD or CPD (CDC4/Fbxw7 
CPD Domain).  This motif and the mechanism of regulation of Fbxw7 interaction has been 
well characterised with several other substrates implicated in neuronal differentiation, 
cell proliferation and cell viability such as Cyclin-E, (Hao et al., 2007a), c-Myc (Yada et al., 
2004), Notch1 (Grim et al., 2006) and c-Jun (Hoeck et al., 2010a).  Fbxw7, as a tumour 
suppressor gene, strictly regulates the turnover of the above oncogenes and functional 
disruption may dysregulate crucial physiological pathways and potentially leads to 
tumerogenesis (Tu et al., 2012, Wang et al., 2012a).  Its functional inactivation by altered 
expression, gene mutations and other unknown mechanisms lead to impaired 
oncoprotein regulation.  As described in Figure 4.15, human DISC1 CPD shares a close 
similarity with the CPD of other known Fbxw7 substrates.  While peptides 139 and 142 
stabilised endogenous DISC1 protein levels in HEK293 cells, it was important to determine 
that the disruptor peptide was specific for DISC1-Fbxw7 interaction and does not 
interfere with the Fbxw7 mediated regulation of other substrates.  Peptide treated 
HEK293 cell lysates were probed for the expression pattern of Notch1, c-Myc, c-Jun and 
Cyclin E along with DISC1 using immunoblot analysis.  
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Figure 5.7  Expression of alternative Fbxw7 substrates remained unaltered in response 
to the lead peptide treatment. 
Cell lysates of HEK293 cells treated with the lead peptides 139 and 142 were analysed 
by Western blotting technique.  Protein expression of various Fbxw7 substrates – DISC1, 
Notch1, c-Myc, c-Jun, and  Cyclin E, were detected by probing with anti DISC1, Notch1, 
c-Myc, c-Jun, and  Cyclin E antibodies respectively.  GAPDH antibody was used as 
loading control. Data shown represent the mean ± SEM of 3 separate biological repeats. 
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Band intensities were quantified by using Odyssey software and statisticaly represented 
in the graphs. This work was carried out by Dr.Christina Elliot, Gardiner Laboratory, 
University of Glasgow. 
 
Cell lysates from HEK293 cells treated with the lead peptides (139 and 142) were probed 
for other known Fbxw7 substrates.  Immunoblots (Figure 5.7) show that the peptides 
specifically stabilised endogenous DISC1 protein levels while the other substrates 
(Notch1, c-Myc, c-Jun, Cyclin E) largely remained unchanged implying that the lead 
peptides specifically disrupt Fbxw7-DISC1 interaction and do not interfere with other 
crucial interactions of Fbxw7. 
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5.3.5  Induced Pluripotent Stem cells as a cell line model  
The exprimental work described in the section has been carried out as part of a 10 week 
Ph.D. placement at Pfizer Neuroscience Research Unit, Cambridge, Boston, MA in 
February  – April 2013. 
 
5.3.5.1   DISC1 animal models – Limitations  
Identification of DISC1 in the Scottish pedigree has garnered much attention by scientists 
who have tried to uncover the molecular mechanisms behind the biological phenomenon 
in order to develop therapeutics from a most promising susceptibility gene for SCZ and 
other associated mental illnesses.  However, research in psychiatric illnesses is severely 
hampered by the lack of availability of human brain tissue, especially live neurons from 
patients.   
 
The mouse has long been an attractive genetic model organism to study psychiatric 
disease, as it has many advantages such as the availability of a range of inbred strains, 
completed genome sequences and advancements in technology to genetically manipulate 
mice in numerous ways.  DISC1 mouse models were invaluable and provided 
developmental and mechanistic insights, which could have been otherwise difficult to 
obtain.  A review by Hanna Jaaro-Peled  discusses all the seven DISC1 mouse models 
generated so far (Jaaro-Peled, 2009).  These mouse models displayed a wide range of 
phenotypes which include both abnormal anatomical changes (example: reduced brain 
volume and neurite outgrowth) and behavioural phenotypes (example: diminished 
working memory and pre pulse inhibition (PPI)).  Q31L and L100P were two ENU (N-ethyl-
N-nitrosourea) induced mutants generated, which exhibited behavioural phenotypes- 
depression like and SCZ like respectively (Clapcote et al., 2007).  MRI studies in these mice 
have also exhibited enlarged lateral ventricles, a common observation in SCZ patients 
(Vita et al., 2006). Koike et al. (2006), reported that 129S6/SvEv mice strain harbour a 
25bp deletion in the DISC1 gene which results in a termination codon in exon 7, which 
abolishes the translation of full length DISC1 protein.  Working memory was shown to be 
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impaired when this variant was transferred to the C57BL/6 genetic background (Koike et 
al., 2006).  A DISC1 knockout mouse would the most useful tool; however, generation of a 
‘true null’ has been challenging so far, as all DISC1 isoforms have not been identified and 
characterised yet (Brandon et al., 2004, Miyoshi et al., 2003a, James et al., 2004a).  Since 
DISC1 was shown to be crucial in neurodevelopment processes, there is also a possible 
risk of lethality during development of KO mice (Schurov et al., 2004a) (Ishizuka et al., 
2006).  A conditional knockout mice in Cre/loxP system was another alternative suggested 
by experts to circumvent the complexity surrounding the KO mice generation (Ishizuka et 
al., 2006).  Kuroda et al, generated transgenic mice lacking exons 2 and 3 (also known as 
Disc1 (∆2-3)) which were shown to have higher threshold for the induction of long-term 
potentiation (LTP) and showed PPI deficits which are a well-known phenomenon 
observed in schizophrenia patients and other neuropsychiatric disorders (Kuroda et al., 
2011). 
 
However, it should be noted that animal models do not completely translate to the 
human condition and their use has always been limited in psychiatric research.  It is 
impractical to generate schizophrenic mice and extremely difficult to study the psychotic 
symptoms such as hallucinations and delusion.  To add to the complexity, most of these 
illnesses are polygenic and involve gene - environment interactions.  Research over the 
last decade failed to develop a cell line/animal disease model for SCZ, which has been a 
major obstacle in drug development, as drug toxicity may vary with the variable ability of 
different species to metabolise drugs.  
 
Since most of the drugs are targeted to regulate protein expression or enzyme activity, it 
is important that the protein of interest is well conserved in the species model.  In light of 
DISC1 being implicated in brain dysfunction, it should be noted that DISC1 protein is 
poorly conserved between various species which may be considered as a major drawback 
in considering the use of rodent derived cell lines for DISC1 studies.  Primate cerebral 
cortex differs substantially from that of rodents in many features, such as cerebral cortex 
size, complexity and the nature and range of stem cell population.  Drug discovery for 
 146 
 
psychiatric illnesses has also been considerably slow owing to the failure of the prognostic 
validity of animal models.   
 
Since my present study focuses on the idea of developing the DISC1/Fbxw7 interaction as 
a putative drug target, it is crucial to choose a relevant cell model for in vitro studies.  The 
DISC1 and Fbxw7 interaction is characterised in the present study and the amino acids 
that are involved in the interaction have been mapped using peptide array studies 
(covered in chapter 4).  Mouse models or mouse primary neuronal cultures are popular 
choices for most in vitro studies in the neuroscience field.  In the present study, since 
protein-protein interaction was being characterised, it was important to consider the 
extent of evolutionary conservation between mouse, rat and human DISC1 protein 
sequences.  
 
 
Figure 5.8  Amino acid homology showing DISC1 CPD alignment within various species.   
Homology analysis was done using the Basic Local Alignment Search Tool (BLAST) at the 
NCBI website (http://www.ncbi.nlm.nih.gov/blast). Non conserved CPD motif residues 
in mouse and rat were highlighted in red.  
 
 
Mouse and rat orthologues of DISC1 are only about 56% identical to the human DISC1 at 
nucleotide and amino acid levels, a fact that suggests the unusually rapid evolution of 
DISC1 (Jaaro-Peled, 2009, Ma et al., 2002b).  From the above Table, it is quite evident that 
the CPD motif is barely conserved in mouse and rat when compared with similar 
sequences of higher primates.  This poses a major obstacle in considering cell lines from 
mouse or rat origin to perform in vitro studies to characterise DISC1 CPD.   
 
 147 
 
Until recent years, most of the research on psychiatric disorders relied on brain imaging 
of patients, genetic studies on lymphocytes from patients and biochemical studies on 
post mortem brain tissue.  Though these approaches led to enormous progress in 
understanding the disease, they could not efficiently address molecular and cellular 
aspects leading to the development and progression of the disease.   
 
Inaccessibility of human brain tissue has been a major hurdle for decades in psychiatric 
research.  Peripheral leukocytes and autopsy samples were the alternatives available for 
investigating the molecular basis of mental illnesses (Altar et al., 2005, Hashimoto et al., 
2006, Saetre et al., 2008).  However, there has been a long standing debate if the findings 
from the above sources can be successfully extrapolated to brain specific diseases, since 
factors such as cause of death, medication, use of alcohol and nicotine may influence 
gene expression and hence fundamental disease related molecular phenomenon may not 
be addressed (Lipska et al., 2006a).  The advent of induced pluripotent stem cell (iPS cell) 
technology opened up new avenues in the field of neurodevelopmental disease research.  
 
 
5.3.5.2   Induced Pluripotent Stem cells (iPSCs)   
iPS cells are adult cells that have been genetically reprogrammed to behave like 
embryonic stem cells by inducing them to express genes (by various methods) that are 
essential for maintaining the defining properties of embryonic stem cells (Nakagawa et 
al., 2008).  The term pluripotency represents cell types with functional capabilities to 
generate cell types from three embryonic germ layers endoderm, mesoderm and 
ectoderm.  Patient specific culture of immortal cells would yield invaluable information 
about disease mechanisms and allow a novel route to investigate these mechanisms for 
the development of novel drugs.  However, until recently this was restricted to cancer 
research.  The Nobel Prize in Physiology or Medicine for 2012 was awarded to Prof.Shinya 
Yamanaka "for the discovery that mature cells can be reprogrammed to become 
pluripotent.  (Reference 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/’). 
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Yamanaka and colleagues generated mouse iPS cells for the first time in 2006, from 
mouse embryonic and adult fibroblasts by viral transduction of Oct3/4, Sox2, c-Myc, and 
Klf4, under ES cell culture conditions (Takahashi and Yamanaka, 2006).  These four factors 
were later used to generate iPS cells from human skin fibroblasts (Takahashi et al., 2007).  
However, there were major drawbacks to the protocols used in these studies, with c-Myc 
being an onco gene and the associated increased risk of tumor development at a later 
stage.  The same group went on to develop a method, whereby, iPS cells were made 
without having to transduce the c-myc gene and use drugs for selection (Nakagawa et al., 
2008).  The method described in the above study also increased the quality of iPS cells 
and reduced the back ground of non iPS cells (Nakagawa et al., 2008).  In later years, 
integration free reprogramming methods were developed which increased the quality 
and yield of iPS cells (Cahan and Daley, 2013).  These pioneering studies were followed by 
the successful generation of iPS cells from patients with various genetic disorders 
including neurological disorders like Huntington’s and Parkinson’s disease (Zhang et al., 
2010, Park et al., 2008).  Patient specific stem cells offer an extraordinary  opportunity to 
reiterate both normal and pathological  human tissue formation in vitro, particularly in 
case of brain diseases, thereby enabling disease investigation and drug target 
development (Park et al., 2008).  It can be understood that after well over a decade of 
initial constraints these area have now been overcome and research in this area is 
currently flourishing.  
 
5.3.5.3   iPS cell technology in brain research 
iPS cell technology offers an excellent alternative and is invaluable in neuropsychiatric 
research.  Their ability to differentiate in to three germ layers (ectoderm, endoderm and 
mesoderm) renders  iPS cells as ideal  patient specific model cell lines for SCZ, where 
aetiology still remains unclear.  Generation of human and patient specific cell models is 
advantageous in developing drug targets in that they allow a limitless supply of human 
patient specific cells that can be differentiated into the cell type of choice where the 
disease specific phenotype can be recapitulated.  This novel research approach facilitates 
the design and verification of disease models which are otherwise not feasible for 
psychiatric illnesses.  
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A number of groups reported the successful generation and use of iPS cells in disease 
modelling to investigate neurological disorders  (Pedrosa et al., 2011, Chiang et al., 2011, 
Zhang et al., 2010, Wernig et al., 2008, Cherry and Daley, 2013).  Brennand et al, (2011) 
employed this principle and reprogrammed fibroblasts from SCZ patients to human iPSC 
and subsequently differentiated these pluripotent cells into glutamatergic neurons.  They   
performed extensive gene expression profiling and looked for morphological changes in 
these disorder specific neurons to investigate the molecular defects in SCZ.  Compared to 
the control neurons, they reported reduced PSD95-protein levels, glutamate receptor 
expression, abnormal Wnt and cAMP signalling along with morphological changes such as 
reduced neuronal connectivity and neurite number in SCZ neurons (Brennand et al., 
2011).   
The ability of iPS cells to efficiently differentiate into any desired cell type such as neurons 
has been successfully demonstrated (Gao et al., 2013), (Pedrosa et al., 2011).  With the 
addition of specific factors to the culture media, iPS cells have been further differentiated 
into brain region specific identities including hindbrain, forebrain and spinal cord, 
permitting large scale production of specific neurons carrying the genetic background 
from the disease carriers (Brennand and Gage, 2012). This also facilitates analysis of the 
differentiated cells under controlled conditions.  iPSC derived neurons are ideal 
particularly for neurodevelopmental disorders like SCZ, since they facilitate recapitulation 
of  the early stages of neuronal differentiation in genetic backgrounds which may increase 
the risk of disease.  They also allow the study of the cellular and molecular events 
triggering the onset of these disorders.   
 
For the purpose of screening the lead peptides (developed in the present study) within a 
short time frame, expandable neuronal progenitors generated from the iPS cells were 
used.   
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Figure 5.9 Application of iPS cell technology in research and drug development 
Adapted from (Robinton and Daley, 2012). 
This novel technology facilitates reprogramming of easily available patient specific skin 
fibroblasts into affected neuronal subtypes.  These differentiated neurons can be used 
for patient genotype specific disease modelling in vitro and serve as a tool to study drug 
targets and develop potential drugs.  
 
 
5.3.5.4   Experimental aims 
The aims of this section of the chapter are as follows: 
1. Explore iPSc technology for disease modelling by differentiating the accessible iPS cells 
reprogrammed from SCZ patients and differentiating them to neuronal progenitor cells 
(NPs).  
2. Characterisation of the neuroprogenitor cells (NPs) by screening of pluripotent and 
neuronal markers. 
3. Study DISC1 and Fbxw7 expression profile in NPs. 
4. Test the novel hypothesis that DISC1-Fbxw7 interaction controls DISC1 protein levels in 
NPs.  
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5.3.5.5   Results 
iPS cells generated from skin biopsies of patients diagnosed with SCZ have been used in 
the present study.  The cells were taken from healthy controls (with no known mutations 
in DISC1 gene) and SCZ patients harbouring a 4bp deletion at the 12th exon-intron 
boundary in the C-terminus of the DISC1 gene.  Neuronal progenitors differentiated from 
these cells were considered suitable for in vitro testing of the putative disruptor peptides 
for the following reasons: 
 
1. Availability: Recent advancements in the field of iPSc research have enabled the 
production of these cell lines without specialised equipment. 
 
2. Origin: Since the iPS cells used in the present study were generated from patients 
diagnosed with SCZ, they allow close recapitulation of the cellular phenomena related to 
SCZ and are apt for use in investigating the underlying molecular events.  
  
3. Disrupted DISC1 gene: One of the major genetic risk factor of SCZ, DISC1 gene carries a 
4bp deletion, resulting in a frame shift mutation which could be translated to a truncated 
protein.  It would be intriguing to investigate if this mutation has a role to play in DISC1 
signalling pathway in these cells.  
  
The iPS cells (except Detroit) used in the present study have been described and 
characterized previously (Chiang et al., 2011, Pedrosa et al., 2011). iPS Detroit cell line 
were generated by Dr.Sandra Engle, Pfizer Inc.   All the cell lines used in this study were 
karyotyped (for chromosomal aberrations) and screened for the expression markers 
(stem cells) at Pfizer. 
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Table 5.2  Description of the iPS cells used in the study   
 
iPS cell 
line 
Assigned 
name 
DISC1 mutation Origin Phenotype Sex Reference 
Control C1-1 none Skin 
biopsy 
Normal M (Chiang et 
al., 2011) 
Control Detroit none Detroit 
551 
fibroblast
s ATCC 
(CCL-110) 
n/a n/a Generated 
by Dr. 
Sandra 
Engle, 
Pfizer Inc. 
Patient D2-1, D2-2 4bp deletion at 
12th intron-exon 
boundary 
Skin 
biopsy 
Chronic 
paranoid 
Schizophrenia 
F (Chiang et 
al., 2011) 
Patient D3-1, D3-2 4bp deletion at 
12th intron-exon 
boundary 
Skin 
biopsy 
Chronic 
undifferentiat
ed 
Schizophrenia 
M (Chiang et 
al., 2011) 
 
 
5.3.5.6   Characterisation of iPS cells and differentiated Neuronal 
progenitors  
Immunocytochemistry based characterisation showed that all of the iPS cell colonies 
showed compact colony morphology and stained positive for the pluripotent markers Tra-
181 and Nanog (Figure 5.12a, 5.12b).  With limited availability of reagents, I was able to 
only screen for Oct4A, a pluripotent marker, using Western blotting analysis (Figure 5.10).   
 
There are four main stages involved in the differentiation process of iPS cell to NPs: 
 (1) Embryoid body (Ebs) formation, where cell aggregates grow in suspension. 
 (2) Plating of the embryoid bodies on defined matrices to form neural rosettes and 
patterning of neural progenitors into specific neuron subtypes.  
(3) Expansion and growth of neural progenitor cells, to generate an appropriate precursor 
population.  
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 (4) Differentiation to specific cell types where neural progenitor cells can develop into 
neurons of specific subtype (This step was not performed in the present study).  
 
 The various stages of neuronal differentiation from iPSc are schematically represented in 
Figure 5.11.  Supplementing minimal growth media with ﬁbroblast growth factor 2 
(FGF2), L-glutamine and ß-mercaptoethanol leads to neural stem cell generation, which is 
characterised by expression of neural markers such as Nestin (Li and Zhang, 2006, Kim et 
al., 2011).  The neuronal progenitors generated, have the potential to be further 
differentiated in to neurons, astrocytes or oligodendrocytes using specific culture 
medium supplements (Chojnacki and Weiss, 2008).  iPS cells described in Table 5.3, were 
karyotyped to check for any possible mutations or carcinogenic gene activation which 
might be  possible as a result of episomal gene transfer (Chiang et al., 2011).  
  
The maintenance and differentiation protocol has been optimized and standardized at 
Pfizer by Dr. Lindsay Wilson, to generate GABAergic neuronal progenitors cells from iPS 
cells by reprogramming.  The detailed protocol has been explained in section 2.3.2.  In 
brief, iPSCs were maintained on Mitomycin C treated (mitotically arrested) MEFs (Mouse 
Embryonic Fibroblasts) in the presence of 10 ng/mL FGF2.  On day 0, iPSc colonies were 
detached from feeder layers and grown on ultra-low adherence plates in suspension 
culture and supplemented with ROCK inhibitor to induce embyoid body (EBs) formation in 
the absence of FGF2.  On day 2, EBs were transferred on to matrigel coated plates.  The 
morphology changes with the progression of differentiation were monitored and 
representative images were detailed in Figure 5.11.  The phenotype of the progenitors 
was also analysed by immunocytochemistry using various neural markers (Figure 5.13 
a,b). 
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Figure 5.10 Immunoblot analysis of expression of pluripotent and neuronal markers. 
Cell lysates collected from the iPS cells and neuronal progenitors from all the six cell 
lines were probed for the presence of pluripotent marker Oct4A and neural progenitor 
stem cell marker Nestin.  GAPDH antibody was used as loading control.  
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Figure 5.11  Schematic of various stages of iPSc differentiation into NPs 
Top panel: Schematic representation of various stages of neuronal differentiation. 
Bottom panel: Representative bright field images taken at different stages of 
differentiation.  Scale: 50µM.  
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Figure 5.12a Immunocytochemistry on iPS cell colonies showing the expression of 
pluripotency marker  
Top panel: Merge image, Middle panel: Tra181 (pluripotency markers), Bottom panel:  
DAPI (nuclear stain).  Scale bar: 50µM 
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Figure 5.12b  Immunocytochemistry on iPS cell colonies showing the expression of 
pluripotency markers  
Top panel: Merge image, Middle panel: Nanog (pluripotency marker), Bottom panel:  
DAPI (nuclear stain).  Scale bar 50µM. 
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Figure 5.13a  Immunocytochemistry on Neuronal progenitors (day 3) showing the 
expression of neural stem cell markers in cell lines (Detroit, C1-1, D2-1)  
NPs stained positive for neural stem cell markers SOX2, PAX6 and NESTIN.  Nucleus 
specific stain DAPI was used.  Scale bar: 50µM.  
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Figure 5.13b  Immunocytochemistry on Neuronal progenitors (day 3) showing the 
expression of neural stem cell markers in cell lines (D2-2, D3-1,D3-2)  
NPs stained positive for neural stem cell markers SOX2, PAX6 and NESTIN.  Nucleus 
specific stain DAPI was used.  Scale bar: 50µM. 
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5.3.5.7   DISC1 and Fbxw7 protein and transcript expression profile in the 
Neuronal progenitors 
Before considering the use of these cell lines for testing my hypothesis, it was important 
to determine whether the cells express DISC1 to levels that can be detected by immuno 
blotting techniques.  DISC1 and Fbxw7 protein expression was quantified in the neuronal 
progenitors derived from the iPS cells using Western blotting to ensure that they have 
detecTable levels to aid further biochemical studies.  α-DISC1 antibody was used to detect 
100kDa isoform of DISC1.  
 
 
 
Figure 5.14   Representative immunoblot showing DISC1 and Fbxw7 protein expression 
profile in the neuronal progenitors differentiated from iPS cells. 
Cell lysates from the NPs were analysed using Western blotting by probing with α DISC1 
(100kDa)  and Fbxw7 (α isoform, 75kDa) antibodies.  GAPDH was used as loading 
control.  
 
 
From Figure 5.14, it is evident that the NPs from patients carrying a DISC1 deletion (D2-1, 
D2-2, D3-1, D3-1) have low DISC1 protein levels compared to that of control subjects 
(Detroit and C1-1).  However, no detecTable differences in expression were observed with 
respect to α-Fbxw7 expression.  This may be attributed to the 4bp deletion on one of the 
alleles of the DISC1 locus which may produce an unstable DISC1 variant. 
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To assess the difference in mRNA transcript levels between the control and patient NPs, 
DISC1 and Fbxw7 gene expression was analyzed using real time PCR.  The relative 
expression of DISC1 in the NPs was assessed in two separate cDNA samples.  Raw CT 
values for five reference genes (TBP, PSMB2, PRLI3A, RPN1 and RPLP0) were entered into 
Normfinder to evaluate the variability of the reference genes (Table 5.3) (Andersen et al., 
2004).  PRLI3A and RPLP0 genes were omitted from further analysis due to high 
variability. The gene expression between cell lines was analyzed using the 2-∆∆CT method 
(Livak and Schmittgen, 2001). 
 
Table 5.3 Table representing stability values of five reference genes obtained using  
Normfinder software 
 
 
The higher the stability value of the reference gene, the higher is the variability of the 
gene expression.  PRLI3A and RPLP0 genes have highest stability of all the reference genes 
considered in the study and hence omitted from further analysis. 
 
 
Figure 5.15 Relative expression of DISC1 transcripts in NPs analysed at day 15 
Shows relative expression of DISC1 transcripts between NPs from different cell lines 
(Detroit and C1-1 cell line were grouped in to ‘control’, D2-1, D2-2, D3-1, D3-2 cell lines 
Primer pair Stability value
TBP 0.007
PSMB2 0.007
PRLI3A 0.011
RPN1 0.008
RPLP0 0.013
 162 
 
were grouped in to patient) determined by real time PCR using Pan DISC1 primers (Life 
technologies) which detect and amplify DISC1 transcripts of all isoforms.  n=2.   
 
 
 
Figure 5.16 Relative expression of Fbxw7 transcripts in NPs analysed at day 15. 
Top panel: Shows relative expression of Fbxw7 transcripts analyzed using Pan Fbxw7 
primers (Life Technologies) which detect and amplify transcripts of all isoforms. Detroit 
and C1-1 cell line were grouped in to ‘control’, D2-1, D2-2, D3-1, D3-2 cell lines were 
grouped in to patient.  Bottom Panel: Shows relative expression of Fbxw7 alpha isoform 
transcripts.  n=2. 
 
From the preliminary RT PCR analysis of DISC1 and Fbxw7 transcripts in the NPs 
generated from the iPS cells, it can be suggested that: 
1. DISC1 transcript levels are higher in patient  NPs (Detroit and C1-1) over those from 
control NPs (D2-1, D2-1, D3-1, D3-2) (Figure 5.15).  Since all the isoforms of DISC1 are not 
characterised to date and isoform specific antibodies nor primer probe sets were not 
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available at the time of this study, the isoform dependent DISC1 expression could not be 
verified.  More biological prepeats should be carried out to gain indepth knowledge on 
the pattern of DISC1 transcript expression and how it may vary during the neuronal 
differentiation of iPS cells.  
2. Fbxw7 transcript levels were analysed using primer probe sets which were specific for a 
common region of the 3 isoforms (α, β, γ) and those specific for the α isoform.  Though 
the transcript levels detected by the pan primer-probe sets were not informative with 
high variation, it was interesting to see that relative mRNA transcript levels of FBXW7 α 
isoform were lower in patient NPs over those in control NPs.  
Although the above data are inconclusive, owing to low biological repeats, it would be 
intriguing to establish a correlation between the expression of these two proteins to 
understand their role in NPs differentiation to expand our knowledge on DISC1 role in 
brain development.  Unfortunately, these studies were not within the scope of this 
project.  
 
5.3.5.8   Proteasomal inhibition causes DISC1 stabilization in NPs 
Ubiquitination, a novel post translational modification of DISC1 protein, was reported in 
the present study (chapter 4).  Ubiquitin chain conjugation to DISC1 was characterised 
and was reported to be readily augmented with proteasome inhibition.  
Immunoprecipitation studies and subsequent Mass spectroscopy studies confirmed the 
presence DISC1-ubiquitin conjugates.  Since the preliminary studies were performed in 
HEK293 cells, it was important to examine this hypothesis in a more relevant cell model 
such as NPs generated from iPS cells, which have an added advantage of being derived 
from SCZ patients.  Due to limited availability of reagents and time constraint, one control 
line (Detroit) and one patient line (D2-1) were selected for further studies.  
NPs derived from Detroit and D2-1 were treated with MG132 at a 10 µM concentration 
for indicated time points (Figure 5.17), followed by cell lysis and Western blot analysis.  
DISC1 and GAPDH protein expression was detected using  anti DISC1 antibody and anti 
GAPDH antibodies respectively.   
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Figure 5.17 Effect of proteasome inhibition (MG132 treatment) on DISC1 protein 
expression in NPs at day 18.  
NP were treated with proteasomal inhibitor MG132  on  day 18 at 10 µM for indicated 
time points followed by Western blot analysis with anti DISC1 (100kDa) and anti GAPDH 
antibodies (n=2).  Quantitative analysis of the immunoblots representing percentage 
change normalized to GAPDH.  Data are mean ± S.E.M. of two experiments on two 
different sets of NPs collected at two consecutive passages.  
 
Proteasomal inhibition in NPs generated from Detroit (control) and D2-1 (patient) iPS cells 
resulted in stabilization of DISC1 (100kDa) protein levels within the first 30 min up to 3 
hours, consistent with the observation made in HEK293 cells.  This indicates that DISC1 
turnover is regulated by the UPS system in these cell lines, which therefore can be used as 
a cell line model to screen the lead peptides.  
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5.3.5.9   Screening of DISC1-Fbxw7 disruptor peptides on NPs generated 
from the iPS cells 
As a more relevant cell model has been proposed (NPs), we next investigated whether the 
disruptor peptides developed in the present study (chapter 5) would stabilise DISC1 in 
these cells.  As within the scope of the project, only fundamental experiments were 
performed by treating the NPs with the peptides that stabilised DISC1 in HEK293 cells 
(peptide 139 and 142).  NPs were treated with peptides at 100µM concentration for 1, 2 
and 3hr followed by Western blot analysis of the cell lysates.  DISC1 protein expression 
was determined by probing with α-DISC1 antibody and GAPDH levels served as a loading 
control.  
 
 
 
 
 
Figure 5.18 Disruptor peptides developed were screened in Neuronal progenitor cells 
for DISC1 stabilisation using immuno blot analysis.  
 NPs from Control (Detroit) and Patient (D2-1) cell lines were lysed after treatment with 
the peptides 139 and 142  at increasing time points from 0 hr (no treatment) up to 3hr 
at 100µM each.  DISC1 protein expression was detected by DISC1 antibody.  GAPDH 
antibody was used as loading control (n=2). 
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Figure 5.19 Quantitative analysis of immuno blots (from Figure 5.18) showing fold ratio 
of DISC1 normalized GAPDH.  
Data are mean ± S.E.M. of two experiments.  Statistical differences could not be 
determined due to low replicate experiments (n=2). 
  
Lead peptide 139 stabilised DISC1 in both the cells lines as seen in Figure 5.18, left panel 
within 3hr of peptide treatment at a 100µM concentration.  Although peptide 142 
stabilised DISC1 protein levels in the Detroit cell line (control) at the 3hr time point, the 
effect was negligible in D2-1.  While the results were promising, more technical and 
biological repeats could not be performed to ascertain this effect of the lead disruptor 
peptides due to time and budget restraints.  
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5.4  Discussion  
In summary, the present chapter explores the potential of (1) DISC1 protein complexes 
for drug discovery and development; (2) peptides that act as substrate-specific Fbox E3 
ligase inhibitors; (3) iPS cell derived NPs as a patient specific cell model to investigate 
disease mechanism and role of DISC1.  
 
A  single gene locus may produce multi compartmentalised proteins by mechanisms such 
as  post translational modification, alternative splicing, alternative transcription and 
translation  initiation (Danpure, 1995).  Genetic studies on psychiatric patients identified a 
SCZ proband as carrying  a balanced t(1;16)(p31.2;q21) translocation, who had a history 
of psychotic episodes with hallucinations and delusions (Millar et al., 2005b).  Biochemical 
studies in cells from different individuals with the translocation revealed that DISC1 
expression was nearly 50% less both at transcript and protein levels in subjects with the 
translocation.  It has been proposed that the translocation is the likely reason for the 
observed reduction in the DISC1 expression and for the individuals with the translocation 
being susceptible to SCZ (Millar et al., 2005b, James et al., 2004a).  The haploinsufficiency 
disease model is one of the widely accepted disease mechanisms in which an individual is 
heterozygous for a gene mutation or a truncation at a particular locus.  RNAi mediated 
knockdown of DISC1 in mouse embryonic brains delayed neuronal migration and 
decreased dendritic arborisation (Kamiya et al., 2005b).      
 
Co-Immunoprecipitation and co-crystal structure (data shown in appendix) confirmed 
complex formation of Fbxw7 and DISC1 (chapter 4).  Having identified Fbxw7 as a putative 
E3 ligase involved in regulating DISC1 turn over, my studies focused on developing the 
Fbxw7 – DISC1 interaction as a putative drug target.  Using advanced peptide array 
technology, it has been possible to map potential Fbxw7 docking sites on the DISC1 CPD 
that aligns with a characterised consensus Φ-X-Φ-Φ-T- P-P-X-S  (Φ- hydrophobic amino 
acid, X – any amino acid) (Orlicky et al., 2003).  Phosphorylation dependent substrate 
recognition and SCF E3 ligase recruitment has been a paradigm confirmed by several 
studies (Orlicky et al., 2003, Hao et al., 2007a, Nash et al., 2001, Skowyra et al., 1997).  My 
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peptide array studies show that in vitro DISC1 CPD interaction with Fbxw7 is enhanced 
following dual phosphorylation (chapter 4), however, the kinase responsible for the 
phosphorylation is not yet known.  As seen in other Fbxw7 substrates it is likely that 
phosphorylation within the CPD may trigger a conformational change, which makes it 
accessible to Fbxw7 (Orlicky et al., 2003). 
 
In the present chapter, we explored the potential of peptides as a proof of concept in 
drug development for psychiatric illness.  I proposed that by targeting DISC1-Fbxw7 
complex formation and interfering with ubiquitination mediated degradation we could 
stabilise DISC1 protein.  Using structure activity relationship studies, a peptide was 
developed which had a potential to stabilise DISC1 protein levels in the cell by modulating 
DISC1-Fbxw7 interaction.  Of the 4 lead peptides, two peptides (139 and 142) have shown 
a significant effect.  Intriguingly, these two peptides had mE and mD substitutions at the 
phopsho sites.  It can be hypothesised that the phospho groups are crucial in the 
interaction and the N methyl capping of the phosphomemitic amino acids (mE and mD)  
therefore retain the negative charge, increase membrane permeability as well as increase 
resistance to proteolytic degradation in cells.  My studies also show that the peptide is 
specific to the DISC1-Fbxw7 interaction as the peptide treatments did not alter 
endogenous levels of other known Fbxw7 substrates such as c-Myc, c-Jun, Notch1 and 
Cyclin-E.  It is crucial to demonstrate this specificity as altering the stability of the other 
substrates may be tumorigenic which is not desirable.  The specificity of the peptide is 
probably due to the differences in affinity that are seen between Fbxw7 and DISC1 
compared with the other substrates.  The Baillie lab has calculated the affinity of Fbxw7 
for the dually phosphorylated DISC1 as 1µM (using isothermal calorimetry) and this is 
weak compared with the 65 nM affinity of Fbxw7 for cyclin E (Orlicky et al., 2003).  So, it is 
possible that the weak DISC1-Fbxw7 interaction can be disrupted by the peptide but the 
others cannot.   
 
It would be interesting to investigate the ability of the peptides to disrupt the DISC1-
Fbxw7 interaction in vivo, however, this was not within the scope of this project as 
peptides are thought not to cross the blood-brain barrier.  It should also be noted that all 
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the recommendations made for amino acid substitutions to increase the peptide efficacy 
were not possible to screen (in my peptide optimisation screens) as some of the non-
natural amino acids (Sar, β-H-ala, βA, Pip, Tic) were not available at the time of this study.  
Implementation and characterisation of these substitutions may further increase the 
potency of the peptide.   
 
Synthesis and purification of these synthetic peptides is extremely time consuming and 
extreme care should be taken while handling and storage as they are susceptible to 
oxidation and bacterial degradation.  Despite the generic complications in developing 
peptide drugs, they do come with certain advantages such as specificity, potency, smaller 
size and their cost of production has been improving with advancements in the field of 
synthetic chemistry making them more accessible.  They are also less immunogenic and 
can have higher tissue penetrance (but probably do not cross blood-brain barrier (Vlieghe 
and Khrestchatisky, 2010).  Since the degradation products of the peptides are amino 
acids, they pose a minimum risk of systemic toxicity and side effects.  The rapid increase 
in the marketing of synthetic therapeutic peptides is a positive signal, which points to the 
potential of more research into and preference for this class of drugs by pharmaceutical 
companies.   
 
The following review provides a list of all the peptide drugs released in to the market to 
date which include peptides ranging from the size of 2 amino acids  (Naaxia for  
conjunctivitis ) to 41 amino acids (Acthrel for Cushing’s syndrome) (Vlieghe et al., 2010).  
However, it is important to consider that a potential CNS drug targeting psychiatric 
illnesses should ideally cross BBB (blood brain barrier) either by passive diffusion or 
carrier mediated active transport.  Research over the past decade focused on developing 
a novel drug delivery system to evade BBB, reviewed (Chen and Liu, 2012).  
 
As the present study sheds light on new DISC1 interactions and the significance of DISC1 
turnover regulation, it also opens new exciting avenues of research.  DISC1 directly 
interacts and negatively regulates the enzyme activity of GSK3β, preventing it from 
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phosphorylating β-catenin (De Rienzo et al., 2011). Two different domains  (amino acids 
1-220 and 356-595) on DISC1 have been mapped to directly interact with purified  GSK3β 
protein using in vitro binding assays (Mao et al., 2009b).  This finding is crucial, as the 
DISC1 CPD (amino acids 196-203) lays well within the proposed GSK3β interacting 
domain.  It is worth noting that GSK3β phosphorylates within the CPD of the other known 
Fbxw7 substrates triggering subsequent ubiquitin conjugation (Pérez-Benavente et al., 
2013, Welcker et al., 2003, Wei et al., 2005, Kitagawa et al., 2009).  GSK3β activity has 
already been implicated in several psychiatric diseases such as SCZ, autism and 
Alzheimer’s disease and has been a common therapeutic target for few decades.  40% 
reduction in GSK3β protein, transcript levels and activity has been observed in post-
mortem frontal cortex of schizophrenic patients (Kozlovsky et al., 2000, Kozlovsky et al., 
2001, Kozlovsky et al., 2004).  As a kinase with a large number of substrates, it can be 
hypothesised that GSK3β may also play a crucial role as an upstream regulator of DISC1 
ubiquitination; however, much more work is needed to verify this.  Further 
characterisation of the lead peptides developed in the present study is absolutely 
necessary and may provide insight in to the DISC1 pathway.  Exploring how these peptide 
affect DISC1 interactions with other proteins identified as risk factors for neurological 
diseases such as DIXDC1, GSK3β, Ndel1 will provide molecular insights which is otherwise 
impossible to obtain in genetic or clinical studies.  
 
 
5.4.1  Use of iPS cells and differentiated NPs and neurons as 
models to facilitate drug discovery   
In the last section, my study explored the potential use of iPS cell technology in disease 
modelling and drug discovery.  Until recent years, iPS cell generation and differentiation 
has been perceived as a strenuous, long and expensive procedure.  It should be noted 
that the first publication on generation of human iPS cells was only 6 years ago and there 
is still much speculation about their potential in drug development.  Considerable 
advancements have been made lately to improve iPS reprogramming techniques and this 
new advanced technology can be considered as a boost for neuroscience research.  Apart 
from serving as indefinite supply of human neurons, these cells also serve as a medium 
that enables the study of human psychiatric illnesses in a neuronal context.  Researchers 
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have successfully employed this approach in modelling other neuronal diseases such as 
Parkinson’s, Alzheimer’s, and Huntington diseases (Wernig et al., 2008, Zhang et al., 2010, 
Yahata et al., 2011).  Non clinical drug evaluation is extremely important before 
advancement into human clinical trials.  Employing iPS cells and differentiated cell lines of 
interest serve this purpose efficiently as they can compare disease and patient specific 
profiles from a similar genetic makeup.     
 
The present chapter describes the results of a study conducted to utilise iPS cells for 
studying disease mechanisms involving a DISC1 mutation.  I also highlight the possible 
downstream application of iPSc and their diiferentiated derivatves for drug screening.  
Interestingly, the proteasome inhibitor MG132 stabilised endogenous DISC1 protein 
levels in the control and patient neuronal progenitors (NPs).  Although, we had seen this 
in a model line (HEK293), it was reassuring that the phenomenon was recapitulated in the 
NPs.  Immunoprecipitation experiments to show ubiquitin chains in the NPs were not 
successful and required further technical optimisation to increase the concentration of 
DISC1-ubiquitin conjugates in the sample to levels that could be detected by biochemical 
methods.   
 
Gratifyingly, immunoblots and quantitative real time PCR data indicated that Fbxw7 and 
DISC1 displayed reasonable expression levels, though comparative expression patterns 
between the control and patient NPs could not be established because of the low number 
of replicates.  Lead peptides which successfully stabilised DISC1 in HEK293 cells (139 and 
142), were tested on the NPs generated from control and patient iPS cells.  Due to time 
constraints, only two replicates were possible.  These preliminary set of experiments 
show increased DISC1 levels.  However, more biological replicates originating from 
different sets of neuronal differentiation are crucial in establishing the effect of the 
peptides.       
 
While the potential use of iPS cell technology is an exciting advance for neuroscience 
research, crucial challenges need to be addressed.  First and foremost, is the possible 
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genetic variability between iPS cell clones which may be attributed to genetic 
recombination or integration of episomal vectors or virus in to the chromosomal DNA.  
Still in its infancy, methods to improve the quality and efficiency of iPS cell generation 
(reprogramming) are still under way.  The protocols employed to differentiate iPS cells 
into desired cell type (media, serum and growth factors) also plays a crucial role in 
replicating the cell properties.  Future research into development of cell type specific 
differentiation protocols, phenotype and genotype characterisation is necessary.  
 
5.5 Chapter summary 
To summarize, the data presented in this chapter explores the potential of PPIs 
(substrate-E3 ligase) as therapeutic drug targets. The lead peptides developed, efficiently 
and specifically disrupted DISC1-Fbxw7 interaction in HEK293 cells. iPSCs differentiated 
NPs were explored as cell line model as they represent a powerful new approach to 
capture the genetic background from human individuals with confirmed diagnoses of SCZ.  
With the provided framework, future experiments should involve complete 
characterisation of the pateint derived iPS cells and their differentiated derivatives (such 
as morphology, DISC1 and Fbxw7 relative expression and how their pattern of expression 
alters in relation to the  various stages of differentiaon). I speculate that this may provide 
crucial information and possibly recapitulate disease onset physiology at the molecular 
level. Investigating the physiological effects (such as neurite outgrowth, number) of the 
lead peptides in terminally differentiated neurons derived from the iPS cells may also 
expand our knowledege on how DISC1 function contributes to neuronal function. 
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6.  
 
HTS for small molecules that modulate 
DISC1-Fbxw7 interaction 
 
 
6.1  Introduction 
PPIs (Protein-Protein Interactions) mediate many cellular signal transduction systems, yet 
notoriously challenging to target due to their large molecular surfaces, lack of profound 
pockets and paucity of appropriate screening libraries, which can target these 
interactions.  One strategy to overcome these difficulties, is to target so-called hot spots, 
a recently evolved concept in PPIs (Mullard, 2012).  Although the complex nature of PPIs 
is dictated by physical features and forces that hold binding partners together are 
challenging to target, certain interactions have a small binding regions, often termed as 
‘hot spots’, on at least one of the partners that can be singled out.  The concept of the 
‘hot spot’ was based on an observation that the bulk of free energy is not evenly 
distributed on the protein surface but concentrated on certain residues (amino acids), 
which are crucial for the interaction (Lea and Simeonov, 2011).  Advancements in protein 
mapping, crystallography and computational analysis led to identification of PPIs as more 
approachable and promising drug targets, opposing to the conventional view.  
 
‘Small molecules” are organic molecules with a molecular weight less than 900 Daltons , 
which target certain biological events such as PPI or enzyme activity (Arkin and Wells, 
2004). The upper molecular weight limit for the small molecules increases the likelihood 
of cell permeability and their potential to target intracellular sites.  Most of the commonly 
used drugs are small molecules, as they have an added advantage of metabolic stability 
and bioavailability over peptide drugs.  As an example, the drug RG7388, developed by 
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Roche Pharmaceuticals to target p53-Mdm2  interaction (RG7388 is a selective, potent 
Mdm2 antagonist) stabilises and activates p53 and is currently in clinical development for 
cancer therapy (Ding et al., 2013).  Projects such as this, have garnered enthusiasm of 
pharmaceutical firms for small molecule inhibitors of PPIs.  
 
Once a suiable drug target is identified, different approaches can be employed to identify 
compound modulators.  HTS is one such widely used approach discussed in section 6.2.  
Functional assays are used in the first round to identify compounds from large chemical 
libraries which give positive or negative response known as ‘hits’ that become the starting 
points of drug discovery.  A chemical or compound library consists of stored compounds 
with associated information about each compound such as structure, molecular weight, 
purity, and other biophysical properties.  Follow up secondary assays are used to test for 
specific artefacts and false positives identified in the primary screens.  
 
In the previous chapter, using advanced peptide array technology and structure activity 
relationship studies, we successfully developed and optimised lead peptides, which 
stabilise DISC1 levels in HEK293 cells.  My work so far explored the potential of the novel 
PPI, DISC1-Fbxw7 as a drug target for psychiatric illnesses. I see this as a promising drug 
target, as loss of DISC1 function is one of the proposed disease mechanisms (Hikida et al., 
2012).   
 
A similar approach has been taken to target Fbxw7 mediated regulation of Cyclin E 
signalling as a therapeutic intervention for cancer (Hao et al., 2007a).  A FP assay was 
constructed from pure protein and peptides that correspond to the binding interface.  
This assay was  used to perform a HTS on a 50,000 compound library which identified 
SCF-I2 (assigned name) to cause inhibition of Sic1 (yeast Cdk1 inhibitor) ubiquitination 
(Orlicky et al., 2010).  Crystal structure elucidation revealed that SCFI2 elicits its inhibitory 
effect by an allosteric mechanism (WD40 domain inhibitor) which was the first of its kind 
to be identified (Orlicky et al., 2010).  Another well-known example where a substrate-E3 
ligase interaction was targeted for drug development was that of the p53-Mdm2 
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complex.  Ubiquitination of p53, a tumour suppressor and transcription factor, is tightly 
regulated by the Mdm2 protein (E3 ligase).  Mdm2 gene overexpression leading to 
inhibition of p53 has been shown in many malignancies.  Hence, the disruption of p53-
Mdm2 complex represents a suitable drug target for cancer therapy (Vassilev et al., 
2004).  Close analysis of the crystal structure of Mdm2 revealed the presence of a 
hydrophobic pocket that was involved in the interaction with the p53 peptide.  This area 
constituted the transactivation domain and was ideal for targeting with small molecules.  
To this end, a  number of HTS studies were undertaken that led to the development of 
Nutlins (imidazole analogues),  which successfully displaced p53 from the Mdm2 leading 
to subsequent stabilisation of p53 protein (Vassilev et al., 2004).   
 
In the present study, one of the shortest DISC1 peptides identified to be interacting with 
the SCFFbxw7 complex in the peptide array studies was an 7-residue stretch of DISC1, which 
is dually phosphorylated at T198 and S202.  This DISC1 peptide was chosen for in vitro assay 
development in light of the  structural model of  Skp1-Fbw7-Cyclin E elucidated by Bing 
Hao and colleagues (Hao et al., 2007a).  As a part of this study by Hao et al, purified Skp1-
Fbxw7 was co-crystallised with Cyclin E peptides - CyclinEdegC peptide ((residues 360–390, 
phosphorylated at Ser372, Thr380, and Ser384) and CyclinEdegN (residues 55–68, 
phosphorylated at Thr62).  Crystallography studies uncovered the residues of these 
peptides that make contact with the WD40 domain of Fbxw7.  Since the DISC1 CPD motif 
is remarkably similar to that of Cyclin E, the labelled DISC1 peptides to be used as tracer 
molecules were designed in order to test whether a similar interaction may also be 
possible with DISC1.  I developed an in vitro FP assay to validate binding of the identified 
and optimised DISC1 CPD peptide.  The assay was also fit to screen small molecule 
libraries; a wide spread approach taken in drug discovery and development.  Ultimately, 
identified and validated hits from this approach could then be used to test the hypothesis 
that by targeting DISC1-Fbxw7, DISC1 protein levels can be regulated. 
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6.2 High Throughput Screening (HTS) 
High Throughput Screening (HTS) is a process of assaying libraries containing large 
numbers of compounds to identify potential effectors of biological activity against 
biological events or targets.  HTS based studies are widely employed by the 
pharmaceutical industry in the initial stages of drug discovery and development. They 
enable testing of large chemical libraries of compounds categorised by their backbone 
structure, size or specific chemical groups, for their activity in a range of cellular and non-
cellular assays.  Testing up to 100,000 compounds per day has become feasible by the 
gradual replacement of cuvettes and dishes with 96 to 3456 well micro well plates and 
the recent advent of automated robotic liquid handling workstations.  This approach has 
garnered much popularity in recent years due to the increased availability of chemical 
libraries and the miniaturization of the sensitive assays (Shinohara and Uesugi, 2007) 
(Duffy et al., 2013).  HTS constitutes a primary screen to identify ‘hits’ (positive response) 
from the compound library, with suitable positive and negative controls.  In general, 
primary screens are less quantitative, tested only in singlets or doublets, usually within a 
concentration range of 1-10 µM (which may again vary depending on the type of assay 
and the biological event being monitored).  The short listed compound hits are then re-
tested in secondary assays, which are more accurate and used for quantification and to 
determine the IC50 following construction of dose response curves and time response 
read outs depending on the assays.  A confirmed hit exhibits the same activity in the 
secondary assays, which is then taken forward to tertiary screens or counter screens for 
optimisation.  Compounds that hold biological activity after this process are often termed 
as ’lead compounds’.  Secondary screens play a crucial role in excluding false positive hits.  
Fluorescence polarization/anisotropy (FP) and Fluorescence/Foerster Resonance Energy 
Transfer (FRET) are homogenous assays preferred by screening groups, as they are 
solution-phase assays.  Having fewer assay components, simple assay steps and 
protocols, they are easier to develop than heterogeneous assays such as ELISA (Enzyme 
Linked Immuno Sorbent Assay) which has multiple components, incubations and wash 
steps.  Following the identification of a suitable drug target, it is important that the assay 
selected for HTS meets certain criteria, such as being executable in 384 or 1536 well plate 
format and response readout via a single parameter (Lea and Simeonov, 2011). 
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6.2.1  Fluorescence Polarisation Assay (FP) 
This assay was first described by Jean Perrin in1926 (F, 1926) (Lea and Simeonov, 2011) 
and gradually expanded by Gregorio Weber and colleagues  in the 1950’s.  This technique 
has since been in use to characterise antigen-antibody, hormone –receptor and ligand-
protein interactions.  Since mid-1990 FP assay has been adapted for use in high 
throughput screening.  
 
Fluorescence based screening methods are rapidly gaining attention in assay 
development.  In recent years, FP assays have become increasingly popular and been 
used for quantitative analysis of  enzyme activity (Zhang et al., 2007) and various 
molecular interactions (Kimple et al., 2008).  The format of this assay, which is mix-read 
with no wash steps, also makes it a popular choice in the field of drug development.  This 
assay is homogenous, solution based and highly sensitive and sometimes can use just Pico 
molar concentrations of the fluorescent probes.  
 
6.2.1.1 Principle of FP assay 
The principle of a FP assay is the measurement of the molecular size-dependent change in 
the polarisation of plane polarised light.  When plane polarised light is passed through a 
sample, the fluorescent molecules in the sample are excited and emit light in the same 
plane if the fluorescent probe is stationary.  However, if the fluorescent molecule tumbles 
and rotates in various planes in its excitation state, it tends to emit light in a different 
plane than the one in which it was excited.  Larger molecules tend to rotate and tumble at 
a slower rate, hence the emitted light, following their excitation remains highly polarised.  
If a molecule is smaller, rotation and tumbling is faster and hence the light is depolarised 
relative to the excitation plane.  The extent of polarisation is read out as polarisation 
units/ milli polarisation units (mP) (Lea and Simeonov, 2011).  
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Figure 6.1 Schematic representation of FP detection system. 
After monochromatic light passes through a vertical polarizing filter, it excites the 
fluorescent molecules (also known as tracer) present in the sample.  Only molecules 
oriented vertically to the plane polarised light absorb this light, become excited and 
subsequently emit this light.  The emitted light is measured in horizontal and vertical 
planes.  Adapted from (Lea and Simeonov, 2011). 
 
The molecular weight of the fluorophore tagged molecule (tracer) is directly proportional 
to the emitted polarisation values.  When the fluorescent molecule is unbound, it rotates 
faster in the excitation phase and hence, the emitted light has low polarisation values.  
However, when it is bound to the protein complex, it rotates slower and hence the 
polarisation values are high.  The extent of molecular rotation of the tracer during 
excitation and emission is measured in polarisation units (1P polarisation unit = 1000 mP 
units) which is calculated as shown in the equation below. 
.  
Equation 6.1 
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In the above equation, Intensity (vertical and horizontal) represent intensity of light 
emitted, vertical and horizontal to the excitation plane.  Applying the principle of FP, we 
set out to develop an assay to monitor the displacement of FITC (Fluorescein 
isothiocyanate) labelled DISC1 CPD peptide from the Skp1-Fbxw7 complex. 
 
6.2.2  Ligand-Receptor kinetics - Basics  
Before discussing the results, it is important to understand the ligand-receptor kinetics 
and the relevant terminology. Ligand-receptor binding is generally explained on the basis 
of the ‘law of mass action’, which assumes that ligand (L) binds to free receptor (R) to 
form a Ligand –Receptor complex [LR].  Assuming this binding is reversible and not taking 
potential non-specific binding into account, the rate of formation of [LR] is equal to rate 
of dissociation of [LR] at equilibrium. 
 
Equation 6.2 
 [L] and [R] represent free ligand and receptor respectively.  kon and koff represent the 
kinetic association and dissociation constants.  It is important to note that this equation is 
valid under the assumption that all receptors and ligands are equally accessible, while the 
binding does not alter either of them.  
Equilibrium can thus be represented as following: 
 
Equation 6.3 
The concentration of the free ligand and free receptor are related at chemical 
equilibrium, determined by Kd.  Kd is the equilibrium dissociation constant, which can be 
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defined as the concentration of the ligand at which half of the receptor sites on the 
protein are occupied.  The Kd of a ligand is inversely proportional to its affinity towards 
the receptor, i.e., the smaller the value of Kd the stronger is the affinity.  
 
Figure 6.2  Simulated hyperbolic curve representing the binding kinetics of receptor and 
ligand. 
 Rt – Total receptor concentration, Kd – Dissociation constant.  
 
Depending on the nature of the inhibitor, the following types of scenarios could be 
possible:  
Competitive inhibition occurs when the inhibitor binds to the receptor’s active site 
reversibly, by competing with the ligand via steric hindrance according to the law of mass 
action.  Competitive inhibitors can be ‘isosteric’ when they bind at the ligand binding site 
of the receptor or allosteric if they bind at a proximal ligand binding site, affecting ligand 
binding at another site by inducing a conformational change in the receptor.  The IC50 is 
defined as inhibitor concentration at which 50% of the bound ligand has been displaced 
form the receptor binding sites.  IC50 values are variable depending on the concentration 
of the ligand, inhibitor and that of the receptor. In the presence of a competitive 
inhibitor, Kd of a ligand effectively increases.  Most of the modern drugs are being 
developed on the basis of competitive inhibition of enzyme activity or ion channels.  ATP 
mimetic protein kinase inhibitors belong to this class.  In the present study, a competitive 
FP assay has been used where an unlabelled ligand (peptide or test compound) and a 
fluorescently labelled DISC1 CPD peptide compete for binding to a Skp1-Fbxw7 protein 
complex.  
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Non-competitive inhibition is also a type of reversible inhibition, which occurs when the 
inhibitor binds to a different site on the receptor than the natural ligand and inhibits the 
biological function of the receptor.  This type of inhibition results in formation of [LRI] and 
[RI] complexes which are non-functional; (R Receptor, L ligand, I inhibitor).  
The following references would be useful for a review of this concept in depth - (Krohn 
and Link, 2003, Prystay et al., 2001, Fang, 2012).  
 
 
6.2   Experimental aims 
Studies outlined previously in this thesis have demonstrated that the conserved CPD 
motif in DISC1 is responsible for DISC1 interaction with the Fbxw7 protein of the Skp1-
Fbxw7 protein complex (chapter 5).  In addition, peptide array studies also revealed that 
dual phosphorylation within this motif enhances Fbxw7 interaction in vitro. As we 
targeted this novel PPI with disruptor peptides in the previous chapter, here we 
investigated if this can be targeted by small molecules. 
 
The aims of the experimental work detailed in this chapter were: 
 
1. To develop and optimise a quantitative, reliable FP assay to quantify and compare the 
binding affinities of DISC1 CPD peptides (singly and double phosphorylated).  
2. Adapt the optimised FP assay to screen large compound libraries in High throughput 
screens (HTS) to identify inhibitors and activators targeting DISC1-Fbxw7 interaction.  
3. Perform secondary screens to confirm the hits identified in the HTS.  
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Figure 6.3 Schematic of targeting DISC1-FBXW7 with small molecule inhibitors. 
Schematic illustration of the FP assay principle in relation to protein-peptide or protein–
ligand interactions (Skp1-Fbxw7 complex with fluorescent DISC1 peptide or small 
molecule inhibitor (I-red sphere)). 
 
In general, a macromolecule is designated as the receptor [R], which is the Skp1-Fbxw7 
protein complex in the present scenario and the binding counterpart as ligand [L], 
labelled DISC1 peptide.  The ligand, DISC1 CPD peptide, has been developed and 
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characterised (chapter 4) after mapping the precise binding sites using peptide array 
technology. This DISC1 peptide, labelled with the FITC fluorophore, gives low mP values 
(milli polarisation units) as a read out when free in solution (unbound state) and high mP 
values when bound to the Skp1-Fbxw7 protein complex.  In competitive inhibition, mP 
values decrease proportionately with the displacement of the fluorescently labelled DISC1 
peptide by an unlabelled competing peptide or small molecule inhibitor.  
   
 
 
 
Figure 6.4  Purified recombinant Skp1-Fbxw7  
Coomassie stained gel picture showing resolved 6His-tagged Skp1-Fbxw7 recombinant 
protein complex (in denaturing conditions).  Each column represents one fraction 
collected from column gel filtration.  The His6 tag on Fbxw7 was then cleaved by TEV 
protease (a 27 kDa catalytic domain of the Nuclear Inclusion a (NIa) protein encoded by 
the Tobacco Etch Virus).  This protein complex serves as a receptor to which the DISC1 
CPD peptide binds in the FP assay. This protein complex was purified by Yunfeng Li, 
Prof. Bing Hao’s laboratory, University of Connecticut, USA. 
 
 184 
 
6.3   Results 
6.3.1  Development and optimisation of a FP assay based on the 
DISC1 peptide -Skp1-Fbxw7 complex 
Initial binding experiments were performed to evaluate the linearity of the assay, which is 
in turn dictated by the stoichiometric ratio of the ligand and the receptor.  High 
concentrations of the sample would inhibit the passage of light, which causes excitation 
of the tracer molecules.  Low concentrations may cause the molecules closer to the light 
to absorb too much light so that little is available for the rest of the molecules in the 
sample.  This could affect the linearity of the assay. The following peptides (Table 6.1) 
were labelled with the FITC fluorophore to determine their binding affinities to the Skp1-
Fbxw7 protein complex.   
 
Table 6.1  Labelled peptides used in the present study 
 
Peptide Sequence Phosphorylation 
status 
Reference 
DISC1 pTpS   FITC-V
195
PPpTPPGpSH
203 
 Doubly 
phosphorylated 
 
DISC1 pT   FITC-V
195
PPpTPPGSH
203 
 Singly 
phosphorylated 
 
Cyclin E   FITC- G
377
LLpTPPQSG
385
  Singly 
phosphorylated 
(Hao et al., 2007a) 
 
The peptide sequences are represented from N to C terminus in bold letters with FITC 
tag on the N terminus.  The amino acid residues were indicated in high case, lower case 
indicates phospho group on the following amino acid (p). Cyclin E CPD peptide was used 
as a positive control to analyse the  efficiency of the  assay as this peptide has been 
characterised in a previous study by Bing Hao and colleagues (Hao et al., 2007a).  
 
Saturation binding experiments also determine the measure of specific receptor (protein 
complex) binding of labelled ligand (peptides in the present study) at equilibrium.  By 
measuring the labelled ligand concentration required to saturate the receptor binding 
sites, these experiments are used to determine Kd (Equilibrium dissociation constant).   
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For the binding experiments, a range of concentrations of recombinant Skp1-Fbxw7 
protein complex (Figure 6.4) was prepared by serial dilution in the assay buffer (PBS with 
0.25% Tween20).  5 µL of the dilutions of Skp1-FXW7 protein complex were pipetted in 
quadruplicates into a black, low binding, round bottomed 384 well plate.  This was 
followed by the addition of 5 µL of 0.1 µM labelled peptides (Table 6.1) making the total 
assay volume 10 µL. Plates were then read using a Mithras plate reader using a 
fluorescence polarisation protocol program which measures the polarisation values at an 
excitation wavelength of 485 nm and an emission wavelength of 520 nm.  The 
concentration range of the protein and that of the tracer peptides were chosen to 
achieve a reasonable signal to noise ratio in the HTS screens.  The concentration of the 
labelled peptide is one of the influencing factors of the assay efficiency. 
 
 
 
Figure 6.5 Saturation experiments and Kd determination 
Saturation experiments were performed by titrating each tracer (FITC labelled peptides 
from Table 6.1) at 0.1 µM with increasing concentration of Skp1-Fbxw7 protein complex 
ranging from 0.05µM to 20 µM in the assay buffer (PBS with 0.25% Tween 20) with 
0.001% DMSO.  mP values are plotted as a function of Skp1-Fbxw7 concentration on a 
logirthmic scale.  Kd values were calculated using non-linear least squares analysis, 
Prism5 software. n=3. 
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From the saturation binding experiments, a Kd value was determined for each tracer 
molecule as represented in Figure 6.5.  Previous in vitro studies identified the doubly 
phosphorylated pThr380/pSer384 Cyclin E motif as high-affinity degron and a singly 
phosphorylated pThr62 motif as a low-affinity degron (Hao et al., 2007). Since Cyclin E 
CPD has close sequence similarity to that of DISC1, we expected similar binding affinities 
with DISC1 peptides. As expected, dually phosphorylated DISC1 CPD peptide 
(pT198/pS202) (Kd 0.69) had 2.8 times more binding affinity over the singly phosphorylated 
DISC1 CPD peptide (pT198/S202) (Kd 1.94).  The binding affinity of Cyclin E (pT) (Kd 1.90) 
peptide was also close to that of DISC1 pT peptide (Kd 1.94).  
 
 
6.3.2  Competitive inhibition experiments  
Competitive binding studies were performed to determine the concentration of a 
ligand/inhibitor required to reduce the specific binding of the labelled ligand to the 
receptor by half (50%) represented by the term Inhibitory Concentration or IC50. IC50 is 
inversely proportional to the receptor binding affinity of the ligand. By determining and 
comparing the IC50 values of various ligands (compounds) determined in a particular 
experiment, the compounds can be ranked based on their relative inhibitory capacity and 
this measure can be used to identify the lead compounds for further optimisation and 
development.  My initial experiments involved testing the ability of unlabelled DISC1 
peptide T (P197pTPPGpSH203 - peptide from which disruptor peptides was developed, 
chapter 5) to displace the labelled DISC1 peptide (DISC1pTpS) from Skp1-Fbxw7 protein 
complex.  Competitive inhibitory effects of the lead disruptor peptides 139 and 142 
(discussed in chapter 5) were also investigated using the principle discussed below.  
[Peptide 139 – G-mE-P-P-G-mE-H;  Peptide 142 - G-mD-P-P-G-mE-H]. 
 
A disruptor peptide or small molecule inhibitor (represented as ‘I’ in the Figure 6.3) 
displaces the labelled peptide (bound) from the complex which then goes back in to 
solution (unbound)  indicated by low mP values (schematic representation in Figure 6.3).  
Inhibitors that bind specifically to the protein complex at the labelled peptide binding 
site, as well as allosteric inhibitors, can be identified when they result in low polarisation 
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values (high depolarisation).  Effective competitive inhibition by such an unlabelled 
peptide also suggests the suitability of the assay to identify other inhibitors. 
 
The Optimised assay protocol for determining the IC50 values for the control (peptide T) 
and lead peptides (139 and 142)  is as follows: 
 
1. A range of concentrations of the competing  peptide (test disruptor peptide) was 
prepared by serial dilutions ranging from 1000 µM to 0.20 µM (final concentration 
in the assay) in the assay buffer. 5 µL/well was pipetted in quadruplicates  in a 384-
well black, low-binding, round-bottomed plate.  Plates were read for background 
fluorescence. 
 
2. 5 µL of Skp1-Fbxw7 complex (0.4 µM final concentration in well) and fluorescent 
DISC1 peptide mix (FITC-VPPpTPPGpSH, 0.1 µM final concentration in well) in the 
assay buffer was added. 
 
3. Plates were read in a Mithras plate-reader using a fluorescence polarisation  
protocol program (excitation and emission wavelengths of 485 nm and 535 nm 
respectively). 
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Figure 6.6 Competitive binding experiments 
Competitive binding FP assay experiments were performed with unlabelled test peptide 
T, 139 and 142.  A range of concentrations chosen for titration of competitive disruptor 
peptides were represented on X axis on logarithmic scale.  IC50 values were determined 
by non-linear least squares analysis, Prism5 Software. 
 
From Figure 6.6, it is evident that unlabelled DISC1 peptide T competitively inhibited the 
binding of labelled DISC1 pTpS peptide in a dose dependent manner as expected, with an 
IC50 of 18.6±0.4 µM (top graph).  However, the lead peptides 139 and 142 (middle and 
bottom graphs) (discussed in chapter 5) did not disrupt the DISC1 peptide tracer from the 
Skp1-Fbxw7 complex.  Though its unclear at this point why these peptides couldn’t 
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displace the tracer molecule, we speculate that low affinites of the lead peptides could be 
one possible explanation.  
 
 
6.3.3  Determination of Z’ factor 
Before we proceed to employ this developed assay in HTS, it is mportant to determine 
the Z’ factor.  A screening window coefficient denoted as Z’ factor determines the 
suitability of a given FP assay for HTS.  Taking replicate error and signal to noise ratio in to 
account, the Z’ factor is determined by the equation below (Zhang et al., 1999).  
 
 
 
Equation 6.4 
 
SDp and SDn are the standard deviation of the signals for positive and negative controls 
and µp and µn are the mean values for the positive and negative controls respectively.  
This factor is defined by the means of positive and negative control and the data variation 
represented by the standard deviation associated with the control (positive and negative) 
measurements.  The Z’ factor therefore indicates the capability of hit identification for an 
assay under defined conditions of screening and is a characteristic parameter of the assay 
quality independent of the test compounds.  The Z’ factor value within a range of 0 < Z' ≤ 
1 is meaningful and the higher the value, higher is the data quality of the assay, dictating 
the suitability of the assay (Z’> 0.5 is a good assay while a value of 1 indicates a perfect 
assay).  Factors such as assay protocol and the efficiency of the instrument influence Z' 
factor and hence, before progressing to perform HTS is it important to optimise the assay 
for conditions, reagents, instrument, protocol and the binding kinetics which can be 
judged by Z' factor (Zhang et al., 1999). 
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Figure 6.7 Calculated Z′-factor for competitive FP-based assays 
Controls and Z’-factor for original competitive FP assay using labelled DISC1pTpS 
peptide (0.1µM) and Skp1-Fbxw7 protein complex (0.4µM). Positive controls 
representing 100% inhibition contain unbound labelled DISC1 peptide, while the Skp1-
Fbxw7 protein bound labelled DISC1 peptide representing 0% inhibition was used as 
negative control.  Each point represents a replicate assay to determine Z' factor.  
 
Solving the equation 6.4  with the data from Figure 6.7, a Z' factor value of 0.74 was 
obtained which indicates that the designed assay and the conditions optimised are 
suiTable for the use of it for HTS (Zhang et al., 1999).  
 
6.3.4  Adapted FP assay protocol for HTS 
For the above described optimisation experiments, the following protocol was designed 
to perform HTS, also taking into consideration, reagent availability (purified recombinant 
protein and peptide) and the size of the compound library.  
 
1) 5µL of each compound (10 µM final concentration in 1% DMSO) was added to each 
well (with a liquid handler availabe at respective screening facilities)  in a 384-well black, 
low-binding, round-bottomed plate using a liquid handler.  Plates were read for 
background Fluorescence. 
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2) 5 µL of Skp1-Fbxw7 complex (0.4 µM final concentration in well) and labelled DISC1 
peptide mix (FITC-VPPpTPPGpSH, 0.1 µM final concentration in well) in the assay buffer 
was added. 
3) Plates were read in a Mithras plate-reader using Fluorescence polarisation protocol 
program (excitation and emission wavelengths of with 485 nm and 535 nm respectively). 
 
6.3.5  High Throughput Assay 1 
Using my initial FP-based competitive binding assay, the assay conditions were optimised 
making this assay protocol amenable for identification of non-peptide, small-molecule 
inhibitors through HTS. 
 
The Prestwick Chemical Library of 1200 small molecules which are approved drugs (FDA), 
were screened to uncover yet unrecognised targets.  Prestwick Phytochemical library of 
320 natural products mostly derived from plants were also screened in our first HTS.  This 
library was screened at Biomolecular Screening & Protein Technologies CRG - Centre for 
Genomic Regulation, Barcelona, Spain.  
 
Reactions were prepared in assay buffer (PBS with 0.25% Tween 20) and contained 5 µL 
of 0.4 µM Skp1-Fbxw7 recombinant protein, 0.1 µM of labelled DISC1 pTpS peptide mix 
and 5 µL of compound (in 1% DMSO) to make a final volume of 10µL.  The order of 
addition of components and the steps involved in the assay is as follows:  compound was 
added to the plate (5 µL each in singlets) and the plate was read for any background 
fluorescence of the compounds.  This was followed by adding protein-tracer mix (total 5 
µL) and the plates were immediately read to give the final polarization readout. Each 
plate had negative controls (equivalent to 0% inhibition) which constitute protein 
complex-tracer mix (5 µL) and 5 µL of assay buffer while the positive controls had the 
protein complex-tracer mix (5 µL) and 500 µM peptide T (5 µL) which gave 100% 
inhibition.   
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The screen was performed twice on the library on two different days using the same 
protocol to give two technical replicates.  mP values of all the compounds were plotted 
on an XY scatter plot against the respective assigned compound ID (well number). 
 
 
Figure 6.8 Summary of the HTS screen 1 (Prestwick chemical library and Prestwick 
phytochemical library). 
Plot (a) represents data for day 1; plot (b) represents data on day 2.  Plot (c) summary of 
the screen from both the days.  mP values were plotted against the corresponding Drug 
IDs/well numbers on a XY scatter plot.  The compound highlighted with green circle was 
shortlisted as a hit in the replicate screens was identified as Merbromin (CAS number - 
129-16-8).  The compounds highlighted in blue circle were the hits obtained only on day 
2 screen identified as Cefsulodin (CAS number - 52152-93-9) and Fusaric acid (CAS 
number - 536-69-6).   
This screen was performed by Dr.Tamara  Martin and Jane Evelyn Findlay, University of 
Glasgow at Biomolecular Screening & Protein Technologies CRG - Centre for Genomic 
Regulation, Barcelona, Spain. 
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CAS number (Chemical Abstracts Service) is a unique numerical code assigned to every 
known chemical, independent of its structure, chemical nature nor properties.  It is more 
useful in identifying a compound or chemical than its chemical name.  Stereoisomers of a 
compound have different assigned CAS number (http://www.cas.org/content/chemical-
substances).  After the screen, the mP values were plotted against each well number (also 
the assigned compound ID) starting from 1.  In Figure 6.8, the replicate screens 
performed were also summarised in a single graph to identify the hits.  Compounds that 
have displaced labelled DISC1 peptide from the Skp1-Fbxw7 complex represented by a 
drop in mP value by at least 20 units (compared to the positive control) were considered 
for further analysis.  Unfortunately, some distortions in the readouts of 5 plates were 
observed on the day 2 screen.  This can be seen in the plots presented in Figure 6.8.  The 
several other parameters that dictate the efficiency of FP assay have been discussed in 
detail in section 6.4.  
 
6.3.5.1  Secondary screens 
Secondary screens are necessary to identify false positive hits or compounds with low 
affinities. Dose dependent experiments were performed to generate dose response 
curves which illustrate the relation between the inhibitor dose and the magnitude of the 
inhibition.  
 
The identified  compounds were shortlisted as putative hits (Figure 6.8) from the screen 
and were purchased from Sigma.  Secondary screens which include experiments to 
identify any quenchers (substances which decrease fluorescence intensity) or false 
positives (example: auto fluorescent compounds) were undertaken.  Compounds showing 
dose dependent inhibition needed to be identified for further characterisation. 
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Figure 6.9  Chemical structures of the hits identified in HTS screen 1 with their generic 
and systemic names  
(IUPAC -International Union of Pure and Applied Chemistry). 
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Figure 6.10  Dose response FP assay curves for Cefsulodin and Fusaric acid 
mP values of the assay were plotted on Y axis against concentration of the compound 
on log scale on X axis.  
 
 
 
 
Figure 6.11  Dose response curve for Merbromin 
mP values of compound only and assay were plotted on Y axis against concentration of 
the drug on log scale on X axis.  
 
FP assays were performed according to the protocol described in section 6.3.4 The 
protein-tracer mix was titrated with various concentrations (0.01 µM – 100 µM) of the 
compounds and the resulting polarization values (mP, Y axis) were plotted against the 
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concentration values of the drugs on a log scale.  The protein-tracer mix concentration 
and the volume was maintained the same in all experiments.  Negative and positive 
control assays were also included. 
 
As can be seen in Figure 6.10, neither Cefsulodin nor Fusaric acid produced any inhibition 
(low polarisation-mP values) of the protein-tracer binding.  These drugs were eliminated 
as false positives, having failed to disrupt the protein-tracer complex concentration-
dependently.  Merbromin which was identified as a hit in both the replicate screens was 
investigated for its inhibitory effect.  The polarisation values of the compound on its own 
(no protein or peptide added) decreased with its increasing concentration, which 
indicates that it is auto fluorescence (Figure 6.11, green curve).  However, when the 
protein-peptide was added to increasing concentration of the compound, polarisation 
values start at a high value and gradually decreases ((Figure 6.11, red curve).  This may 
indicate the binding of the compound to the protein complex at low concentrations, 
however, it is difficult to hypothesise on the increased polarization values at higher 
concentrations of the compound (in the assay) as the auto fluorescent nature of the 
compound could have a prominent effect on the sensitivity of the assay.  A non-
fluorescent assay is necessary to clarify the ability of Merbromin to modulate DISC1-
Fbxw7 complex. Merbromin was disregarded as a possible lead. 
 
6.3.6  High Throughput Screen 2 
A second HTS was performed at Scottish Bioscreening Facility, University of Glasgow.  
7000 compounds from Pharmacological Diversity Set (PDS) from Enamine, Kiev have been 
screened in this HTS.  Compounds in the library were pre-plated and maintained as 
described previously (Duffy et al., 2013).  The vendor for all the compounds in the library 
assured 90% purity (assessed by liquid chromatography–mass spectrometry and proton 
nuclear magnetic resonance spectrometry).  The library was designed based on the 
predicted pharmacological properties of the compounds and each compound has been 
predicted to have nearly 3000 different biological activities (Duffy et al., 2013). 
Compounds were clustered based on their activity and irrespective of their chemical 
structures and all toxic compounds were excluded (Duffy et al., 2013).  
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Figure 6.12 Representative graph of the HTS data from one 384 well plate (plate 20).  
Each well was assigned with a number.  mP values (Y axis) were plotted against the 
corresponding well number (compound) on X axis. 
 
Table 6.2  Putative activators identified in the HTS screen 2 based on fluorescence 
polarisation. 
 
CAS (Chemical Abstract Service) number, microplate ID, well ID in the corresponding 
microplate, molecular weight (MW). 
 
The above-mentioned library screen was performed as described in section 6.3.4.  The 
assay conditions were maintained across both the HTS.  However, due to limited 
availability of reagents such as purified protein complex and the peptides at the time the 
study, the complete library (total library size is 23,000 compounds) could not be 
screened.  Refer to the appendix for the complete screening data. 
 
The lower limit for the mP value read out for the compounds to identify potential hits 
(inhibitors) was set at 150 (based on the read out of the positive control wells in each 
plate). Unfortunately, none of the compounds inhibited the interaction.  However, certain 
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P
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compounds caused positive binding of DISC1 and Skp1-Fbxw7 complex, which implies 
that this PPI is stronger in the presence of these compounds (also termed as activator).  
However, secondary assays are required to confirm these observations.  Table 6.1 depicts 
the activator hits identified in the screen. As can be seen in the Table, all the hits 
identified had their polarisation value above the set upper limit set as 200mP based on 
the positive control.  
 
6.4  Discussion 
The novel PPI (protein-protein interaction) of DISC1-Fbxw7, identified in the present 
study has been validated as a potential therapeutic target.  In this chapter, a FP assay was 
developed, optimised for HTS and employed to identify small molecule inhibitors that 
disrupt binding of the DISC1 CPD peptide and Skp1-Fbxw7 complex.  I propose that 
blocking the interaction between the two proteins by small molecules would inhibit DISC1 
ubiquitination and subsequent proteasomal degradation of DISC1 protein.   
 
My results, outlined in the present chapter support the feasibility of using fluorescence 
based FP assay to characterise molecular interactions and provides an in vitro assay for 
the DISC1-Fbxw7 interaction.  This can be considered as useful technique to quantify the 
interaction while also being suitable for HTS. This represents an advance in the field, as 
one of the interacting partners, DISC1, is hard to purify as it has a high tendency to 
aggregate (Bader et al., 2012).  Since the assay can be performed on a miniature scale, it 
is cost effective, while also being highly reproducible.  Previous work using peptide array 
technology shows that both singly and dually phosphorylated DISC1 CPD (DISC1 pT198 
and DISC1 pT198/pS202 peptides) were bound by the Fbxw7 protein.  However, from my 
FP assays it was evident that the Kd of the DISC1pTpS was lower (0.69 µM) than that of 
DISC1 pT (1.2µM) suggesting the dual phosphorylation is required for high affinity binding 
of Fbxw7 enhancing DISC1 degradation.  Developing mutants of these phosphorylation 
sites followed by ubiquitination experiments would be useful in understanding the  
relevance of this phosphorylation events to DISC1 stability in cells.  This data is 
comparable with the previous findings where Fbxw7 was shown to recognise doubly 
phosphorylated CPD in CyclinE (Hao et al., 2007a) and β-TrCP1 (Wu et al., 2003).  This 
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data also supports the proposed hypothesis of multi phosphorylated CPD mediated DISC1 
interaction with Fbxw7and its subsequent degradation.  Fbxw7 has a binding pocket 
within the WD40 domain and additional pockets on the surface exposed to the solvent.  
These pockets were found to make crucial intermolecular contacts with the phospho 
residues and the moieties flanking them (Wu et al., 2003, Hao et al., 2007a).  Since the 
DISC1 CPD has a close resemblance to that of Cyclin E, we propose a similar binding 
model for DISC1 involving the phospho-residues.   
 
Orlicky et al employed a FP assay to identify small molecule inhibitors of substrate 
recognition component of CDC4 (yeast homologue of Fbxw7) (Orlicky et al., 2010).  A 
similar approach was taken in the present study to identify small molecule inhibitors of 
DISC1-Fbxw7 complex.  During my optimisation experiments, control peptide (Peptide T) 
and the lead peptides (139 and 142) were tested for their ability to displace the labelled 
peptide from the receptor (Skp1-Fbxw7).  Although, the control peptide nicely displaced 
the labelled DISC1 peptide in a dose dependent manner with an IC50 of 18.6±0.4 µM, lead 
peptides 139 and 142, which stabilised DISC1 levels in HEK293 cells (chapter 5), failed to 
disrupt the peptide-protein interaction.  While this does not necessarily mean that the 
peptides do not target the PPI under study, we propose that more intense 
characterisation is needed and it is necessary to explore the factors that may interfere 
with the assay.  In this context, it is important to note that FP may not be ideal for 
identifying weak interactions/inhibitors and is dependent on the peptide-protein Kd 
(Huang, 2003).  This may be difficult to overcome by using high inhibitor or disruptor 
peptide concentrations, as it may lead to abnormal polarisation values due to aggregation 
or nonspecific binding (Lea and Simeonov, 2011).  Hydrophobicity of the peptides may 
also have an influence on their activity and it has been shown that at high concentrations 
they tend to form micelle like particles (Lea and Simeonov, 2011).  While peptide 
purification is a laborious task, it is important to note that their purity is crucial in 
dictating the sensitivity of an in vitro assay.  The labelled peptides were obtained at the 
purity of about 85% and hence experiments using higher purity grade should be 
performed to evaluate the efficiency of the HTS (determined by Z' factor).  Practical 
limitations such as limited purified protein availability restricted further in vitro 
characterisation of the lead peptides 139 and 142 in the present study. 
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In our first HTS (HTS1 – section-6.3.5) three compounds (Cefsulodin, Fusaric acid, 
Merbromin) were identified as hits and taken forward for secondary screens.  As a 
complementary approach, a literature search was carried out which revealed that 
Cefsulodin is a narrow spectrum third generation analogue of cephalosporin, which is 
active only against Pseudomonas aeruginosa (Tsuda et al., 1988).  It has been proposed 
that penicillin binding protein 3 (PBP3) is the principle target for this drug though it has 
not been characterised properly.  Earlier studies implicated its use in combination with 
other antibiotics in treating haematological malignancies; other potential therapeutic 
uses could not be established (Tsuda et al., 1988).  Fusaric acid is a mycotoxin produced 
by several species in genus Fusarium (belong to the family of filamentous fungi).  It has 
been known to decrease plant viability and toxic to certain gram positive bacteria and 
mycobacterium (Fischer et al., 1980).  However, its clinical use as antimicrobial is 
restricted.  Its mode of action has not been established yet.  A review by Hexiang Wang 
and T.B.Ng detailed the pharmacological effects of Fusaric acid on various physiological 
systems.  One such effect is its potential to elevate dopamine levels while decreasing 
norepinephrine levels supporting its role as a dopamine β-hydroxylase (DBH) inhibitor 
(Wang and Ng, 1999, Fischer et al., 1980).  DBH is a key enzyme involved in catalysing the 
conversion of dopamine to noradrenalin.  Clinical studies have established an association 
between DBH gene polymorphism and smoking status within SCZ population (Zhang et al., 
2012).  I considered this as attractive hit as dopamine signalling dysfunction has been 
reported to play a key role in the aetiology of SCZ associated disorders as proposed by 
Stein and Wise,  also known as the Dopamine  hypothesis (Stein and Wise, 1971, Davis et 
al., 1991, Cubells et al., 2011, Ella et al., 2012, Zhang et al., 2012).  The compound 
shortlisted as a hit in the two replicates of HTS1 is Merbromin (trade name 
mercurochrome). It is used as a topical antiseptic.  It has been identified as a pan active 
inhibitor of various Protein methyltransferases (PMT) in an independent HTS screen 
(Ibanez et al., 2012). 
 
In the secondary screens, Cefsulodin and Fusaric acid failed to displace the labelled DISC1 
peptide from the protein complex and were considered as false positives.  However, 
Merbromin was identified as an autofluorescent compound, evident from low mP values 
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with increasing concentration of compound on its own (with no protein-peptide mix 
added).  As suggested earlier, a non-fluorescent assay should be performed before 
omitting this compound as a potential hit.  
 
In the second HTS (HTS2, section 6.3.6) 7000 compounds were screened from 
Pharmacological Diversity Set (PDS) from Enamine (Kiev). Unfortunately, none of the 
compounds inhibited Skp1-Fbxw7 binding of DISC1. However, certain compounds (listed 
in Table 6.1) have shown increased polarisation (compared to the positive control), which 
may infer that in the presence of these compounds, the binding was stronger (or more 
receptor sites were occupied by the ligand).  Assuming that these compounds may 
increase the DISC1-Fbxw7 interaction, they were shortlisted.  It can be hypothesised that 
the hits may have a potential to directly or allosterically enhance DISC1-Fbxw7 
interaction, which can only be confirmed after further secondary screens and 
characterisation.  Due to financial restrictions and time constraint further secondary 
screens for the putative hits could not be performed.  A gradual fall in the polarisation 
values was observed with increasing well number in all the plates in HTS screen 2 (data 
presented in the appendix of this thesis).  I speculate that as it took nearly 20 minutes to 
read each plate, time drift may have caused a temperature increase leading to assay 
reagent evaporation which may have inturn resulted in a fall in the mP values.  
 
From the two HTS campaigns carried out for this study, no dose-dependently active and 
chemically meaningful hits were obtained.  Possible reasons for this are: Quality of the 
chemical library has a crucial role to play in the number of the hits of the screen.  Only 
8500 compounds were screened (total in screen 1 and 2) in this study, which is relatively 
small compared to the libraries screened by pharmaceutical companies constituting 
millions of compounds.  Screening compound libraries posed major challenges such as 
auto fluorescence, quenchers, temperature control and evaporation due to low assay 
volumes. 
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A possible alternative to resource-demanding HTS of small molecule libraries is ‘drug 
design’.  Increasing availability of crystallographic protein structures and advancements in 
computers technology allows for virtual screening and in silico modelling.  There has been 
much focus on developing algorithms which allow one to identify possible ligands.  These 
can then be chemically synthesised or purchased if commercially available, and their 
binding properties analysed using conventional assays.  Hits may then be optimized using 
further rounds of in silico screening/modelling and conventional assays.  In simple terms, 
computer aided drug design has successfully led to the development of a number of FDA 
approved drugs (Durrant et al., 2009).  This approach could be an alternative way to 
develop DISC1-Fbxw7 inhibitors, given that Skp1-Fbxw7 crystal structure has been solved 
(Hao et al., 2007a, Wang et al., 2004, Orlicky et al., 2010) and a suitable assay to test 
possible hits has been developed in this work.  DISC1 expression levels were shown to be 
high during active brain developmental and to regulate neurogenesis and this supports 
the role of abnormal levels of DISC1 in the pathophysiology of associated 
neurodevelopmental disorders.  Hence, I propose that modulation of DISC1 protein levels 
is an attractive potential mechanism. 
 
6.5 Chapter summary 
To summarize, in this chapter, we developed a reliable, quantitative FP assay using which 
we characterised and quantified DISC1- [Skp1-Fbxw7] interaction.  Using this assay, we 
have shown that doubly phosphorylated DISC1 CPD has a higher affinity over the singly 
phosphorylated CPD peptide providing in depth information on DISC1-Fbxw7 binding 
affinity.  Furthermore, the FP assay was used in two HTS campaigns to screen a total of 
8520 small molecules to identify potential modulators of the interaction.  Although no 
confident inhibitors of the interaction were found, contemplated potential activators 
were shortlisted for future analysis.  I propose that more intense optimisation of the 
assay and screening of more libraries would be fruitful. 
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7.  
 
Final Discussion 
 
 
7.1  Background 
Since the discovery of DISC1 in a Scottish pedigree, carrying a highly penetrant balanced 
translocation (1q42.1; 11q14.3), there has been accumulating evidence to support its 
multiple roles in neurogenesis, migration and synapse signalling.  These aspects make it a 
promising candidate gene for SCZ (Bradshaw et al., 2008, Bradshaw and Porteous, 2010, 
Maher and LoTurco, 2012).  DISC1’s multi compartmental localisation and a broad 
interactome support its involvement in multiple signalling pathways.  Recent studies have 
associated DISC1 with other major chronic mental disorders such as autism, depression 
and bipolar disorder and it has been proposed that all DISC1 related illnesses should be 
categorised as ‘DISCopathies’ (Korth, 2009, Korth, 2012).  
 
Although several DISC1 SNPs and haplotypes were identified to be associated with these 
neurological disorders, there has been no established consensus as to the disease causing 
mutation (Lipska et al., 2006b, Saetre et al., 2008).  Moreover, the role of DISC1 in 
subjects with no known mutations has garnered much attention.  While, DISC1 
haploinsufficiency was one of the initially proposed mechanisms in the Scottish 
translocation, there have been no reports of low levels of mRNA transcripts or protein 
levels in SCZ patients (Leliveld et al., 2008, Lipska et al., 2006b).  However, short splice 
variants were shown to be specifically upregulated in SCZ patients (Nakata et al., 2009).  
This is intriguing as these reported short isoforms resemble the Scottish truncation gene 
product, which may suggest that regulation of specific alternative splicing of these splice 
variants could be one of underlying disease mechanisms.  
 204 
 
 
A classical hallmark of neurological disorders is abnormal processing or misfolding of 
proteins, which in some cases, leads to toxic aggregate formation (Taylor et al., 2002). 
DISC1 protein aggregates have been reported by several groups and high expression of 
heat shock proteins (molecular chaperones) have been found to be up regulated in SCZ 
brains.  Hence disruption in DISC1 processing was one of the other disease mechanisms 
suggested (Hikida et al., 2012, Leliveld et al., 2008).   
 
Post translational modifications are crucial in maintaining protein integrity, folding and 
cellular turnover, and UPS dysfunction has been previously reported in psychiatric 
illnesses (Lehman, 2009, Layfield et al., 2005).  A more recent study also reported UPS 
dysfunction and brain specific abnormalities in UPS related mRNA transcripts in patients 
suffering from SCZ (Rubio et al., 2013, Bousman et al., 2010, Altar et al., 2005).  Owing to 
the overlapping nature of UPS related abnormalities and phenotypes observed with loss 
of DISC1 function, we proposed that exploring and uncovering the yet unknown PTMs on 
DISC1 would provide answers, as well as open new avenues to understand the underlying 
pathophysiology on DISC1 associated disorders.  
 
In the following sections, I briefly review my results and discuss the wider implications of 
my intriguing findings.   
 
 
7.2 Consequences of DISC1 SUMOylation on its 
neurological functions 
My initial work (results chapter 3) focussed on investigating DISC1 as a putative SUMO 
substrate.  SUMOylation is a Ubl (ubiquitin Like).  Posttranslational modification, which 
plays a vital role in neuronal signalling pathways contributing to synapse formation, ion 
channel activity, spine morphogenesis and synaptic transmission; reviewed in (Martin et 
al., 2007, Wilkinson and Henley, 2010).  For the first time I provide the experimental 
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evidence that DISC1 can be SUMOylated.  I identified potential SUMO acceptor lysine 
(K643), although the presence of other sites may not be ruled out.  From previous 
reports, mitochondrial and neuronal fractions had enriched SUMOylation of substrates 
and since DISC1 localisation and regulation of mitochondrial dynamics has been studied 
and its dysfunction has been observed in SCZ and other neuropsychiatric disorders (James 
et al., 2004b, Millar et al., 2005a), I propose that in-depth characterisation of this PTM 
may provide answers to questions concerning the mechanistic behind DISC1’s 
involvement in mitochondrial dysfunction.   
 
Transgenic mice expressing mutant DISC1 (C terminal truncated DISC1), under control of 
CaMKII promoter, displayed abnormal phenotypes consistent with those observed in SCZ 
patients, such as enlarged ventricles, altered spine density and fewer parvalbumin-
positive neurons (Hikida et al., 2007, Ayhan et al., 2011).  This established a strong 
association between DISC1 with post synaptic physiology.  A direct correlation has been 
established between the presynaptic neuronal expression of DISC1 and presynaptic 
glutamate release (Maher and LoTurco, 2012).  SUMOylation of synapse associated 
substrates regulates presynaptic glutamate release depending on the stimulus.  Different 
stimuli may promote SUMOylation or deSUMOylation of different subsets of proteins, 
which in turn affects the release the neurotransmitter (Feligioni et al., 2009).  It would be 
interesting to investigate the SUMOylation status of DISC1 at the synapse (one approach 
could be the use of SUMO “dead” mutant of DISC1) to understand the precise role of 
DISC1 in synapse signalling.   
 
I also provide preliminary evidence of one of many possible consequences of this 
modification on DISC1, such as altered protein interactions, in this case with DIXDC1.  
Although inconclusive, if this indeed is true, this could have major physiological 
consequences as this protein complex regulates neurogenesis and cortical development 
(Singh et al., 2010).  This PTM event on DISC1 may act to regulate neuronal progenitor 
proliferation via its interaction with DIXDC1.  As a multifunctional scaffold protein, DISC1 
has the ability to orchestrate multiple signalling pathways via its broad “interactome” and 
we speculate that SUMO conjugation would have a major impact by either creating new 
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binding surfaces or inhibiting interactions possibly mediated by conformational changes 
on DISC1.   
 
One of the other consequences, is altered sub cellular localisation regulated by reversible 
dynamic PTMs such as SUMOylation and Ubiquitination.  Another well studied protein 
SUMO substrate is PML (Promyelocytic leukemia protein), which is SUMO conjugated and 
localised in a sub nuclear structures known as PML nuclear bodies.  Many other SUMO-
modified proteins have been shown to be co-localised in these transcription PML nuclear 
bodies (Zhong et al., 2000, Gill, 2004).  Since DISC1 also partially co-localises with PML 
nuclear bodies (Sawamura et al., 2008), I speculate that SUMO modified DISC1 may be 
targeted to these PML bodies which are associated with cell proliferation and 
differentiation (Zhong et al., 2000). DISC1 interacts with ATF4 (Activating Transcription 
Factor) and modulates cAMP-dependent cAMP-response element (CRE)-mediated 
transcription.  DISC1 variants 37W and 607F disrupted nuclear targeting of WT DISC1 in a 
dominant negative manner (Malavasi et al., 2012).  It can be speculated that these 
variants could have an altered propensity to undergo PTM (either SUMOylation or 
ubiquitination) which may alter their sub cellular targeting.  The above mentioned are just 
a few of examples of the possible consequences of DISC1 SUMOylation and I propose that 
it may have a more complex role in neuronal signalling.  
 
The above points may be addressed by further experimental work which could not be 
done during my studies due to time constraints:  
 
1. Detection of SUMOylated DISC1 using the UFDS method in a more relevant cell line, 
such as primary neuronal cultures or iPSc originated neurons.  Immunostaining could be 
performed to identify the localisation and distribution pattern of SUMO conjugated DISC1 
and its tendency to form aggregates.  
2. Mass spectroscopy studies with high quality samples followed by site directed 
mutagenesis would provide firm evidence of all possible SUMO acceptor sites on DISC1. 
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3. Although DISC1 is less conserved in human and rodents, the SUMO site (K643) site is 
conserved in both.  Hence, investigating the SUMOylation status of DISC1 in DISC1 mouse 
models would be useful.  It is intriguing that this site is missing in the C terminal 
truncation (Scottish translocation) and hence the lack of this PTM may contribute to its 
dominant negative character.  
 
Other PTMs such as phosphorylation may be required as a triggering event to initiate 
DISC1 SUMOylation.  PKA mediated phosphorylation at S710 (S713 in human) has been 
shown to regulate neuronal migration during cortical development (Ishizuka et al., 
2011b).  SUMOylation on phosphor dead (S710A) and phosphor mimicking (S710D) DISC1 
mutants, using the UFDS method, may identify a possible physiological link between 
these two PTM events.  
 
 
7.3 DISC1 turn over regulation via ubiquitin mediated 
proteasomal degradation 
As discussed in chapter 5, I demonstrate for the first time that the turnover of DISC1 is 
mediated by the UPS pathway.  My data suggests that DISC1 is ubiquitinated and its 
degradation is inhibited in the presence of proteasome inhibitor, MG132 in a time and 
dose dependent manner.  Previous studies have reported that DISC1 antibodies 
consistently detect high molecular weight bands (above 100kDa), especially in developing 
cerebral cortex  (Morris et al., 2003, James et al., 2004a, Sawamura et al., 2005a).  
Although, these DISC1 associated high molecular weight bands were proposed to be 
DISC1 dimers, from my findings, these bands may also relate to the SUMOylated or 
ubiquitinated DISC1 species.  Spatial and temporal regulation of DISC1 protein expression 
during brain development also suggest that complex regulatory mechanisms may be 
involved in regulating DISC1 turnover (Brandon et al., 2004, Miyoshi et al., 2003a, Ozeki et 
al., 2003a).  Since, many of the proteins functioning at the synapse are either activated, 
inactivated or degraded upon suitable stimuli; an upstream deficiency in the UPS would 
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disrupt the synapse signalling reported in SCZ (Vawter et al., 2001, Altar et al., 2005).  I 
speculate DISC1 could be one such crucial substrate involved.  
 
Although, my work primarily focused on the proteolytic role of the UPS, it is important to 
note that ubiquitin conjugation to DISC1 may have other potential functional 
consequences.  Until recently, a common notion existed that substrates with K48 chains 
are normally targeted for proteasomal degradation while those with K63 chains to 
lysosomes and DNA repair mechanisms (Nagao et al., 2006) (Nathan et al., 2013). 
However, there has been emerging evidence supporting the role of these chain 
formations in other cellular events.  For example, Met4 (transcriptional activator) is 
conjugated by single K48 type Ubiquitin chain catalysed by E3 ligase, Cdc34–SCFMet30 (Flick 
et al., 2004).  This conjugation inactivates Met4 activity instead of targeting it for 
degradation.  As such, this study provided the first line of evidence for the non proteolytic 
role of K48 type ubiquitin chain conjugation (Flick et al., 2004).  Several mechanisms have 
been proposed to explain the differential fate of the ub conjugated substrates dictated by 
the type of chains (Nathan et al., 2013).  One mechanism that was widely accepted was 
the presence of various classes of  DUB’s which specifically recognise the substrates and 
promote their deubiquitination (Finley, 2009).   
Although through my findings, I address some important aspects of DISC1 protein 
regulation, my work also raises some interesting questions such as: 
1. What is the stimulus that triggers DISC1 ubiquitination?  How does the developmental 
profile of ubiquitinated DISC1 vary?  What is the role of DISC1 ubiquitination in 
neurogenesis mediated by its protein interactions?  
2. Is there cross-talk between the UPS and SUMOylation pathways with respect to DISC1?  
Do they compete for same acceptor lysine residues or promote or inhibit other PTMs?  
These are questions that should be addressed if further time and funding can be sought. 
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7.3.1. Significance of Fbxw7 dependent DISC1 protein turn over 
As discussed in chapter 4, siRNA library screen identified Fbxw7 as a potential Fbox 
protein, which regulated DISC1 ubiquitination as a component of an SCF E3 ligase 
complex.  Also known as hCdc4 and hSel-10, scientific literature emphasizes Fbxw7 as a 
therapeutic target for cancer therapy (Kanei-Ishii et al., 2008, Wang et al., 2012a, 
Iriuchishima et al., 2011).  With the increasing identification of neuronal proteins as 
Fbxw7 substrates, its role brain specific physiological pathways have garnered much 
attention lately.  
 
High levels of Fbxw7 mRNA transcripts were detected from E13.5 with predominant 
expression in granule cell (GC) layers (Jandke et al., 2011). Fbxw7 expression was also 
identified to be significantly high in adult brain regions such as hippocampus and 
cerebellum.  This is interesting in the context of strong expression and association of 
DISC1 with hippocampus structure and function (Lipska et al., 2006a, Faulkner et al., 
2008, Meyer and Morris, 2008, Austin et al., 2004).  Regional specific shRNA knockdown 
of DISC1 hampers the migration of early born GC in the dentate gyrus (Meyer and Morris, 
2009), while its knockdown was shown to enhance migration of adult born granule cells in 
the dentate gyrus (Kvajo et al., 2008). However, literature searches did not reveal any 
inverse correlation of DISC1 and Fbxw7 expression during development as we expected.  
While the complexity surrounding the isoform specific regulation of these proteins is one 
possible reason, it can also be speculated that Fbxw7 may also target yet unknown 
upstream substrates of the DISC1 pathway.  Hence, the role played by DISC1 may be 
spatio-temporally distinct, varying with the stimuli which dictates its function.  
 
Two important substrates of Fbxw7 are c-Jun and Notch, which regulate neuronal 
apoptosis and neurogenesis respectively (Lütolf et al., 2002, Hoeck et al., 2010a).  
Cerebellum specific deletion of Fbxw7 reduced the size of the cerebellar vermis, with 
increased Notch 1 and phosphorylated c-Jun levels, implying a crucial role of Fbxw7 in 
cerebellar morphogenesis (Jandke et al., 2011). Studies also reported that Fbxw7−/− 
embryos die in utero at E10.5-11.5 with reported abnormalities in brain (Zhou et al., 
2013b). I speculate that the abnormal anatomical changes observed in Fbxw7 conditional 
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knockout mice could also be associated with DISC1 turnover, whose protein levels are 
tightly regulated during early development.  My findings support the critical role of Fbxw7 
in brain development by identifying DISC1 as its substrate and I suggest a complex 
interaction between these proteins in regulating various cellular pathways.  However, 
further work is required to elucidate how FBXW-DISC1 interaction contributes to the 
development of the brain.  
 
 
7.4 Targeting novel PPI, DISC1-Fbxw7 interaction: scope 
for therapeutic intervention  
Upon identification of a conserved phosphodegron (CPD) on DISC1, I performed peptide 
array studies and identified the shortest stretch of the CPD domain that might be involved 
in the interaction with Fbxw7.  This sequence within the DISC1 CPD, was optimised using 
peptide array studies by various substitutions with non-natural amino acids while the net 
charge of the peptide remained unaltered, to increase the peptides physiological stability 
and affinity and towards the Fbxw7 substrate binding domain (WD40).  Following a series 
of optimisation rounds, lead peptides 139 and 142 were selected for testing on cells, to 
investigate their ability to stabilise DISC1 as per my hypothesis.  These peptides stabilised 
DISC1 in a dose and time dependent manner in the HEK293 cell line, while the other 
substrates of Fbxw7 (c-Myc, Cyclin E and Notch) were unaltered.  I propose that the 
differences in affinity between Fbxw7 and DISC1 (low) compared to other substrates 
including Cyclin E (high) allows the peptides to be substrate specific.  
 
I suggest that the peptides can be a starting point for the development of novel 
therapeutics.  The lead cell permeable peptides which specifically stabilise DISC1 in cells 
offer an attractive alternative to proteasome inhibitors which affect a larger pool of 
substrates leading to side effects.  Performing physiological assays of DISC1 function, such 
as assessing neurite outgrowth and neurite number, following peptide treatment in a 
relevant neuronal cell line (such as iPS derived neurons) may explain the mechanism of 
reported disease phenotypes.   
 211 
 
 
Furthermore, the Skp1-Fbxw7  protein complex (Schulman et al., 2000), was crystallized 
bound to a 15 residue, doubly phosphorylated DISC1 peptide P193EVPPpTPPGpSHSAFT207  
(X ray crystallography work was performed by Yunfeng Li, Prof. Bing Hao’s laboratory, 
University of Connecticut, USA; Figures in appendix section 7). This crystal structure 
(Figure in appendix) shows a striking resemblance to that of Cyclin EdegronC - residues 360–
390, phosphorylated at Ser372, Thr380, and Ser384) (Hao et al., 2007a).  My findings 
therefore suggest that the doubly phosphorylated DISC1 is recognised by Fbxw7 following 
Cyclin E paradigm. 
 
I also explored the use of patient specific iPS differentiated neurons for potential as 
disease models.  As an emerging revolutionary tool, iPS technology holds a therapeutic 
application for drug screening.  For neurodevelopmental disorders such as SCZ, which 
involve complex gene environment interactions, the use of the human neurons 
developed by this method offer a considerable advantage over animal models,  as human 
DISC1 is significantly different from those in rodents.  They also offer a unique 
opportunity to recapitulate the disease phenotype and elucidate the disease mechanism.  
Patient specific iPS cells have been generated by various groups (Brennand et al., 2011, 
Brennand and Gage, 2012, Chiang et al., 2011).  In the present study, I used neuronal 
progenitors but not fully differentiated neurons due to the limitations of cell number and 
time constraints.  DISC1 protein levels in the patient derived neuronal progenitors were 
low compared to those in controls subjects, and were ideal to test out hypothesis of 
targeting DISC1-Fbxw7 interaction to rescue DISC1 protein levels.  My preliminary results 
were promising as the lead peptides stabilised DISC1 levels, however, more experimental 
repeats are required to validate this effect.  Assessing the pattern of expression of DISC1 
and Fbxw7 at various stages of differentiation from iPS cells to neurons and comparative 
analysis of how this profile varies between control subjects and patients would be 
intriguing.  Although similar studies were performed in post mortem brain samples 
(Lipska et al., 2006b), they may not resemble the physiological levels in live neurons.  
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I suggest that the following list of experiments would further enhance our understanding 
of DISC1 function: 
1. Site specific mutational studies within DISC1 CPD, followed by assessment of DISC1 
ubiquitination and turnover.  
2. Phosphorylation has been shown to be a prerequisite for β-TrCP1 and Fbxw7 to 
recognise their cognate substrates-β catenin and Cyclin E respectively (Wu et al., 2003, 
Hao et al., 2007a).  My findings of phosphorylated CPD mediated DISC1 ubiquitination is 
comparable to the models proposed in the above studies.  However, I speculate that 
GSK3β could be the source kinase as for the other Fbxw7 substrates.  This may be 
challenging to explore as a priming phosphorylation of the substrate by a different kinase 
is often required for GSK3β phosphorylation.  
3. It may be useful to investigate the effect of GSK3β activators and inhibitors on DISC1-
Fbxw7 interaction since Wnt/GSK3β signalling has been identified as a critical signalling 
pathway in psychiatric disorders.  
4.  It would be interesting to identify any DISC1 common or rare mutants falling within 
DISC1 CPD region.  Certain DISC1 variants (A83V, R264Q and L607F) failed to activate Wnt 
pathway and diminished neuronal progenitor proliferation (Singh et al., 2011).  Similarly, 
a recent study reported that patients carrying R264Q variant were resistant to anti-
psychotic medication (Mouaffak et al., 2011).  Although the precise mechanism is not 
known, I speculate that these variants affect DISC1 protein stability and my findings 
provide a frame work and open new avenues to explore the underlying disease 
mechanism.  
 
 
 
 
7.4.1. Small molecule modulators of DISC1-Fbxw7 interaction 
Experimental work discussed in chapter 6, concerned the process of screening for small 
molecule modulators that affect via DISC1-Fbxw7 protein interaction.  A reliable and 
quantitative FP assays was developed based on DISC1 CPD mediated interaction with 
Fbxw7, which was adapted to perform HTS on two different compound libraries to 
identify modulators of this interaction.  The hit identified in the first HTS, a fluorescent 
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compound, Merbromin requires intense characterisation in secondary screens using non 
fluorescence based techniques to corroborate its potential to be developed as a drug.  
Certain compounds in the second screen were identified to increase the DISC1-Fbxw7 
interaction (activators).  Assessment of their potential to modulate this PPI may identify 
compounds which may be developed further to act as DISC1 down regulators.  These 
would be useful for the investigation of DISC1 function in animal studies.   
 
 
7.5 Final Conclusion 
My study identified novel post translational modifications (SUMOylation and 
Ubiquitination) on DISC1 which would advance the understanding of how DISC1 protein 
function in various cellular pathways is regulated.  With the identification of SCFFbxw7 as 
the E3 ligase that regulates DISC1 ubiquitination and subsequent elucidation of their 
binding sites, I uncovered the DISC1-Fbxw7 PPI as a promising drug target.  I optimised 
two lead peptides (139 and 142) to inhibit this interaction and in so doing arrived at a 
new class of therapeutic approaches directed at the up regulation of DISC1 via inhibition 
of its destruction by the proteasome.  I also developed an in vitro assay to identify small 
molecule disruptors which could provide a novel, targeted therapeutic strategy for the 
treatment of SCZ and associated disorders which involve loss or gain of DISC1 function.  I 
propose that the modulation of this interaction may in turn modulate its function, 
targeting the neurodevelopmental processes, underlying the pathophysiology of DISC1 
associated illnesses that delay or prevent the onset of the psychiatric illness. 
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Appendices 
 
8.1 Fbox siRNA screen data 
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Figure 8.1 Fbox siRNA knock screen in HEK293 cells – Effect on DISC1 protein levels.  
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8.2 X-ray crystallography studies : Co-crystallisation of 
DISC1 phosphodegron peptide and Skp1-Fbxw7 complex 
 
 
 
Figure 8.2a Crystal structure of the Skp1-Fbw7-DISC1 CPD peptide complex 
General architecture of Skp1-Fbxw7 complex, with the secondary structure elements of 
Skp1 (blue), F box domain, and linker domains (green) labelled accordingly.  The DISC1 
CPD peptide (NVPPTpTPPGpSC) can be seen binding to the WD40 domain.  The overall 
structure of Skp1-Fbxw7 complex remains the same as described in (Hao et al., 2007a). 
 
Crytallogrpahy studies were performed by Dr.Yunfeng Li, Prof. Bing Hao’s laboratory, 
University of Connecticut, USA 
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Figure 8.2b Crystal structure of the Skp1-Fbw7-DISC1 CPD peptide complex 
Fbxw7 WD40 domain (green) can be seen as a β propeller structure forming 8 blades 
with the bound DISC1 CPD peptide (NVPPTpTPPGpSC). 
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Figure 8.2c Molecular surface representation of WD40 domain bound DISC1 and CyclinE 
CPD peptides individualy.   
DISC1 pT and pS make contacts with Fbxw7 WD40 domain similar to CyclinE paradigm, 
while Cyclin E has additional interaction (Glycine on the C terminus) which may 
contribute to its higher affinity.  
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Figure 8.2d Summary of key contacts between FBXW7 and DISC1 CPD 
Blue residues represent amino aicds in FBXW7 WD40 and black resdues are DISC1 CPD.  
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8.3 Disruptor peptide development and optimisation 
 
 
Figure 8.3a Peptide array studies to optimise and develop disruptor peptide to inhibit 
DISC1- [Skp1-Fbxw7] interaction. Optimisation part 1. 
Lane 1- Spot number, Lane 2-Coomassie stained array, Lane 3- Test array, Lane 4- 
Peptide sequence  
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Figure 8.3b Peptide array studies to optimise and develop disruptor peptide to inhibit 
DISC1- [Skp1-Fbxw7] interaction. Optimsiation part 2. 
Lane 1- Spot number, Lane 2-Coomassie stained array, Lane 3- Test array, Lane 4- 
Peptide sequence  
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8.4 High Throughput Screen 2 (HTS2) data  
 
 
 
 
 
Figure 8.4a 384 well plate layouts for the High Throughput Screens 
Green area represents the 384well plate.  Controls include positive control (with 100% 
inhibition) and negative control (with inhibition of protein-protein interaction) 
described in chapter 6, Section 6.3.1. 
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Figure legend in next page. 
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Figure 8.4 High Throughput Screen data (HTS Screen 2) 
mP values were plotted against the well number for each plate.  Described in Chapter 6, 
Section 6.3.6.  
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8.5 Amino acid structures, three letter and single letter 
representation 
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Figure 8.5a  Amino acids structures, used in the peptide array studies 
 
 
Figure 8.5b  Schematic of L and D isomers of an amino acid with R side chain 
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